UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10–Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30, 2020~~March 31, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from [ ] to [ ]

Commission file number: 000-55768

HealthLynked Corp.
(Exact name of registrant as specified in its charter)

Nevada		47-1634127
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

~~1035 Collier Center Way~~1265 Creekside Parkway, Suite 3,302, Naples FL ~~34110~~34108
(Address of principal executive offices)

(800) 928-7144
(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November 16, 2020,~~May 17, 2021, there were ~~186,807,929~~228,092,306 shares of the ~~issuer’s~~issuer's common stock, par value $0.0001, ~~outstanding and 2,750 shares of the issuer’s Series B Preferred shares par value $0.001,~~ outstanding.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

HEALTHLYNKED CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30,			December 31,			March 31,			December 31,
	2020			2019			2021			2020
ASSETS	(Unaudited)						(Unaudited)
Current Assets
Cash	$	1,713,124		$	110,441		$	3,341,728		$	162,184
Marketable securities		44,477			---
Accounts receivable, net of allowance for doubtful accounts of $13,972 and $13,972 as of September 30, 2020 and December 31, 2019, respectively		193,744			83,251
Accounts receivable, net of allowance for doubtful accounts of $13,972 and $13,972 as of March 31, 2021 and December 31, 2020, respectively								125,305			87,153
Inventory		105,200			70,460			111,402			95,200
Prepaid expenses		80,552			119,328
Deferred offering costs		---			19,203
Prepaid expenses and other								41,070			59,003
Total Current Assets		2,137,097			402,683			3,619,505			403,540

Property, plant and equipment, net of accumulated depreciation of $817,971 and $794,799 as of September 30, 2020 and December 31, 2019, respectively		458,674			513,788
Goodwill and intangible assets, net of accumulated amortization of $12,064 and $5,908 as of September 30, 2020 and December 31, 2019, respectively		2,585,330			1,336,958
Property, plant and equipment, net of accumulated depreciation of $204,353 and $177,457 as of March 31, 2021 and December 31, 2020, respectively								417,790			437,286
Intangible assets, net of accumulated amortization of $336,538 and $151,776 as of March 31, 2021 and December 31, 2020, respectively								5,417,000			5,601,762
Goodwill								1,148,105			1,148,105
ROU lease assets and deposits		314,992			293,125			417,497			435,855

Total Assets	$	5,496,093		$	2,546,554		$	11,019,897		$	8,026,548

LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)
LIABILITIES AND SHAREHOLDERS’ EQUITY

Current Liabilities
Accounts payable and accrued expenses	$	1,362,516		$	836,465		$	876,581		$	1,891,749
Deferred revenue		51,714			---
Contract liabilities								67,059			89,425
Lease liability, current portion		105,233			201,523			162,770			150,251
Due to related party, current portion		300,600			493,457			300,600			300,600
Notes payable to related party, current portion		---			743,955
Government notes payable, current portion		595,669			---

Convertible notes payable, net of original issue discount and debt discount of $-0- and $777,668 as of September 30, 2020 and December 31, 2019, respectively		1,153,279			1,542,036
Government and vendor notes payable, current portion								438,281			411,427
Convertible notes payable, net of original issue discount and debt discount of $-0- and $-0- as of March 31, 2021 and December 31, 2020, respectively								—			1,336,350
Contingent acquisition consideration, current portion		548,069			100,000			689,083			701,961
Derivative financial instruments		---			991,288
Total Current Liabilities		4,117,080			4,908,724			2,534,374			4,881,763

Long-Term Liabilities
Government notes payable, long term portion		450,000			---
Government and vendor notes payable, long term portion								644,545			722,508
Contingent acquisition consideration, long term portion		378,528			400,000			1,447,057			798,479
Lease liability, long term portion		198,667			80,510			228,288			273,790

Total Liabilities		5,144,275			5,389,234			4,854,264			6,676,540

Shareholders’ Equity (Deficit)
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 166,827,824 and 109,894,490 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively		16,683			10,990
Series B convertible preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 2,750,000 and -0- shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively		2,750			---
Common stock issuable, $0.0001 par value; 1,465,238 and 1,047,904 shares as of September 30, 2020 and December 31, 2019, respectively		182,092			159,538
Shareholders’ Equity
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 226,075,381 and 187,967,881 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively								22,608			18,797
Series B convertible preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 2,750,000 and 2,750,000 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively								2,750			2,750
Common stock issuable, $0.0001 par value; 2,803,770 and 2,150,020 shares as of March 31, 2021 and December 31, 2020, respectively								424,317			262,273
Additional paid-in capital		20,012,306			13,016,446			35,324,321			22,851,098
Accumulated deficit		(19,862,013	)		(16,029,654	)		(29,608,363	)		(21,784,910	)
Total Shareholders’ Equity (Deficit)		351,818			(2,842,680	)
Total Shareholders’ Equity								6,165,633			1,350,008

Total Liabilities and Shareholders’ Equity (Deficit)	$	5,496,093		$	2,546,554
Total Liabilities and Shareholders’ Equity							$	11,019,897		$	8,026,548

See the accompanying notes to these Unaudited Condensed Consolidated Financial Statements

HEALTHLYNKED CORP.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(UNAUDITED)

Three Months Ended
March 31,
2021 2020
Revenue
Patient service revenue, net $ 1,514,376 $ 1,336,940
Consulting and event revenue 87,655 —
Product revenue 182,663 —
Total revenue 1,784,694 1,336,940

Operating Expenses and Costs
Practice salaries and benefits 663,937 765,121
Other practice operating expenses 730,784 563,691
Medicare shared savings expenses 211,507 —
Cost of product revenue 168,596 —
Selling, general and administrative expenses 1,366,137 510,976
Depreciation and amortization 211,658 24,786
Total Operating Expenses and Costs 3,352,619 1,864,574

Loss from operations (1,567,925 ) (527,634 )

Other Income (Expenses)
Loss on extinguishment of debt (5,589,994 ) (467,937 )
Change in fair value of debt (19,246 ) 35,965
Amortization of original issue and debt discounts on notes payable and convertible notes — (292,163 )
Change in fair value of derivative financial instruments — 740,355
Change in fair value of contingent acquisition consideration (635,700 ) (6,621 )
Interest expense (10,588 ) (62,181 )
Total other expenses (6,255,528 ) (52,582 )

Net loss before provision for income taxes (7,823,453 ) (580,216 )

Provision for income taxes — —

Net loss $ (7,823,453 ) $ (580,216 )

Deemed dividend - amortization of beneficial conversion feature and down round adjustment to warrants (88,393 ) —

Net loss to common stockholders $ (7,911,846 ) $ (580,216 )

Net loss per share to common stockholders, basic and diluted:
Basic $ (0.04 ) $ (0.01 )
Fully diluted $ (0.04 ) $ (0.01 )

Weighted average number of common shares:
Basic 213,279,052 114,601,960
Fully diluted 213,279,052 114,601,960

See the accompanying notes to these Unaudited Condensed Consolidated Financial Statements

2
HEALTHLYNKED CORP.
CONDENSED CONSOLIDATED STATEMENT OF ~~OPERATIONS~~CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT)
THREE MONTHS ENDED MARCH 31, 2021 AND 2020
(UNAUDITED)

Three Months Ended
September 30, Nine Months Ended
September 30,
2020 2019 2020 2019
Revenue
Patient service revenue, net $ 1,054,806 $ 1,172,561 $ 3,502,836 $ 2,845,941
Medicare shared savings revenue 767,744 --- 767,744 ---
Consulting revenue 217,605 --- 268,025 ---
Total revenue 2,040,155 1,172,561 4,538,605 2,845,941

Operating Expenses
Practice salaries and benefits 590,690 708,571 1,910,897 1,762,662
Other practice operating expenses 548,667 521,341 1,633,380 1,287,432
Medicare shared savings expenses 759,848 --- 824,084 ---
General and administrative 958,874 733,360 2,116,159 2,084,630
Depreciation and amortization 25,151 24,980 74,811 48,345
Total Operating Expenses 2,883,230 1,988,252 6,559,331 5,183,069

Loss from operations (843,075 ) (815,691 ) (2,020,726 ) (2,337,128 )

Other Income (Expenses)
Loss on sales of marketable securities (281,606 ) --- (281,606 ) ---
Gain (loss) on extinguishment of debt (450,999 ) 4,904 (1,347,371 ) (62,459 )
Change in fair value of debt (79,062 ) (28,885 ) (198,764 ) (88,991 )
Financing cost --- (12,009 ) --- (133,244 )
Amortization of original issue and debt discounts on notes payable and convertible notes (65,816 ) (362,728 ) (530,930 ) (841,725 )
Change in fair value of derivative financial instruments 12,802 158,691 739,485 574,205
Change in fair value of contingent acquisition consideration 45,996 --- 687 ---
Interest expense (72,535 ) (69,562 ) (193,134 ) (176,229 )
Total other expenses (891,220 ) (309,589 ) (1,811,633 ) (728,443 )

Net loss before provision for income taxes (1,734,295 ) (1,125,280 ) (3,832,359 ) (3,065,571 )

Provision for income taxes --- --- --- ---

Net loss $ (1,734,295 ) $ (1,125,280 ) $ (3,832,359 ) $ (3,065,571 )

Deemed dividend - amortization of beneficial conversion feature (63,862 ) --- (63,862 ) ---

Net loss to common stockholders $ (1,798,157 ) $ (1,125,280 ) $ (3,896,221 ) $ (3,065,571 )

Net loss per share to common stockholders, basic and diluted:
Basic $ (0.01 ) $ (0.01 ) $ (0.03 ) $ (0.03 )
Fully diluted $ (0.01 ) $ (0.01 ) $ (0.03 ) $ (0.03 )

Weighted average number of common shares:
Basic 147,366,619 102,644,860 129,234,540 96,603,087
Fully diluted 147,366,619 102,644,860 129,234,540 96,603,087
Number of Shares Common Additional Total
Common Preferred Common Preferred Stock Paid-in Accumulated Shareholders'
Stock Stock Stock Stock Issuable Capital Deficit Equity (Deficit)
(#) (#) ($) ($) ($) ($) ($) ($)
Balance at December 31, 2020 187,967,881 2,750,000 18,797 2,750 262,273 22,851,098 (21,784,910 ) 1,350,008

Sales of common stock 14,793,864 — 1,479 — 2,981,367 — 2,982,846
Fair value of warrants allocated to proceeds of common stock — — — — 1,406,515 — 1,406,515
Conversion of convertible notes payable to common stock 13,538,494 — 1,354 — 4,060,194 — 4,061,548
Fair value of warrants issued and modified in connection with conversion and retirement of convertible notes payable — — — — — 3,201,138 — 3,201,138
Fair value of warrants issued for professional services — — — — — 32,426 — 32,426
Consultant and director fees payable with common shares and warrants 475,000 — 48 — 114,500 122,781 — 237,329
Shares and options issued pursuant to employee equity incentive plan 240,310 — 24 — (14,956 ) 52,337 — 37,405
Exercise of stock warrants 9,047,332 — 905 — 62,500 613,316 — 676,721
Exercise of stock options 12,500 — 1 — 3,149 — 3,150
Net loss — — — — — — (7,823,453 ) (7,823,453 )

Balance at March 31, 2021 226,075,381 2,750,000 22,608 2,750 424,317 35,324,321 (29,608,363 ) 6,165,633

Balance at December 31, 2019 109,894,490 — 10,990 — 159,538 13,016,446 (16,029,654 ) (2,842,680 )

Sale of common stock 4,187,566 — 419 — (59,000 ) 407,181 348,600
Fair value of warrants allocated to proceeds of common stock — — — — — 88,833 — 88,833
Conversion of convertible notes payable to common stock 4,672,612 — 467 — 51,652 600,441 — 652,560
Consultant and director fees payable with common shares and warrants — — — — 60,212 6,666 — 66,878
Shares and options issued pursuant to employee equity incentive plan 132,500 — 13 — (7,161 ) 45,724 — 38,576
Net loss — — — — — — (580,216 ) (580,216 )

Balance at March 31, 2020 118,887,168 — 11,889 — 205,241 14,165,291 (16,609,870 ) (2,227,449 )

See the accompanying notes to these Unaudited Condensed Consolidated Financial Statements

HEALTHLYNKED CORP.
CONDENSED CONSOLIDATED STATEMENT OF ~~CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT)~~CASH FLOWS
~~THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020~~
(UNAUDITED)

Number of Shares Common Additional Total
Shareholders’
Common Preferred Common Preferred Stock Paid-in Accumulated Equity
Stock Stock Stock Stock Issuable Capital Deficit (Deficit)
(#) (#) ($) ($) ($) ($) ($) ($)
Balance at December 31, 2019 109,894,490 --- 10,990 --- 159,538 13,016,446 (16,029,654 ) (2,842,680 )

Sale of common stock 4,187,566 --- 419 --- (59,000 ) 407,181 348,600
Fair value of warrants allocated to proceeds of common stock --- --- --- --- --- 88,833 --- 88,833
Conversion of convertible notes payable to common stock 4,672,612 --- 467 �� --- 51,652 600,441 --- 652,560
Consultant and director fees payable with common shares and warrants --- --- --- --- 60,212 6,666 --- 66,878
Shares and options issued pursuant to employee equity incentive plan 132,500 --- 13 --- (7,161 ) 45,724 --- 38,576
Net loss --- --- --- --- --- --- (580,216 ) (580,216 )

Balance at March 31, 2020 118,887,168 --- 11,889 --- 205,241 14,165,291 (16,609,870 ) (2,227,449 )

Acquisition of Cura Health Management LLC 2,240,838 --- 224 --- --- 201,451 --- 201,675
Sale of common stock 3,180,312 --- 318 --- 24,651 228,808 --- 253,777
Fair value of warrants allocated to proceeds of common stock --- --- --- --- --- 33,482 --- 33,482
Conversion of convertible notes payable to common stock 6,669,320 --- 667 --- (51,652 ) 584,268 --- 533,283
Consultant and director fees payable with common shares and warrants 111,110 --- 11 --- 34,705 8,989 --- 43,705
Shares and options issued pursuant to employee equity incentive plan 163,027 --- 16 --- 39,397 --- 39,413
Net loss --- --- --- --- --- --- (1,517,848 ) (1,517,848 )

Balance at June 30, 2020 131,251,775 --- 13,125 --- 212,945 15,261,686 (18,127,718 ) (2,639,962 )

Contingent acquisition consideration issued 1,835,626 --- 184 --- 292,599 --- 292,783
Sales of common stock 4,829,289 --- 483 --- (23,901 ) 340,582 --- 317,164
Fair value of warrants allocated to proceeds of common stock --- --- --- --- --- 57,444 --- 57,444
Sale of common and preferred stock in exchange for marketable securities
24,522,727

2,750,000

2,452

2,750

---

3,061,687

---

3,066,889

Conversion of convertible notes payable to common stock 2,855,191 --- 286 --- --- 479,387 --- 479,673
Gain on extinguishment of related party debt allocated to additional paid in capital --- --- --- --- --- 283,862 --- 283,862
Consultant and director fees payable with common shares and warrants 1,003,751 --- 100 --- (6,952 ) 136,611 --- 129,759
Shares and options issued pursuant to employee equity incentive plan 529,465 --- 53 --- --- 98,448 --- 98,501
Net loss --- --- --- --- --- --- (1,734,295 ) (1,734,295 )

Balance at September 30, 2020 166,827,824 2,750,000 16,683 2,750 182,092 20,012,306 (19,862,013 ) 351,818
Three Months Ended
March 31,
2021 2020
Cash Flows from Operating Activities
Net loss $ (7,823,453 ) $ (580,216 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 211,658 24,786
Stock based compensation, including amortization of prepaid fees 307,160 118,257
Amortization of original issue discount and debt discount on convertible notes — 292,163
Change in fair value of derivative financial instruments — (733,734 )
Loss on extinguishment of debt 5,589,994 467,937
Change in fair value of debt 19,246 (35,965 )
Change in fair value of contingent acquisition consideration 635,700 —
Changes in operating assets and liabilities:
Accounts receivable (38,152 ) 9,090
Inventory (16,202 ) (19,141 )
Prepaid expenses and deposits 4,032 62,562
ROU lease assets 24,234 80,760
Accounts payable and accrued expenses (83,854 ) (10,556 )
Lease liability (24,956 ) (76,236 )
Due to related party, current portion — 16,106
Contract liabilities (22,366 ) —
Net cash used in operating activities (1,216,959 ) (384,187 )

Cash Flows from Investing Activities
Acquisition of property and equipment (7,399 ) —
Net cash provided by investing activities (7,399 ) —

Cash Flows from Financing Activities
Proceeds from sale of common stock 4,389,361 437,433
Proceeds from exercise of options and warrants 65,650 —
Proceeds from issuance of convertible notes — 344,000
Repayment of convertible notes — (373,094 )
Proceeds from related party loans — 149,000
Repayment of related party loans — (79,327 )
Repayment of notes payable (51,109 ) —
Net cash provided by financing activities 4,403,902 478,012

Net increase in cash 3,179,544 93,825
Cash, beginning of period 162,184 110,441

Cash, end of period $ 3,341,728 $ 204,266

(continued)

HEALTHLYNKED CORP.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(UNAUDITED)
Three Months Ended
March 31,
2021 2020
Supplemental disclosure of cash flow information:
Cash paid during the period for interest $ 232 $ 15,016
Cash paid during the period for income tax $ — $ —
Schedule of non-cash investing and financing activities:
Initial derivative liability and fair value of beneficial conversion feature and original issue discount allocated to proceeds of variable convertible notes payable $ — $ 72,890
Common stock issuable issued during period $ 66,161 $ 66,175
Incremental fair value of warrants modified to extend maturity date of convertible notes payable 126,502
Conversion of convertible note payable to common shares $ 4,061,549 $ 652,560
Fair value of warrants issued in connection with conversion of convertible notes payable $ 3,074,637 $ —
Accrued liabilities relieved upon cashless exercise of warrants $ 614,221 $ —
Adoption of lease obligation and ROU asset $ — $ 43,297
Derivative liabilities written off with repayment of convertible notes payable $ — $ 51,798
Derivative liabilities written off with conversion of convertible notes payable $ — $ 52,087
Reduction in contingent acquisition consideration $ — $ 200,328
See the accompanying notes to these Unaudited Condensed Consolidated Financial Statements

~~HEALTHLYNKED CORP.~~
~~CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ DEFICIT~~
~~THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2019~~
~~(UNAUDITED)~~
Number of Shares Common Additional Total
Common Common Stock Paid-in Accumulated Shareholders’
Stock Stock Issuable Capital Deficit Deficit
(#) ($) ($) ($) ($) ($)
Balance at December 31, 2018 85,178,902 8,518 26,137 7,531,553 (10,501,055 ) (2,934,847 )

Sale of common stock 3,261,978 326 --- 693,832 --- 694,158
Fair value of warrants allocated to proceeds of common stock --- --- --- 139,068 --- 139,068
Shares issued with convertible notes payable 28,000 3 --- 4,673 --- 4,676
Fair value of warrants issued for professional services --- --- --- 54,257 --- 54,257
Conversion of convertible notes payable to common stock 2,512,821 251 --- 534,980 --- 535,231
Consultant fees payable with common shares and warrants 270,000 27 19,960 6,850 --- 26,837
Shares and options issued pursuant to employee equity incentive plan 113,750 12 --- 61,223 --- 61,235
Exercise of stock warrants 2,098,427 210 --- (210 ) --- ---
Exercise of stock options 113,141 11 --- (11 ) --- ---
Net loss --- --- --- --- (1,060,717 ) (1,060,717 )

Balance at March 31, 2019 93,577,019 9,358 46,097 9,026,215 (11,561,772 ) (2,480,102 )

Acquisition of Hughes Center for Functional Medicine 3,968,254 397 --- 999,603 --- 1,000,000
Sale of common stock 567,953 57 34,418 110,989 --- 145,464
Fair value of warrants allocated to proceeds of common stock --- --- --- 15,582 --- 15,582
Fair value of warrants allocated to proceeds of convertible notes payable --- --- --- 225,323 --- 225,323
Shares issued with convertible notes payable 50,000 5 --- 12,495 --- 12,500
Fair value of warrants issued for professional services --- --- --- --- --- ---
Conversion of convertible notes payable to common stock 740,002 74 --- 138,688 --- 138,762
Consultant fees payable with common shares and warrants 30,000 3 24,833 39,510 --- 64,346
Shares and options issued pursuant to employee equity incentive plan 135,313 13 --- 59,384 --- 59,397
Exercise of stock warrants 2,000,000 200 --- --- --- 200
Net loss --- --- --- --- (879,574 ) (879,574 )

Balance at June 30, 2019 101,068,541 10,107 105,348 10,627,789 (12,441,346 ) (1,698,102 )

Sale of common stock 1,827,182 183 (9,418 ) 255,579 --- 246,344
Shares issued with convertible notes payable 32,500 3 --- 6,939 --- 6,942
Conversion of convertible notes payable to common stock 330,892 33 --- 63,626 --- 63,659
Consultant fees payable with common shares and warrants 230,000 23 20,873 46,091 --- 66,987
Shares and options issued pursuant to employee equity incentive plan 100,000 10 --- 34,540 --- 34,550
Repurchase of treasury stock --- --- --- (1,200 ) --- (1,200 )
Net loss --- --- --- --- (1,125,280 ) (1,125,280 )

Balance at September 30, 2019 103,589,115 10,359 116,803 11,033,364 (13,566,626 ) (2,406,100 )
~~See the accompanying notes to these Unaudited Condensed Consolidated Financial Statements~~

~~HEALTHLYNKED CORP.~~
~~CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS~~
~~(UNAUDITED)~~
Nine Months Ended
September 30,
2020 2019
Cash Flows from Operating Activities
Net loss $ (3,832,359 ) $ (3,065,571 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 74,811 48,345
Stock based compensation, including amortization of prepaid fees 436,038 431,626
Amortization of original issue discount and debt discount on convertible notes 530,930 841,725
Loss on sales of marketable securities 281,606 ---
Financing cost --- 133,244
Change in fair value of derivative financial instruments (739,485 ) (574,205 )
Loss on extinguishment of debt 1,347,371 62,459
Change in fair value of debt 198,764 88,991
Change in fair value of contingent acquisition consideration (687 ) ---
Amortization of lease assets 200,372 206,485
Changes in operating assets and liabilities:
Accounts receivable (20,297 ) (5,044 )
Inventory (34,740 ) (33,841 )
Prepaid expenses and deposits 51,575 (33,110 )
Accounts payable and accrued expenses 615,434 322,254
Lease liability (197,877 ) (201,544 )
Due to related party, current portion 46,370 49,252
Deferred revenue (52,321 ) ---
Net cash used in operating activities (1,094,495 ) (1,728,934 )

Cash Flows from Investing Activities
Proceeds from sale of marketable securities 2,740,806 ---
Acquisition, net of cash acquired (164,005 ) (465,000 )
Payment of contingent acquisition consideration (137,390 ) ---
Acquisition of property and equipment (13,541 ) (10,056 )
Net cash provided by (used in) investing activities 2,425,870 (475,056 )

Cash Flows from Financing Activities
Proceeds from sale of common stock 1,099,300 1,240,616
Proceeds from exercise of warrants --- 200
Proceeds from issuance of convertible notes 827,500 1,540,000
Repayment of convertible notes (1,882,405 ) (608,992 )
Proceeds from related party loans 149,000 ---
Repayment of related party loans (967,756 ) ---
Proceeds from government loans 1,045,669 ---
Repurchase and retirement of treasury stock --- (1,200 )
Net cash provided by financing activities 271,308 2,170,624

Net increase (decrease) increase in cash 1,602,683 (33,366 )
Cash, beginning of period 110,441 135,778

Cash, end of period $ 1,713,124 $ 102,412
~~(continued)~~
5

~~HEALTHLYNKED CORP.~~
~~CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS~~
~~(UNAUDITED)~~

Nine Months Ended
September 30,
2020 2019
Supplemental disclosure of cash flow information:
Cash paid during the period for interest $ 202,768 $ 23,573
Cash paid during the period for income tax $ --- $ ---
Schedule of non-cash investing and financing activities:
Initial derivative liability and fair value of beneficial conversion feature and original issue discount allocated to proceeds of variable convertible notes payable $ 211,497 $ 1,276,703
Common stock issuable issued during period $ 66,161 $ 35
Fair value of warrants issued for professional service $ --- $ 54,257
Conversion of convertible note payable to common shares $ 1,665,516 $ 737,652
Fair value of common shares issued with convertible notes payable $ --- $ 24,118
Cashless exercise of options and warrants $ --- $ 221
Adoption of lease obligation and ROU asset $ 219,744 $ 560,050
Fair value of shares issued as acquisition consideration $ 201,675 $ 1,000,000
Fair value of contingent acquisition consideration liability recorded at acquisition date $ 1,057,785 $ 500,000
Derivative liabilities written off with repayment of convertible notes payable $ 328,000 $ 390,434
Derivative liabilities written off with conversion of convertible notes payable $ 135,300 $ ---
Fair value of shares issued as contingent acquisition consideration $ 292,783 $ ---
Reduction in contingent acquisition consideration $ 200,328 $ ---
Fair value of marketable securities received as consideration for sale of common and preferred shares $ 3,006,889 $ ---
Fair value of warrants allocated to proceeds of fixed convertible notes payable $ --- $ 225,323
Gain on extinguishment of related party debt allocated to additional paid in capital $ 283,862 $ ---
~~See the accompanying notes to these Unaudited Condensed Consolidated Financial Statements~~

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~SEPTEMBER 30, 2020~~MARCH 31, 2021
(UNAUDITED)

NOTE 1 -– BUSINESS AND BUSINESS PRESENTATION

HealthLynked Corp. (the “Company”) was incorporated in the State of Nevada on August 4, 2014. On September 2, 2014, the Company filed Amended and Restated Articles of Incorporation with the Secretary of State of Nevada setting the total number of authorized shares at 250,000,000 shares, which included up to 230,000,000 shares of common stock and 20,000,000 shares of “blank check” preferred stock. On February 5, 2018, the Company filed an Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of Nevada to increase the number of authorized shares of common stock to 500,000,000 shares.

As of ~~September 30, 2020,~~March 31, 2021, the Company operated in ~~three~~four distinct divisions: the Health Services Division, the Digital Healthcare Division, the ACO/MSO (Accountable Care Organization / Managed Service Organization) Division, and the Medical Distribution Division. The Health Services division is comprised of the operations of (i) Naples Women’s Center (“NWC”), a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology) and General Practice, (ii) Naples Center for Functional Medicine (“NCFM”), a Functional Medical Practice acquired in April 2019 that is engaged in improving the health of its patients through individualized and integrative health care, and (iii) Bridging the Gap Physical Therapy (“BTG”), a physical therapy practice in Bonita Springs, FL opened in January 2020 that provides hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery. The Digital Healthcare division develops and ~~plans to operate~~operates an online personal medical information and record archive system, the “HealthLynked Network,” which ~~will enable~~enables patients and doctors to keep track of medical information via the Internet in a cloud-based system. The ACO/MSO Division is comprised of the business acquired of Cura Health Management LLC (“CHM”) and its subsidiary ACO Health Partners LLC (“AHP”), which were acquired by the Company on May 18, 2020. CHM and AHP operate an Accountable Care Organization (“ACO”) and Managed Service Organization (“MSO”) that assists physician practices in providing coordinated and more efficient care to patients via the Medicare Shared Savings Program (“MSSP”) as administered by the Centers for Medicare and Medicaid Services (the “CMS”), which rewards providers for efficiency in patient care. The Medical Distribution Division is comprised of the operations of MedOffice Direct LLC (“MOD”), a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States acquired by the Company on October 19, 2020.

These unaudited condensed consolidated financial statements reflect all adjustments including normal recurring adjustments, which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the United States of America (“GAAP”). These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the years ended December 31, ~~2019~~2020 and ~~2018,~~2019, respectively, which are included in the Company’s Form 10-K, filed with the United States Securities and Exchange Commission on March ~~30, 2020.~~31, 2021. The Company assumes that the users of the interim financial information herein have read, or have access to, the audited consolidated financial statements for the preceding period, and that the adequacy of additional disclosure needed for a fair presentation may be determined in that context. The results of operations for the three ~~and nine~~ months ended ~~September 30, 2020~~March 31, 2021 are not necessarily indicative of results for the entire year ending December 31, ~~2020.~~2021.

On a consolidated basis, the Company’s operations are comprised of the parent company, HealthLynked Corp., and its ~~five~~six subsidiaries: NWC, NCFM, BTG, CHM, AHP and ~~AHP.~~MOD. All significant intercompany transactions and balances have been eliminated upon consolidation. In addition, certain amounts in the prior periods’ consolidated financial statements have been reclassified to conform to the current period presentation.

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES

A summary of the significant accounting policies applied in the presentation of the accompanying consolidated financial statements follows:

Basis of Presentation

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

All amounts referred to in the notes to the consolidated financial statements are in United States Dollars ($) unless stated otherwise.

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~SEPTEMBER 30, 2020~~MARCH 31, 2021
(UNAUDITED)

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about fair valuation of acquired intangible assets, cash flow and fair value assumptions associated with measurements of contingent acquisition consideration and impairment of intangible assets and goodwill, valuation of inventory, collection of accounts receivable, the valuation and recognition of stock-based compensation expense, valuation allowance for deferred tax assets, borrowing rate consideration for right-of-use (“ROU”) lease assets including related lease liability and useful life of fixed assets.

~~Adopted Accounting Pronouncements~~Revenue Recognition

Effective January 1, 2019, the Company adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases (“ASU 2016-02”) using the required modified retrospective approach. ASU 2016-02 requires lessees to record most leases on their balance sheets but recognize expenses on their income statements in a manner similar to current accounting. See discussion below under the caption “Leases” in this Note 2 and in Note 9 for more detail on the Company’s accounting policy with respect to lease accounting.
Effective January 1, 2019, the Company adopted ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees and supersedes the guidance in Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. The adoption of this guidance did not materially impact the Company’s financial statements and related disclosures.
~~Revenue Recognition~~
Patient service revenue

Patient service revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients and third-party payors (including health insurers and government programs) and ~~includes~~include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Company bills patients and third-party payors within days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected charges. The Company believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Company does not believe it is required to provide additional goods or services to the patient.

The Company determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. The Company determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients.

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment ~~arrangements~~arrangements with major third-party payors follows:

● Medicare: Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates.

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

● Medicaid: Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.

● Other: Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.
8
~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
~~NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)~~

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact, if any, such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims.

Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations.

The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Company estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Patient services provided by NCFM and BTG are provided on a cash basis and not submitted through third party insurance providers. Contract liabilities related to prepaid BTG patient service revenue were $54,369 and $35,779 as of March 31, 2021 and December 31, 2020, respectively.

Medicare Shared Savings Revenue

The Company earns Medicare shared savings revenue based on performance of the population of patient lives for which it is accountable as an ACO against benchmarks established by the MSSP. Because the MSSP, which was formed in 2012, is relatively new and has limited historical experience, the Company cannot accurately predict the amount of shared savings that will be determined by CMS. Such amounts are determined annually when the Company is notified by CMS of the amount of shared savings earned. Accordingly, the Company recognizes Medicare shared savings revenue in the period in which the CMS notifies the Company of the exact amount of shared savings to be paid, which historically has occurred during the ~~three-month period~~fiscal quarter ended September 30 for the program year ended December 31 of the previous year. The Company was notified of the amount of Medicare shared savings and received payment for such savings in September 2020. Accordingly, the Company recognized Medicare shared savings revenue of $767,744 in the ~~three and nine months~~year ended ~~September 30,~~December 31, 2020. Based on the ACO operating agreements, the Company bears all costs of the ACO operations until revenue is recognized. At that point, the Company shares in up to 100% of the revenue to recover its costs incurred. No revenue Medicare Shared Savings revenue was earned during the three months ended March 31, 2021 and 2020.

Consulting and Event Revenue

Also pursuant to ASC 606, the Company recognizes service revenue as services are provided, with any unearned but paid amounts recorded as a ~~deferred revenue~~contract liability at each balance sheet date.
~~Deferred Revenue~~
~~The Company’s deferred~~ Contract liabilities related to consulting revenue ~~liability balance was $51,714~~were $-0- and ~~$-0-~~$47,864 as of ~~September 30, 2020~~March 31, 2021 and December 31, ~~2019.~~2020, respectively. Event revenue, comprised of admission fees for summit events, is recognized when an event is held.

8
HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~SEPTEMBER 30, 2020~~MARCH 31, 2021
(UNAUDITED)

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Product Revenue
Revenue is derived from the distribution of medical products that are sourced from a third party. The Company recognizes revenue at a point in time when title transfers to customers and the Company has no further obligation to provide services related to such products, which occurs when the product ships. The Company is the principal in its revenue transactions and as a result revenue is recorded on a gross basis. The Company has determined that it controls the ability to direct the use of the product provided prior to transfer to a customer, is primarily responsible for fulfilling the promise to provide the product to its customer, has discretion in establishing prices, and ultimately controls the transfer of the product to the customer. Shipping and handling costs billed to customers are recorded in revenue. Contract liabilities related to product revenue were $12,690 and $5,782 as of March 31, 2021 and December 31, 2020, respectively. There were no contract assets as of March 31, 2021 or December 31, 2020.
Sales are made inclusive of sales tax, where such sales tax is applicable. Sales tax is applicable on sales made in the state of Florida, where the Company has physical nexus. The Company has determined that it does not have economic nexus in any other states. The Company does not sell products outside of the United States.
The Company maintains a return policy that allows customers to return a product within a specified period of time prior to and subsequent to the expiration date of the product. The Company analyzes the need for a product return allowance at the end of each period based on eligible products. Product return allowance was $24,264 and $26,839 and as of March 31, 2021 and December 31, 2020, respectively.
Contract Liabilities
Contract liabilities represent payments from customers for consulting services, patient services and medical products that precede the Company’s service or product fulfillment performance obligation. The Company’s contract liabilities balance was $67,059 and $89,425 as of March 31, 2021 and December 31, 2020, respectively.

Provider shared savings expense

Provider shared savings expense represents payments made to the ACO’s participating providers. The pool of provider shared savings expense paid to all participating providers, as well as the amounts paid to each individual participating provider from the pool, is determined by ACO management. Shared Savings expense is recognized in the period in which the size of the payment pool is determined, which typically corresponds to the period in which the shared saving payment is received from CMS and shared savings revenue is recognized. This typically occurs in the second half of the year following the completion of the program year. The Company was notified of the amount of Medicare shared savings and received payment for such savings in September 2020 totaling $767,744, of which $388,884 had been determined to provider shared savings expense that will be paid to the providers in the fourth quarter of 2020. This amount was recognized as provider shared savings expense and accrued as of September 30, 2020.

Cash and Cash Equivalents

For financial statement purposes, the Company considers all highly liquid investments with original maturities of three months or less to be cash and cash equivalents. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At March 31, 2021 and December 31, 2020, the Company had $3,087,985 and $18,227 in excess of the FDIC insured limit, respectively.

Accounts Receivable

Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers’ accounts receivable during the related period which generally approximates ~~48%~~48.1% of total billings. Trade accounts receivable are recorded at this net amount. As of and ~~September 30, 2020~~March 31, 2021 and December 31, ~~2019,~~2020, the Company’s gross patient services accounts receivable were ~~$190,492~~$233,107 and ~~$188,503,~~$165,464, respectively, and net patient services accounts receivable were ~~$97,819~~$112,125 and ~~$97,223,~~$71,655, respectively, based upon net reporting of accounts receivable. As of ~~September 30, 2020~~March 31, 2021 and December 31, ~~2019,~~2020, the Company’s allowance of doubtful accounts was $13,972 and $13,972, respectively. The Company also had ~~$109,897~~$13,180 and $15,498 accounts receivable related to amounts billed under consulting ~~contracts.~~contracts as of and March 31, 2021 and December 31, 2020, respectively.

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Leases

Upon transition under ASU 2016-02, the Company elected the suite of practical expedients as a package applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. For new leases, the Company will determine if an arrangement is or contains a lease at inception. Leases are included as ROU assets within other assets and ROU liabilities within accrued expenses and other liabilities and within other long-term liabilities on the Company’s consolidated balance sheets.

ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s leases do not provide an implicit rate. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company adopted ASU 2016-02 in the first quarter of 2019. See Note 98 for more complete details on balances as of the reporting periods presented herein. The adoption had no material impact on cash provided by or used in operating, investing or financing activities on the Company’s ~~unaudited condensed~~ consolidated statements of cash flows.

Inventory

Inventory consisting of supplements, is stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method. Outdated inventory is directly charged to cost of goods sold.

Goodwill and Intangible Assets

Goodwill is recognized as the excess cost of an acquired entity over the net amount assigned to assets acquired and liabilities assumed. Goodwill is not amortized, but rather tested for impairment on an annual basis and more often if circumstances require. Impairment losses are recognized whenever the implied fair value of goodwill is less than its carrying value.

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
~~NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)~~

The Company recognizes an acquired intangible apart from goodwill whenever the intangible arises from contractual or other legal rights, or whenever it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their estimated useful lives unless the estimated useful life is determined to be indefinite. Amortizable intangible assets are being amortized primarily over useful lives of five years. The straight-line method of amortization is used as it has been determined to approximate the use pattern of the assets. Impairment losses are recognized if the carrying amount of an intangible that is subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value.

The Company also maintains intangible assets with indefinite lives, which are not amortized. These intangibles are tested for impairment on an annual basis and more often if circumstances require. Impairment losses are recognized whenever the implied fair value of these assets is less than their carrying value. No impairment charges were recognized in the three ~~or nine~~ months ended ~~September 30, 2020~~March 31, 2021 or ~~2019.~~2020.

Concentrations of Credit Risk

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts. The Company relies on a sole supplier for the fulfillment of all of its product sales made through MOD, which was acquired by the Company in October 2020.

Property and Equipment

Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized.

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. ~~There was no impairment as of or for the periods ended September 30, 2020 or 2019.~~

Convertible Notes

Convertible notes are regarded as compound instruments, consisting of a liability component and an equity component. The component parts of compound instruments are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. This amount is recorded as a liability on an amortized cost basis until extinguished upon conversion or at the instrument’s maturity date. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized as additional paid-in capital and included in equity, net of income tax effects, and is not subsequently remeasured. After initial measurement, they are carried at amortized cost using the effective interest method. Convertible notes for which the maturity date has been extended and that qualify for debt extinguishment treatment are recorded at fair value on the extinguishment date and then ~~revalue~~revalued at the end of each reporting period, with the change recorded to the statement of operations under “Change in Fair Value of Debt.”

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
~~NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)~~

Derivative Financial Instruments

The Company reviews the terms of convertible debt, equity instruments and other financing arrangements to determine whether there are embedded derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Also, in connection with the issuance of financing instruments, the Company may issue freestanding options or warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. Derivative financial instruments are initially measured at their fair value. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. To the extent that the initial fair values of the freestanding and/or bifurcated derivative instrument liabilities exceed the total proceeds received, an immediate charge to income is recognized, in order to initially record the derivative instrument liabilities at their fair value. The discount from the face value of convertible debt instruments resulting from allocating some or all of the proceeds to the derivative instruments is amortized over the life of the instrument through periodic charges to income.

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. If reclassification is required, the fair value of the derivative instrument, as of the determination date, is reclassified. Any previous charges or credits to income for changes in the fair value of the derivative instrument are not reversed. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.

Fair Value of Assets and Liabilities

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs:

● Level 1 – Fair value based on quoted prices in active markets for identical assets or liabilities;

● Level 2 – Fair value based on significant directly observable data (other than Level 1 quoted prices) or significant indirectly observable data through corroboration with observable market data. Inputs would normally be (i) quoted prices in active markets for similar assets or liabilities, (ii) quoted prices in inactive markets for identical or similar assets or liabilities or (iii) information derived from or corroborated by observable market data;

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
● Level 3 – Fair value based on prices or valuation techniques that require significant unobservable data inputs. Inputs would normally be a reporting entity’s own data and judgments about assumptions that market participants would use in pricing the asset or liability.

The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs.

Prior to January 1, 2020, the Company utilized the closed-form Black-Scholes option pricing model to estimate the fair value of options, warrants, beneficial conversion features and other Level 3 financial assets and liabilities. Effective January 1, 2020, the Company changed to a binomial lattice option pricing model. The Company believes that the binomial lattice model results in a better estimate of fair value because it embodies all of the requisite assumptions (including the underlying price, exercise price, term, volatility, and risk-free interest-rate) necessary to fair value these instruments and, unlike the Black-Scholes model, also accommodates assumptions regarding investor exercise behavior and other market conditions that market participants would likely consider in negotiating the transfer of such an instruments.

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
~~NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)~~

Stock-Based Compensation

The Company accounts for stock-based compensation to employees and nonemployees under ASC 718 “Compensation – Stock Compensation” using the fair value-based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. Effective January 1, 2020, the Company uses a binomial lattice pricing model to estimate the fair value of options and warrants granted. In prior periods, the Company used the Black-Scholes pricing model.

Income Taxes

The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. No Income Tax has been provided for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2021 or 2020, ~~or 2019,~~ since the Company has sustained a loss for both periods. Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, management has determined a full valuation allowance for the deferred tax assets, since it is more likely than not that the deferred tax assets will not be realizable.

Recurring Fair Value Measurements

The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of cash held as demand deposits, money market and certificates of deposit, marketable investments, accounts receivable, short-term borrowings, accounts payable, accrued liabilities, and derivative financial instruments approximated their fair value.

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Deemed ~~dividend~~Dividend

The Company incurs a deemed dividend on Series B Convertible Preferred Voting Stock (the “Series B Preferred”). As the intrinsic price per share of the Series B Preferred was less than the deemed fair value of the Company’s common stock on the date of issuance of the Series B Preferred, the Series B Preferred contains a beneficial conversion feature as described in FASB ASC 470-20, “Debt with Conversion and Other Options.” The difference in the stated conversion price and estimated fair value of the common stock is accounted for as a beneficial conversion feature and affects income or loss available to common stockholders for purposes of earnings per share available to common stockholders. The Company incurs further deemed dividends on certain of its warrants containing a down round provision equal to the difference in fair value of the warrants before and after the triggering of the down round adjustment.

Net Loss per Share

Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the years three ~~and nine~~ months ended ~~September 30,~~March 31, 2021 and 2020, ~~and 2019,~~ the Company reported a net loss and excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of ~~September 30, 2020~~March 31, 2021 and December 31, ~~2019,~~2020, potentially dilutive securities were comprised of (i) ~~50,470,118~~59,742,034 and ~~47,056,293~~51,352,986 warrants outstanding, respectively, (ii) ~~3,249,250~~3,066,750 and ~~3,269,250~~3,111,750 stock options outstanding, respectively, (iii) ~~10,298,333~~-0- and ~~23,210,423~~10,298,333 shares issuable upon conversion of convertible notes, respectively, (iv) ~~300,000~~200,000 and ~~332,500~~200,000 unissued shares subject to future vesting requirements granted pursuant to the Company’s Employee Incentive Plan, and (v) up to 13,750,000 and 13,750,000 shares of common stock issuable upon conversion of Series B Preferred.

Common stock awards

The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded on the consolidated statement of comprehensive loss in the same manner and charged to the same account as if such settlements had been made in cash.

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
~~NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)~~

Warrants

In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes pricing model as of the measurement date. Effective January 1, 2020, the Company uses a binomial lattice pricing model to estimate the fair value of compensation options and warrants. In prior periods, the Company used the Black-Scholes pricing model. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period or at the date of issuance, if there is not a service period. ~~Warrants~~Certain of the Company’s warrants include a so-called down round provision. The Company accounts for such provisions pursuant to ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging, which calls for the recognition of a deemed dividend in the amount of the incremental fair value of the warrant due to the down round when triggered, warrants granted in connection with ongoing arrangements are more fully described in Note ~~15,~~14, Shareholders’ Equity ~~(Deficit)~~.

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Business Segments

The Company uses the “management approach” to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. Using the management approach, the Company determined that it has ~~three~~four operating segments: Health Services (multi-specialty medical group including the NWC OB/GYN practice, the NCFM practice acquired in April 2019 and the BTG physical therapy practice launched in 2020), Digital Healthcare (develops and markets the “HealthLynked Network,” an online personal medical information and record archive system), ~~and~~ ACO/MSO (comprised of the ACO/MSO business acquired with CHM in May 2020, which assists physician practices in providing coordinated and more efficient care to patients via the MSSP), and Medical Distribution (comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices acquired by the Company on October 19, 2020).

Recent Accounting Pronouncements

~~Effective January 1,~~In December 2019, the ~~Company adopted~~FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting ~~Standards Update (“ASU”) No. 2016-02, Leases~~for Income Taxes (“ASU ~~2016-02”~~2019-12”) ~~using~~. ASC 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the ~~required modified retrospective approach. ASU 2016-02 requires lessees~~disclosure requirements of income taxes. The standard is effective for public companies with fiscal years beginning after December 15, 2020, with early adoption permitted. The Company does not expect the adoption of this standard to ~~record most leases~~have a material impact on their balance sheets but recognize expenses on their income statements in a manner similar to current accounting. See discussion below under the caption “Leases” in this Note 2 and in Note 9 for more detail on the Company’s accounting policy with respect to lease accounting.its consolidated financial statements.

~~Effective January~~In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) (“ASU 2016-13”) which introduces new guidance for the accounting for credit losses on certain instruments within its scope. ASU 2016-13 introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. For trade receivables, the Company will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses, which reflects losses that are probable. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. On July 1, ~~2019,~~2020, the Company adopted ASU ~~2018-07, Compensation~~2016-13 under the modified retrospective approach by initially applying ASU 2016-13 at the adoption date, rather than at the beginning of the earliest comparative period presented. This guidance was adopted with no material impact to the Company’s consolidated financial statements.
In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other - ~~Stock Compensation~~Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software, including hosting arrangements that include an internal-use software license. This guidance was adopted with no material impact to the Company’s consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic ~~718)~~820): ~~Improvements~~Disclosure Framework – Changes to ~~Nonemployee Share-Based Payment Accounting. ASU 2018-07 expands~~ the ~~scope of Topic 718~~Disclosure Requirements for Fair Value Measurement, (ASU 2018-13). The new standard removes certain disclosures, modifies certain disclosures and adds additional disclosures related to ~~include share-based payment transactions for acquiring goods and services from nonemployees and supersedes the guidance in Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees.~~fair value measurement. The new standard became effective on January 1, 2020. The adoption of this guidance did not ~~materially~~have a material impact on the Company’s consolidated financial ~~statements and related disclosures.~~statements.

In ~~January 2016,~~August 2018, the FASB issued ASU ~~No. 2016-01,~~ ~~Financial Instruments — Overall: Recognition and Measurement~~2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.” The ASU clarifies certain aspects of ~~Financial Assets and Financial Liabilities.~~ASU 2015-05, “Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement,” which was issued in April 2015. Specifically, the ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license).” The ~~guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance~~ASU is effective ~~in the first quarter of~~for fiscal ~~2019. We~~years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. The Company adopted this guidance effective January 1, ~~2019.~~2020. The adoption of this guidance did not ~~materially~~have a material impact ~~our~~on the consolidated financial ~~statements and related disclosures.~~
~~In July 2017, the FASB issued ASU No. 2017-11,~~ ~~Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging~~, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December 15, 2018, and interim periods within those periods. We adopted this guidance effective January 1, 2019. The adoption of this guidance did not materially impact our financial statements and related disclosures.
In February 2018, the Financial Accounting Standards Board (“FASB”) issued ASC Update No 2018-02 (Topic 220) Income Statement – Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This ASC update allows for a reclassification into retained earnings of the stranded tax effects in accumulated other comprehensive income (“AOCI”) resulting from the enactment of the Tax Cuts and Jobs Act (“TCJA”). The updated guidance is effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance effective January 1, 2019. The adoption of this guidance did not materially impact our financial statements and related disclosures.
statements.
14

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~SEPTEMBER 30, 2020~~MARCH 31, 2021
(UNAUDITED)

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

In ~~June~~November 2018, the FASB issued ASU ~~2018-07, Compensation - Stock Compensation~~No. 2018-18, Collaborative Arrangements (Topic ~~718)~~808): ~~Improvements~~Clarifying the Interaction between Topic 808 and Topic 606. The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to ~~Nonemployee Share-Based Payment Accounting,~~sales to ~~expand~~third parties together with revenue. This guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The guidance per ASU 2018-18 is to be adopted retrospectively to the ~~scope~~date of initial application of Topic ~~718 to include share-based payment transactions for acquiring goods and services from nonemployees and supersedes the~~606. The Company adopted ASU 2018-18 on January 1, 2020. The adoption of this guidance ~~in Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. Under ASU 2018-07, equity-classified nonemployee share-based payment awards are measured at the grant date fair value~~did not have a material impact on the ~~grant date The probability of satisfying performance conditions must be considered~~Company’s consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12 Simplifying the Accounting for ~~equity-classified nonemployee share-based payment awards with such conditions.~~Income Taxes, which eliminates the need for an organization to analyze whether the following apply in a given period: (1) exception to the incremental approach for intra-period tax allocation; (2) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (3) exceptions in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU ~~2018-07~~No. 2019-12 is effective for fiscal years beginning after December 15, ~~2018, with early adoption permitted. We adopted~~2020, and interim periods within those fiscal years. The Company does not expect that this ~~guidance effective January 1, 2019. The adoption of this guidance did not materially impact our~~standard will have a material effect on its consolidated financial ~~statements and related disclosures.~~statements.

In ~~July 2018,~~March 2020, the FASB issued ASU ~~2018-09~~2020-03, “Codification Improvements to ~~provide clarification and correction of errors to the Codification.~~Financial Instruments”: The amendments in this update ~~cover multiple Accounting Standards Updates. Some~~are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the ~~update may require transition guidance with~~Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective ~~dates~~ for ~~annual periods~~smaller reporting companies for fiscal years beginning after December 15, ~~2018. We adopted this guidance effective January 1, 2019.~~2022 with early application permitted. The Company is currently evaluating the impact the adoption of this guidance ~~did not materially~~may have on its consolidated financial statements.
In August 2020, the FASB issued ASU 2020-06 Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) related to the measurement and disclosure requirements for convertible instruments and contracts in an entity’s own equity. The pronouncement simplifies and adds disclosure requirements for the accounting and measurement of convertible instruments and the settlement assessment for contracts in an entity’s own equity. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2021 and early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact ~~our~~that this standard will have on its consolidated financial ~~statements and related disclosures.~~statements.

No other new accounting pronouncements were issued or became effective in the period that had, or are expected to have, a material impact on our ~~unaudited condensed~~ consolidated Financial Statements.

NOTE 3 – ~~GOING CONCERN MATTERS AND~~ LIQUIDITY

As of ~~September 30, 2020,~~March 31, 2021, the Company had acash balances of $3,341,728, working capital ~~deficit~~ of ~~$1,979,983~~$1,085,131 and accumulated deficit ~~$19,862,013.~~$29,608,363. For the ~~nine~~three months ended ~~September 30, 2020,~~March 31, 2021, the Company had a net loss of ~~$3,896,221~~$7,823,453 and net cash used by operating activities of ~~$1,094,495.~~$1,216,959. Net cash ~~provided by~~used in investing activities was ~~$2,425,870, including $2,740,806 received from the sale of marketable securities received in an August 2020 financing transaction.~~$7,399. Net cash provided by financing activities was ~~$271,308, resulting principally~~$4,403,902, including $4,389,361 received from ~~$1,045,669 proceeds from loans~~sales of common stock in private placement transactions and ~~grants issued by~~puts pursuant to the ~~federal government under the Payroll Protection Act, $827,500 net~~July 2016 $3 million investment agreement (the “Investment Agreement”) and $65,650 proceeds from the ~~issuance~~exercise of stock options and warrants. During January 2021, the holder of $1,038,500 fixed rate convertible debt converted the entire face value of $1,038,500, plus $317,096 of accrued interest on such notes, ~~and $149,000 proceeds from~~into 13,538,494 shares of common stock pursuant to the ~~issuance~~original conversion terms of ~~related party loans.~~the underlying notes. The carrying value of the converted debt at the time of conversion, which equaled its fair value, was $1,355,596. Following the conversion, the Company ~~also repaid $1,882,405 of~~had no further convertible ~~notes and $967,756 of related party loans during 2020.~~debt outstanding.

The ~~Company’s cash balance~~Company intends that the longer term (i.e., beyond twelve months) cost of completing additional intended acquisitions, implementing its development and revenues generated are not currently sufficient and cannot be projected to cover its operating expenses for the next twelve months from the date of this report. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans include attempting to improve its business profitability and its ability to generate sufficient cash flow from its operations to meet its needs on a timely basis, obtaining additional working capital funds through equity and debt financing arrangements, and restructuring on-going operations to eliminate inefficiencies to raise cash balance in order to meet its anticipated cash requirements for the next twelve months from the date of this report. However, there can be no assurance that these plans and arrangements will be sufficient to fund the Company’s ongoing capital expenditures, working capital, and other requirements. Management intends to make every effort to identify and develop sources of funds. The outcome of these matters cannot be predicted at this time. There can be no assurance that any additional financings will be available to the Company on satisfactory terms and conditions, if at all.
The ability of the Company to continue as a going concern is dependent upon its ability to raise additional capital and achieve profitable operations. The accompanying consolidated financial statements do not include any adjustmentssales efforts related to the ~~recoverability or classification~~HealthLynked Network and maintaining existing and expanding overhead and administrative costs will be financed from (i) cash on hand resulting from fund raising efforts in 2021, (ii) profits generated by NCFM, BTG and CHM (including expected Medicare Shared Savings revenue projected to be received annually in the third fiscal quarter of ~~asset-carrying amounts or~~each year), and (iii) the ~~amounts and classification~~use of ~~liabilities~~further outside funding sources. No assurances can be given that ~~may result should~~ the Company will be ~~unable~~able to ~~continue as~~access additional outside capital in a ~~going concern.~~ timely fashion. If necessary funds are not available, the Company’s business and operations would be materially adversely affected and in such event, the Company would attempt to reduce costs and adjust its business plan.

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 3 – LIQUIDITY (CONTINUED)

A novel strain of coronavirus, COVID-19, that was first identified in China in December 2019, has surfaced in several regions across the world and resulted in travel restrictions and business slowdowns or shutdowns in affected areas. In March 2020, the World Health Organization declared the outbreak of COVID-19 a pandemic. The outbreak of the pandemic is materially adversely affecting the Company’s employees, patients, communities and business operations, as well as the U.S. economy and financial markets. The further spread of COVID-19, and the requirement to take action to limit the spread of the illness, may impact our ability to carry out our business as usual and may materially adversely impact global economic conditions, our business and financial condition, including our potential to conduct financings on terms acceptable to us, if at all. The extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
~~NOTE 3 – GOING CONCERN MATTERS AND LIQUIDITY (CONTINUED)~~
~~The Company intends that the cost of completing intended acquisitions, implementing its development and sales efforts related~~In response to the HealthLynked Network, maintaining existing and expanding overhead and administrative costs, and repaying its outstanding convertible notes, which have an aggregate face value of $1,038,500 as of September 30, 2020, will be financed from (i) anticipated profits generated by NCFM, CHM and AHP, and MOD, which was acquired in October 2020, and (ii) outside funding sources, including the put rights associated with the Investment Agreement entered into in July of 2016 (the “Investment Agreement”), sales of common stock, government loans and issuance of additional convertible notes. In May 2020, the Investment Agreement, which was scheduled to expire on May 15, 2020, was extended an additional two years to May 15, 2022. No assurances can be given thatCOVID-19, the Company ~~will be able to access sufficient outside capital~~implemented additional safety measures in ~~a timely fashion in order to repay the convertible notes before they mature. If necessary funds are not available, the Company’s business~~its patient services locations and ~~operations would be materially adversely affected and in such event, the Company would attempt to reduce costs and adjust~~ its ~~business plan.~~corporate headquarters.

NOTE 4 ~~– MARKETABLE SECURITIES~~
On August 20, 2020, the Company entered into a contribution agreement (the “Contribution Agreement”) with Michael T. Dent, Trustee of the Mary S. Dent Gifting Trust dated January 31, 2006 (the “Gifting Trust”), Michael Thomas Dent, Trustee under the Michael Thomas Dent Declaration of Trust dated March 23, 1998, as amended (the “MTD Trust” and together with the Gifting Trust, the “Trusts”), and Michael T. Dent, the Chief Executive Officer and Chairman of the board of directors of the Company. Pursuant to the Contribution Agreement, the Trusts contributed an aggregate of 76,026 freely trading shares of common stock of NeoGenomics, Inc. (“NEO” and the “NEO Shares”) (NASD:NEO) with a fair value of $3,006,889 to the Company. In consideration for the foregoing, the Company issued the Trusts an aggregate of 2,750,000 shares of the Company’s newly designated Series B Preferred stock and an aggregate of 24,522,727 shares of the Company’s common stock (collectively, the “August 2020 Equity Transaction”).
During the three and nine months ended September 30, 2020, the Company sold 74,900 of the NEO Shares and received proceeds of $2,740,806, realizing losses of $281,606. As of September 30, 2020, the Company held 1,126 NEO Shares with a fair value of $44,477.
~~NOTE 5~~ – ACQUISITIONS

Hughes Center for Functional Medicine – April 2019

On April 12, 2019, the Company acquired a 100% interest in Hughes Center for Functional Medicine (“HCFM”), a medical practice engaged in improving the health of its patients through individualized and integrative health care. Under the terms of acquisition, the Company paid HCFM shareholders $500,000 in cash, issued 3,968,254 shares of the Company’s common stock and agreed to an earn-out provision of $500,000 that may be earned based on the performance of HCFM in the years ended on the first, second and third anniversary dates of the acquisition closing. The total consideration fair value represents a transaction value of $1,799,672. The Company accounted for the transaction as an acquisition of a business pursuant to ASC 805, “Business Combinations” (“ASC 805”).

Following the acquisition, HCFM was rebranded as NCFM and was combined with NWC to form the Company’s Health Services segment. As a result of the acquisition, the Company is expected to be a leading provider of Functional Medicine in Southwest Florida. The Company also expects to reduce costs in its Health Services segment through economies of scale.

The total consideration fair value represents a transaction value of $1,764,672. The following table summarizes the fair value of consideration ~~paid for HCFM:~~paid:

Cash $ 500,000
Common Stock (3,968,254 shares) 1,000,000
Contingent acquisition consideration subject to earn-out 299,672

Fair Value of Total Consideration $ 1,799,672

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
~~NOTE 5 – ACQUISITIONS (CONTINUED)~~
Cash $ 500,000
Common Stock (3,968,254 shares) 1,000,000
Fair Value of Contingent Acquisition Consideration 299,672
Less cash received (35,000 )

Fair Value of Total Consideration $ 1,764,672

The fair value of the 3,968,254 common shares issued as part of the acquisition consideration was determined using the intraday volume weighted average price of the Company’s common shares on the acquisition date. The terms of the earn out require the Company to pay the former owner of HCFM up to $100,000, $200,000 and $200,000 on the first, second and third anniversary, respectively, based on achievement by NCFM of revenue of at least $3,100,000 (50% weighting) and EBITDA of at least $550,000 (50% weighting) in the year preceding each anniversary date. The fair value of the contingent acquisition consideration related to the future earn-out payments was calculated using a probability-weighted discounted cash flow projection. The fair value of the contingent acquisition consideration is remeasured at the end of each reporting period and changes are included in the statement of operations under the caption “Change in fair value of contingent acquisition consideration.” During the three months ended ~~September 30,~~March 31, 2021 and 2020, and 2019, the Company recognized losses on the change in the fair value of contingent acquisition consideration related to the HCFM acquisition of $1,185 and $-0-, respectively. During the nine months ended September 30, 2020 and 2019, the Company recognized losses on the change in the fair value of contingent acquisition consideration of ~~$12,512~~$11,308 and ~~$-0-,~~$6,621, respectively. ~~During the nine months ended September 30, 2020, the Company paid the seller $47,000 in satisfaction of the first year of earn-out.~~

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 4 – ACQUISITIONS (CONTINUED)

The following table summarizes the estimated fair values of the assets acquired at the acquisition date. There were no liabilities assumed in the acquisition of HCFM.

Cash $ 35,000
Hyperbaric Chambers 452,289 $ 452,289
Medical Equipment 29,940 29,940
Computer Equipment/Software 19,739 19,739
Office Furniture & Equipment 23,052 23,052
Inventory 72,114 72,114
Leasehold Improvements 25,000 25,000
Website 41,000 41,000
Patient Management Platform Database 1,101,538 1,101,538

Fair Value of Identifiable Assets Acquired $ 1,799,672 $ 1,764,672

The fair value of the website of $41,000 was determined based upon the cost to reconstruct and put into use applying current market rates. The fair value of the Patient Management Platform Database of $1,101,538 was estimated by applying the income approach. Under the income approach, the expected future cash flows generated by the Patient Management Platform Database are estimated and discounted to their net present value at an appropriate risk-adjusted rate of return. Significant factors considered in the calculation of the rate of return are the weighted average cost of capital and return on assets, as well as the risks inherent in the business. Cash flows were estimated based on EBITDA using forecasted revenue and costs. The measure is based on significant inputs that are not observable in the market (i.e. Level 3 inputs). Key assumptions include (i) a capitalization rate of 11.75% (ii) sustainable growth of 5% and (iii) a benefit stream using EBITDA cash flow. The Company finalized the purchase price allocation in March 2020 and determined that no goodwill was included in the acquisition.

Cura Health Management LLC – May 2020

On May 18, 2020, the Company acquired a 100% interest in ~~Cura Health Management LLC (“CHM”)~~CHM and its wholly owned subsidiary ~~ACO Health Partners, LLC (“AHP”).~~AHP. CHM and AHP assist physician practices in providing coordinated and more efficient care to patients via the MSSP. The Company accounted for the transaction as an acquisition of a business pursuant to ASC ~~805, “Business Combinations” (“ASC 805”).~~805. Following the acquisition, the business of CHM ~~will comprise~~comprised the Company’s ACO/MSO Division.

Under the terms of acquisition, the Company paid CHM shareholders the following consideration: (i) $214,000 in cash paid at closing, (ii) 2,240,838 shares of HealthLynked common stock issued at closing, (iii) up to $223,500 additional cash and $660,000 in additional shares of HealthLynked common payable at the time CHM receives the final assessment of the calculation of MSSP savings for the 2019 program year, with this amount prorated based on a target MSSP payment (plus other ancillary revenue) of $1,725,000, and (iv) up to $437,500 based on the business achieving annual revenue of $2,250,000 and annual profit of $500,000 in each of the four years following closing.

The total consideration fair value represents a transaction value of $1,423,465. The following table summarizes the fair value of consideration paid:
Cash paid at closing $ 214,000
Shares issued at closing (2,240,838 shares) 201,675
Cash and shares contingent upon 2019 program year MSSP payment target 778,192
Cash contingent upon four-year earn-out 279,593
Less cash received (49,995 )

$ 1,423,465

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~SEPTEMBER 30, 2020~~MARCH 31, 2021
(UNAUDITED)

NOTE 54 – ACQUISITIONS (CONTINUED)
~~The total consideration fair value represents a transaction value of $1,473,460. The following table summarizes the fair value of consideration paid:~~
Cash paid at closing $ 214,000
Shares issued at closing 201,675
Cash and shares contingent upon 2019 program year MSSP payment target 778,192
Cash contingent upon four-year earn-out 279,593

$ 1,473,460

The fair value of the 2,240,838 common shares issued at closing was determined using the intraday average high and low trading price of the Company’s common shares on the acquisition date. The terms of the earn out require the Company to pay the former owners of CHM (i) up to $223,500 additional cash and to $660,000 of additional shares of Company common stock when CHM receives the final assessment of the calculation of 2019 plan year MSSP revenue (the “Current Earnout”), and (ii) up to $62,500, $125,000, $125,000 and $125,000 on the first, second, third and fourth anniversary, respectively, based on achievement by the underlying business of revenue of at least $2,250,000 (50% weighting) and profit of at least $500,000 (50% weighting) in the year preceding each anniversary date (the “Future Earnout”). During September 2020, pursuant to a Second Amendment to the Agreement and Plan of Merger and in satisfaction of the Current Earnout, the Company paid $90,389 cash, issued 1,835,625 shares and agreed that the balance of the Current Earnout that was not earned in 2020, being $124,043 cash and $366,300 in shares of Company common stock, would be deferred until the first future earnout year in which MSSP revenue exceeds $1.725 million and revenue from other services exceeds $605,000.

The fair value of the contingent acquisition consideration related to both the Current Earnout and the Future Earnout were calculated using a probability-weighted discounted cash flow projection. The fair value of the contingent acquisition consideration is remeasured at the end of each reporting period and changes are included in the statement of operations under the caption “Change in fair value of contingent acquisition consideration.” During the three months ended ~~September 30,~~March 31, 2021 and 2020, ~~and 2019,~~ the Company recognized ~~gains~~losses on the change in the fair value of contingent acquisition consideration ~~related to the CHM acquisition~~ of $47,181 and $-0-, respectively. During the nine months ended September 30, 2020 and 2019, the Company recognized gains on the change in the fair value of contingent acquisition consideration related to the CHM acquisition of $13,200$33,252 and $-0-, respectively.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:

Cash $ 49,995
Accounts receivable 90,197 $ 90,197
Prepayments 15,294 15,294
ACO physician contracts 1,073,000 1,073,000
Goodwill 381,856 381,856
Accounts payable (32,846 ) (32,848 )
Deferred revenue (104,034 ) (104,034 )

Fair Value of Identifiable Assets Acquired and Liabilities Assumed $ 1,473,460 $ 1,423,465

The fair value of the ACO Physician Contracts of $1,073,000 was estimated by applying the income approach. Under the income approach, the expected future cash flows generated by the ACO Physician Contracts are estimated and discounted to their net present value at an appropriate risk-adjusted rate of return. Significant factors considered in the calculation of the rate of return are the weighted average cost of capital and return on assets, as well as the risks inherent in the business. Cash flows were estimated based on EBITDA using forecasted revenue and costs. The measure is based on significant inputs that are not observable in the market (i.e. Level 3 inputs). Key assumptions include (i) a capitalization rate of 24.24% (ii) sustainable growth of 5.00% and (iii) a benefit stream using EBITDA cash flow. Goodwill of $381,856 arising from the acquisition consists of value associated with the legacy name. None of the goodwill recognized is expected to be deductible for income tax purposes.

MedOffice Direct LLC – October 2020
On October 19, 2020, the Company acquired a 100% interest in MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States. With over 13,000 name brand medical products in over 150 different categories, MOD leverages pricing discounts with a small unit-of-measure direct-to-consumer shipping model to make ordering medical supplies more convenient and cost effective for its users. The Company accounted for the transaction as an acquisition of a business pursuant to ASC 805. Following the acquisition, the business of MOD comprised the Company’s Medical Distribution Division.
Under the terms of acquisition, the Company paid the following consideration: (i) 19,045,563 shares of Company common stock issued at closing, (ii) partial satisfaction of certain outstanding debt obligations of MOD in the amount of $703,200 in cash paid by the Company, and (iii) up to 10,004,749 restricted shares of the Company’s common stock over a four-year period based on MOD achieving prescribed revenue targets in calendar years 2021 through 2024.
18
HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 4 – ACQUISITIONS (CONTINUED)
Dr. Michael Dent, the Chief Executive Officer and the Chairman of the Board of Directors of the Company, George O’Leary, the Chief Financial Officer and a director of the Company, and Robert Gasparini, a director of the Company, were members of MOD and received consideration in connection with Company’s acquisition of MOD as follows: (1) Dr. Dent received 10,573,745 Company common shares at closing, may earn up to 5,554,452 additional Company common shares pursuant to the earn-out, and received $457,200 cash repayment of debt, (2) Mr. O’Leary received 1,130,213 Company common shares at closing, may earn up to 593,707 additional Company common shares pursuant to the earn-out, and received $66,000 cash repayment of debt, and (3) Mr. Gasparini received 99,437 Company common shares at closing and may earn up to 52,235 additional Company common shares pursuant to the earn-out.
The total consideration fair value represents a transaction value of $3,999,730. The following table summarizes the fair value of consideration paid:
Shares issued at closing (19,045,563 shares) $ 2,704,470
Payment of MOD debt obligations in cash 703,200
Shares contingent upon four-year earn-out 649,108
Less cash received (57,048 )

$ 3,999,730
The fair value of the 19,045,563 common shares issued at closing was determined using the average closing price for the five days prior to the closing date of October 19, 2020. The terms of the earn out require the Company to issue to the former equity members of MOD up to 1,9688,448 shares, 3,154,264 shares, 2,631,195 shares and 2,250,842 shares, respectively, (the “MOD Earnout Shares”) based on achievement by the underlying business of revenue of at least $1,500,000 in 2021, $1,875,000 in 2022, $2,344,000 in 2023 and $2,930,000 in 2024. The MOD Earnout Shares are issuable by April 30 of the year following the measurement year.
The fair value of the contingent acquisition consideration related to the MOD Earnout Shares was calculated using a probability-weighted discounted cash flow projection. The fair value of the contingent acquisition consideration is remeasured at the end of each reporting period and changes are included in the statement of operations under the caption “Change in fair value of contingent acquisition consideration.” During the three months ended March 31, 2021 and 2020, the Company recognized losses on the change in the fair value of contingent acquisition consideration related to the MOD Earnout Shares of $591,140 and $-0-, respectively.
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:
Website $ 3,538,000
Goodwill 766,249
Accounts payable and accruals (160,762 )
Notes payable (90,759 )
Deferred revenue (52,998 )

Fair Value of Identifiable Assets Acquired and Liabilities Assumed $ 3,999,730
The fair value of the website of $3,538,000 was estimated by applying the income approach. Under the income approach, the expected future cash flows generated by the asset are estimated and discounted to their net present value at an appropriate risk-adjusted rate of return. Significant factors considered in the calculation of the rate of return are the weighted average cost of capital and return on assets, as well as the risks inherent in the business. Cash flows were estimated based on EBITDA using forecasted revenue and costs. The measure is based on significant inputs that are not observable in the market (i.e. Level 3 inputs). Key assumptions include (i) a discount rate of 23.48% (ii) sustainable growth of 3.00% and (iii) a benefit stream using EBITDA cash flow. The website is being amortized over a five-year expected life. Goodwill of $766,249 arising from the acquisition consists of value associated with the legacy name. None of the goodwill recognized is expected to be deductible for income tax purposes.
19

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~SEPTEMBER 30, 2020~~MARCH 31, 2021
(UNAUDITED)

NOTE 5 – ~~ACQUISITIONS (CONTINUED)~~
~~Pro Forma Financial Information~~
The following represents the pro forma consolidated income statement as if HCFM and CHM had been included in the consolidated results of the Company for the entire nine-month period ending September 30, 2020 and 2019:
Nine Months Ended
September 30,
2020 2019
Revenue $ 4,740,283 $ 3,741,591
Net loss $ (3,846,293 ) $ (2,994,648 )
These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of HCFM and CHM to reflect the additional depreciation and amortization that would have been charged assuming the fair value adjustments to property, plant and equipment and intangible assets had been applied on January 1, 2020 and 2019, respectively.
~~NOTE 6 – DEFERRED OFFERING COSTS~~PREPAID EXPENSES AND ~~PREPAID EXPENSES~~OTHER

On March 22, 2017, the Company granted to the ~~Investor~~investor in the Investment Agreement warrants to purchase 4,000,000 shares at $0.25 per share, 2,000,000 shares at $0.50 per share and 1,000,000 shares at $1.00 per share. On June 7, 2017, the Company also granted warrants to purchase 200,000 shares at $0.25 per share, 100,000 shares at $0.50 per share and 50,000 shares at $1.00 per share to an advisor as a fee in connection with the Investment Agreement. The aggregate fair value of these warrants totaling $153,625 was recorded as a deferred offering cost and ~~is being~~was amortized over the initial period during which the Company was able access the financing, which began on May 15, 2017 and ended on May 15, 2020. The Company recognized general and administrative expense related to the cost of the warrants of $-0- and $12,802 in the three months ~~ended September 30,~~ending March 31, 2021 and 2020, ~~and 2019, respectively, and $19,203 and $38,46 in the nine months ended September 30, 2020 and 2019,~~ respectively.
On December 6, 2018, the Company granted three-year warrants to purchase 240,000 shares at an exercise price of $0.20 per share to two advisors for services to be provided over a three-month period. The fair value of the warrants of $35,462 was amortized over a three-month service period. During the three months ended September 30, 2020 and 2019, the Company recognized $-0- and $25,611, respectively, to general and administrative expense related to the warrants. The Company recognized general and administrative expense related to the warrants of $-0- and $-0- in the three months ended September 30, 2020 and 2019, respectively, and $-0- and $25,611 in the nine months ended September 30, 2020 and 2019, respectively.

NOTE 76 – PROPERTY, PLANT, AND EQUIPMENT

Property, plant and equipment at ~~September 30, 2020~~March 31, 2021 and December 31, ~~2019 are~~2020 were as follows:

September 30, December 31, March 31, December 31,
2020 2019 2021 2020

Capital lease equipment $ --- $ 251,752
Medical equipment 484,126 482,229 $ 484,126 $ 484,126
Furniture, telephone and office equipment 792,519 529,123
Furniture, office equipment and leasehold improvements 138,017 130,617

Total property, plant and equipment 1,276,645 1,263,104 622,143 614,743
Less: accumulated depreciation (817,971 ) (749,316 ) (204,353 ) (177,457 )

Property, plant and equipment, net $ 458,674 $ 513,788 $ 417,790 $ 437,286

Depreciation expense during the three months ended ~~September 30,~~March 31, 2021 and 2020 was $26,896 and ~~2019 was $23,083 and $22,913, respectively. Depreciation expense during the nine months ended September 30, 2020 and 2019 was $68,655 and $44,503,~~$22,742, respectively.

1920

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~SEPTEMBER 30, 2020~~MARCH 31, 2021
(UNAUDITED)

NOTE 87 – INTANGIBLE ASSETS AND GOODWILL

Intangible assets at ~~September 30, 2020~~March 31, 2021 and December 31, ~~2019 are~~2020 were as follows:

September 30, December 31, March 31, December 31,
2020 2019 2021 2020

NCFM: Medical database $ 1,101,538 $ 1,230,000 $ 1,101,538 $ 1,101,538
NCFM: Website 41,000 41,000 41,000 41,000
CHM: ACO physician contracts 1,073,000 --- 1,073,000 1,073,000
Goodwill 381,856 71,866
MOD: Website 3,538,000 3,538,000

Total intangible assets 2,597,394 1,342,866 5,753,538 5,753,538
Less: accumulated amortization (12,064 ) (5,908 ) (336,538 ) (151,776 )

Intangible assets, net $ 2,585,330 $ 1,336,958 $ 5,417,000 $ 5,601,762

Goodwill and intangible assets arose from the acquisitions of NCFM in April 2019, ~~and~~ CHM in May 2020, and MOD in October 2020. The NCFM medical database is assumed to have an indefinite life and is not amortized and the website is being amortized on a straight-line basis over its estimated useful life of five years. The CHM ACO physician contracts are assumed to have an indefinite life and are not amortized. The MOD website is being amortized on a straight-line basis over its estimated useful life of five years. Goodwill represents the excess of consideration transferred over the fair value of the net identifiable assets acquired related to the acquisition of ~~CHM.~~CHM and MOD.

Amortization expense in the three months ended ~~September 30,~~March 31, 2021 and 2020 was $184,762 and ~~2019 was $2,067 and $2,067, respectively. Amortization expense in the nine months ended September 30, 2020 and 2019 was $6,156 and $3,842,~~$2,044, respectively. No impairment charges were recognized related to goodwill and intangible assets in the three ~~or nine~~ months ended ~~September 30, 2020~~March 31, 2021 or ~~2019.~~2020.

NOTE 98 – LEASES

The Company has ~~three~~four operating leases for office space related to its NWC, NCFM and BTG practices and to its corporate headquarters that expire in July 2023, May 2022, March 2023, and ~~March~~November 2023, respectively. As of ~~September 30, 2020,~~March 31, 2021, the Company’s weighted-average remaining lease term relating to its operating leases was ~~2.4~~2.2 years, with a weighted-average discount rate of ~~33.89%~~32.71%. The Company was also lessee in a capital equipment finance lease for medical equipment entered into in March 2015 that expired in March 2020.

The table below summarizes the Company’s lease-related assets and liabilities as of ~~September 30, 2020~~March 31, 2021 and December 31, ~~2019:~~2020:

As of September 30, 2020 As of December 31, 2019
Operating Financing Total Operating Financing Total March 31, December 31,
Leases Leases Leases Leases Leases Leases 2021 2020
Lease assets $ 297,050 $ --- $ 297,050 $ 273,196 $ 4,482 $ 277,678 $ 385,653 $ 417,913

Lease liabilities
Lease liabilities (short term) $ 105,233 $ --- $ 105,233 $ 197,041 $ 4,482 $ 201,523 $ 162,770 $ 150,251
Lease liabilities (long term) 198,667 --- 198,667 80,510 --- 80,510 228,288 273,790
Total lease liabilities $ 303,900 $ --- $ 303,900 $ 277,551 $ 4,482 $ 282,033 $ 391,058 $ 424,041

21
HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~SEPTEMBER 30, 2020~~MARCH 31, 2021
(UNAUDITED)

NOTE 98 – LEASES (CONTINUED)

Lease expense in the three ~~and nine~~ months ended ~~September 30,~~March 31, 2021 and 2020 ~~and 2019~~ was as follow:

Three Months Ended
September 30, Nine Months Ended
September 30, Three Months Ended
March 31,
2020 2019 2020 2019 2021 2020

Operating leases $ 61,526 $ 85,573 $ 242,891 $ 239,974 $ 65,511 $ 90,682
Financing leases --- 4,587 4,587 13,761 — 4,587

Total lease expense $ 61,526 $ 90,160 $ 247,478 $ 253,735 $ 65,511 $ 95,269

Maturities of operating ~~and capital~~ lease liabilities were as follows as of ~~September 30, 2020:~~March 31, 2021:

Operating Capital Total
Leases Leases Commitments
2020 $ 50,882 $ --- $ 50,882
2021 205,430 --- 205,430
2021 (April to December) $ 213,854
2022 159,561 --- 159,561 238,637
2023 68,457 --- 68,457 140,944
Total lease payments 484,330 --- 484,330 593,435
Less interest (180,430 ) --- (180,430 ) (202,377 )
Present value of lease liabilities $ 303,900 $ --- $ 303,900 $ 391,058

NOTE 109 – ~~DEFERRED REVENUE~~CONTRACT LIABILITIES

Amounts related to ~~deferred~~ contract ~~revenue in the three~~liabilities as of March 31, 2021 and ~~nine months ended September 30,~~December 31, 2020 ~~and 2019 was~~were as follow:

Three Months Ended
September 30, Nine Months Ended
September 30,
2020 2019 2020 2019

Balance, beginning of period $ 106,281 $ --- $ --- $ ---
Acquisition of CHM --- --- 104,034 ---
Payments received for unearned revenue 163,038 --- 215,705 ---
Revenue earned (217,605 ) --- (268,025 ) ---

Balance, end of period $ 51,714 $ --- $ 51,714 $ ---
March 31, December 31,
2021 2020

Patient services paid but not provided $ 54,369 $ 35,779
Consulting services paid but not provided — 47,864
Unshipped products 12,690 5,782
$ 67,059 $ 89,425

~~Deferred revenue~~Contract liabilities relates to contracted consulting services at CHM for which payment has been made but services have not yet been rendered as of the measurement date, physical therapy services purchased as a prepaid bundle for which services have not yet been provided, and MOD products that have been ordered and paid for by the customer but which have not been shipped as of the measurement date. The Company typically satisfies its performance obligations related to such contracts upon completion of ~~service.~~service or shipment of product. Payment is typically made in the ~~month~~period prior to the services being provided.

2122

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~SEPTEMBER 30, 2020~~MARCH 31, 2021
(UNAUDITED)

NOTE 1110 – ~~NOTES PAYABLE AND OTHER~~ AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS

Amounts due to related parties as of ~~September 30, 2020~~March 31, 2021 and December 31, ~~2019~~2020 were comprised of deferred compensation in the ~~following:~~amount of $300,600.

September 30, December 31,
2020 2019
Due to related party:
Deferred compensation, Dr. Michael Dent $ 300,600 $ 300,600
Accrued interest payable to Dr. Michael Dent --- 192,857
Total due to related party 300,600 493,457

Notes payable to related party:
Notes payable to Dr. Michael Dent and family (all current) $ --- $ 743,955
Retired Notes Payable to Dr. ~~Michael~~ Dent

Our founder and CEO, Dr. Michael Dent, ~~has~~ made loans to the Company from time to time in the form of unsecured promissory notes payable (the “Dent Notes”). The ~~carrying values~~Dent Notes were repaid in full during September 2020 and had no balance as of March 31, 2021 or December 31, 2020. Prior to repayment, the Dent Notes ~~as of September 30, 2020 and December 31, 2019 were as follows:~~
Interest September 30, December 31,
Inception Date Maturity Date Rate 2020 2019
January 12, 2017 December 31, 2020 10% $ --- $ 38,378 *
January 18, 2017 December 31, 2020 10% --- 21,904 *
January 24, 2017 December 31, 2020 10% --- 54,696 *
February 9, 2017 December 31, 2020 10% --- 32,715 *
April 20, 2017 December 31, 2020 10% --- 10,754 *
June 15, 2017 December 31, 2020 10% --- 34,560 *
August 17, 2017 December 31, 2020 10% --- 20,997 *
August 24, 2017 December 31, 2020 10% --- 39,312 *
September 7, 2017 December 31, 2020 10% --- 36,586 *
September 21, 2017 December 31, 2020 10% --- 27,621 *
September 29, 2017 December 31, 2020 10% --- 12,487 *
December 21, 2017 December 31, 2020 10% --- 14,318 *
January 8, 2018 December 31, 2020 10% --- 76,415 *
January 11, 2018 December 31, 2020 10% --- 9,164 *
January 26, 2018 December 31, 2020 10% --- 17,712 *
January 3, 2014 December 31, 2020 10% --- 296,336 *

$ --- $ 743,955
* ~~Denotes that note payable is reflected at fair value~~
On September 21, 2020, the Company and Dr. Dent entered into an agreement pursuant to which the Company repaid all obligations under the notes payable to Dr. Dent in exchange for one-time cash payment of $780,256. The payment was calculated as the face value of the Dent Notes of $646,000, plus $134,256 of interest accrued on the notes issued in 2017 and 2018. As part of the Agreement, Dr. Dent agreed to forgive interest of $105,003 accrued on the remaining Dent Notes. In connection with the agreement and repayment, the Company realized a gain of $283,863, being the excess of the carrying value of the Dent Notes over the consideration paid. This amount was recorded to additional paid in capital.
~~As denoted in the table above, prior to extinguishment certain of our notes payable to Dr. Dent~~ were carried at fair value and revalued at each period end, with changes to fair value recorded to the statement of operations under “Change in Fair Value of Debt.” The changes in fair value during the three months ended ~~September 30,~~March 31, 2021 and 2020 were $-0- and ~~2019 were $32,968 and $5,986,~~$(21,362), respectively. ~~The changes in fair value during~~No interest was accrued on the ~~nine months ended September 30, 2020 and 2019 were $80,935 and $18,070, respectively. The fair value of these notes~~Dent Notes as of ~~September 30,~~March 31, 2020 ~~and~~or December 31, ~~2019~~2020. Interest expense on the Dent Notes was $-0- and ~~$743,955,~~$34,117 in the three months ended March 31, 2021 and 2020, respectively.

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~

~~NOTE 11 – NOTES PAYABLE AND OTHER AMOUNTS DUE TO RELATED PARTY (CONTINUED)~~Other Amounts Due to Dr. Dent

On January 7, 2020, the Company entered into a Merchant Cash Advance Factoring Agreement ~~(“MCA”)~~ with a trust controlled by Dr. Dent, pursuant to which the Company received an advance of ~~$150,000 before closing fees~~$149,000 (the “2020 MCA”). The Company iswas required to repay the 2020 MCA, which acts like an ordinary note payable, at the rate of $7,212 per week until the balance of $187,500 is repaid, which was scheduled for July 2020. At inception, the Company recognized a note payable in the amount of $187,500 and a discount against the note payable of $38,500. The discount ~~is being~~was amortized over the life of the instrument. The Company made installment payments against the MCA of ~~$36,059~~$-0- and ~~$-0-,~~$79,327, respectively, during the three months ended ~~September 30, 2020~~March 31, 2021 and ~~2019, and $187,500 and $-0-, respectively, during the nine months ended September 30, 2020 and 2019.~~2020. The Company recognized amortization of the discount in the amount of $-0- and ~~$-0-,~~$18,012, respectively, during the three months ended ~~September 30, 2020~~March 31, 2021 and ~~2019, and $38,500 and $-0-, respectively, during the nine months ended September 30, 2020 and 2019.~~2020. The 2020 MCA was repaid in full and retired during July 2020.

~~Interest accrued on the above~~NOTE 11 – GOVERNMENT AND VENDOR NOTES PAYABLE
Government and vendor notes payable as of ~~September 30, 2020~~March 31, 2021 and December 31, ~~2019 was $-0- and $192,888, respectively. Interest expense on~~2020 were comprised of the above unsecured promissory notes was $14,159 and $16,598 for the three months ended September 30, 2020 and 2019, respectively, and $86,446 and $49,252 for the nine months ended September 30, 2020 and 2019, respectively.following:

~~NOTE 12 – GOVERNMENT NOTES PAYABLE~~
March 31, December 31,
2021 2020

PPP loans $ 632,826 $ 632,826
Disaster relief loans 450,000 450,000
Vendor note — 51,109
Total government and vendor notes payable 1,082,826 1,133,935
Less: long term portion (644,545 ) (722,508 )
Government and vendor notes payable, current portion $ 438,281 $ 411,427

OnDuring May 8,and June 2020, the Company and certain of its subsidiaries received an aggregate of ~~$585,969~~$621,069 in loans under the Paycheck Protection Program (the “PPP”). The Company also acquired a PPP loan in the MOD acquisition with an inception date of April 3, 2020 and a face value of $11,757. The PPP loans, administered by the U.S. Small Business Administration (the “SBA”) and processed through Wells Fargo bank, were issued under the recently enacted Coronavirus Aid, Relief, and Economic Security Act, also known as the CARES Act. The loans bear interest at 1% per annum and mature in May 2022. Principal and interest payments are deferred for the first six months of the loans. Pursuant to the terms of the PPP, principal amounts may be forgiven if loan proceeds are used for qualifying expenses as described in the CARES Act, including costs such as payroll, benefits, employer payroll taxes, rent and utilities. The Company used the proceeds from the PPP loans in accordance with the CARES Act, and as such believes that the PPP loans will be waived when the instituting bank processes the waiver request, which is expected in second quarter 2021.

During June, July and August 2020, the Company and its subsidiaries received an aggregate of $450,000 in Disaster Relief Loans from the SBA. The loans bear interest at 3.75% per annum and mature 30 years from issuance. Mandatory principal and interest payments begin 12 months from the inception date of each loan.

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 11 – GOVERNMENT AND VENDOR NOTES PAYABLE (CONTINUED)
In connection with the October 19, 2020 of MOD, the Company acquired (i) a PPP loan with an inception date of April 3, 2020 and a face value of $11,757, and (ii) a note payable to MOD’s primary product vendor with a remaining principal balance of $79,002 as of the acquisition date that was paid in full during the three months ended March 31, 2021.

Interest accrued on government ~~loans~~and vendor notes payable as of ~~September 30, 2020~~March 31, 2021 and December 31, ~~2019~~2020 was ~~$4,716~~$19,845 and ~~$-0-,~~$12,240, respectively. Interest expense on the loans was ~~$3,855~~$7,605 and $-0- for the three months ended ~~September 30,~~March 31, 2021 and 2020, ~~and 2019, respectively, and $4,716 and $-0- for the nine months ended September 30, 2020 and 2019,~~ respectively.
23
~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~

NOTE 1312 – CONVERTIBLE NOTES PAYABLE

Convertible notes payable as of ~~September 30, 2020~~March 31, 2021 and December 31, ~~2019~~2020 were comprised of the following:

September 30, December 31,
2020 2019

$550k Note - July 2016 $ 607,628 * $ 548,010 *
$50k Note - July 2016 63,053 * 56,866 *
$111k Note - May 2017 118,108 * 118,606 *
$357.5k Note - April 2019 364,490 * 328,728 *
$154k Note - June 2019 --- 50,000
$136k Notes - July 2019 --- 135,850
$78k Note III - July 2019 --- 78,000
$230k Note - July 2019 --- 230,000
$108.9k Note - August 2019 --- 108,947
$142.5k Note - October 2019 --- 142,500
$103k Note V - October 2019 --- 103,000
$108.9k Note II - October 2019 --- 108,947
$128.5k Note - October 2019 --- 128,500
$103k Note VI - November 2019 --- 103,000
$78.8k Note II - December 2019 --- 78,750
1,153,279 2,319,704
Less: unamortized discount --- (777,668 )
Convertible notes payable, net of original issue discount and debt discount $ 1,153,279 $ 1,542,036
* - ~~Denotes that convertible note payable is carried at fair value~~

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
March 31, December 31,
2021 2020

$550k Note - July 2016 $ — $ 719,790
$50k Note - July 2016 — 71,611
$111k Note - May 2017 — 120,659
$357.5k Note - April 2019 — 424,290
— 1,336,350
Less: unamortized discount — —
Convertible notes payable, net of original issue discount and debt discount $ — $ 1,336,350

~~NOTE 13 – CONVERTIBLE NOTES PAYABLE (CONTINUED)~~
~~Amortization~~Interest expense and amortization of debt discount recognized on each convertible note outstanding during the three ~~and nine~~ months ended ~~September 30,~~March 31, 2021 and 2020 ~~and 2019~~ were as follows:

Amortization of Debt Discount Interest Expense Amortization of Debt Discount
Three Months Ended
September 30, Nine Months Ended
September 30, Three Months Ended March 31, Three Months Ended March 31,
2020 2019 2020 2019 2021 2020 2021 2020

$103k Note I - October 2018 $ --- $ --- $ --- $ 33,972
$103k Note II - November 2018 --- --- --- 44,952
$153k Note - November 2018 --- 1,733 --- 91,451
$103k Note III - December 2018 --- --- --- 42,611
$78k Note I - January 2019 --- 4,286 --- 52,000
$78k Note II - January 2019 --- 6,346 --- 47,858
$103k Note III - April 2019 --- 28,628 --- 56,012
$104.5k Note - April 2019 --- 26,268 --- 49,109
$104.5k Note II - April 2019 --- 26,268 --- 49,109
$550k Note - July 2016 $ 2,351 $ 8,225 $ — $ —
$50k Note - July 2016 219 1,247 — —
$111k Note - May 2017 333 4,694 — —
$357.5k Note - April 2019 --- 91,230 --- 166,593 1,469 829 — —
$103k Note IV - May 2019 --- 31,906 --- 50,633
$154k Note - June 2019 --- 38,710 1,093 50,071 — 46 — 1,093
$67.9k Note - July 2019 --- 16,277 7,252 16,277 — 707 — 7,252
$67.9k Note II - July 2019 --- 16,277 2,813 16,277 — 177 — 2,813
$78k Note III - July 2019 --- 20,512 6,208 20,512 — 492 — 6,208
$230k Note - July 2019 --- 46,503 58,527 46,503 — 3,041 — 58,526
$108.9k Note - August 2019 --- 7,784 21,038 7,785 — 2,545 — 20,960
$142.5k Note - October 2019 21,804 --- 92,663 --- — 5,739 — 35,430
$103k Note V - October 2019 --- --- 29,143 --- — 2,568 — 28,213
$108.9k Note II - October 2019 --- --- 33,205 --- — 2,716 — 21,730
$128.5k Note - October 2019 --- --- 51,705 --- — 3,204 — 31,949
$103k Note VI - November 2019 --- --- 39,450 --- — 2,568 — 28,720
$78.8k Note II - December 2019 --- --- 27,111 --- — 1,963 — 15,917
$131.3k Note - January 2020 1,158 --- 16,205 --- — 2,805 — 6,945
$78k Note IV - January 2020 1,608 --- 14,955 --- — 1,603 — 6,030
$157.5k Note - March 2020 7,432 --- 20,044 --- — 906 — 2,365
$157.5k Note II - April 2020 9,127 --- 21,436 ---
$135k Note - April 2020 7,744 --- 17,718 ---
$83k Note II - April 2020 6,675 --- 13,767 ---
$128k Note - April 2020 10,268 --- 18,097 ---

$ 65,816 $ 362,728 $ 492,430 $ 841,725 $ 4,372 $ 46,075 $ — $ 274,151

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~SEPTEMBER 30, 2020~~MARCH 31, 2021
(UNAUDITED)

NOTE 1312 – CONVERTIBLE NOTES PAYABLE (CONTINUED)

~~Unamortized debt discount on outstanding~~There were no unamortized discounts as of March 31, 2021 or December 31, 2020 related to convertible notes ~~payable as of September 30, 2020 and December 31, 2019 were comprised of the following:~~
Unamortized Discount as of
September 30, December 31,
2020 2019

$154k Note - June 2019 $       --- $ 21,175
$67.9k Note - July 2019 --- 20,497
$67.9k Note II - July 2019 --- 20,497
$78k Note III - July 2019 --- 32,657
$230k Note - July 2019 --- 125,684
$108.9k Note - August 2019 --- 59,392
$142.5k Note - October 2019 --- 107,070
$103k Note V - October 2019 --- 70,686
$108.9k Note II - October 2019 --- 72,592
$128.5k Note - October 2019 --- 106,732
$103k Note VI - November 2019 --- 81,740
$78.8k Note II - December 2019 --- 58,946

$ --- $ 777,668

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
~~NOTE 13 – CONVERTIBLE NOTES PAYABLE (CONTINUED)~~
~~Interest expense recognized on each convertible note outstanding during the three and nine months ended September 30, 2020 and 2019 were as follows:~~
Interest Expense
Three Months Ended
September 30, Nine Months Ended
September 30,
2020 2019 2020 2019

$550k Note - July 2016 $ 8,318 $ 8,318 $ 24,773 $ 24,682
$50k Note - July 2016 1,260 1,260 3,753 3,740
$111k Note - May 2017 2,042 4,168 8,755 12,369
$171.5k Note - October 2017 --- --- --- 1,785
$103k Note I - October 2018 --- --- --- 2,653
$103k Note II - November 2018 --- --- --- 3,584
$153k Note - November 2018 --- 297 --- 7,008
$103k Note III - December 2018 --- --- --- 4,261
$78k Note I - January 2019 --- 321 --- 3,889
$78k Note II - January 2019 --- 513 --- 3,868
$103k Note III - April 2019 --- 2,596 --- 5,079
$104.5k Note - April 2019 --- 2,634 --- 4,924
$104.5k Note II - April 2019 --- 2,634 --- 4,924
$357.5k Note - April 2019 9,012 12,650 18,751 23,101
$103k Note IV - May 2019 --- 2,596 --- 4,120
$154k Note - June 2019 --- 3,882 46 5,021
$67.9k Note - July 2019 --- 1,507 707 1,507
$67.9k Note II - July 2019 --- 1,507 177 1,507
$78k Note III - July 2019 --- 1,624 492 1,624
$230k Note - July 2019 --- 4,663 3,041 4,663
$108.9k Note - August 2019 --- 1,045 2,564 1,045
$142.5k Note - October 2019 3,592 --- 12,884 ---
$103k Note V - October 2019 --- --- 2,653 ---
$108.9k Note II - October 2019 --- --- 3,970 ---
$128.5k Note - October 2019 --- --- 5,149 ---
$103k Note VI - November 2019 --- --- 3,527 ---
$78.8k Note II - December 2019 --- --- 3,344 ---
$131.3k Note - January 2020 467 --- 6,545 ---
$78k Note IV - January 2020 427 --- 3,975 ---
$157.5k Note - March 2020 2,848 --- 7,681 ---
$157.5k Note II - April 2020 2,848 --- 6,688 ---
$135k Note - April 2020 2,441 --- 5,585 ---
$83k Note II - April 2020 1,819 --- 3,752 ---
$128k Note - April 2020 2,805 --- 4,945 ---

$ 37,879 $ 52,215 $ 133,757 $ 125,354

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
~~NOTE 13 – CONVERTIBLE NOTES PAYABLE (CONTINUED)~~payable.

Certain of ~~our~~the Company’s convertible notes payable are also carried at fair value and revalued at each period end, with changes to fair value recorded to the statement of operations under “Change in Fair Value of Debt.” The changes in fair value during the three ~~and nine~~ months ended ~~September 30,~~March 31, 2021 and 2020 ~~and 2019~~ and the fair value as of such instruments as of ~~September 30, 2020~~March 31, 2021 and December 31, ~~2019~~2020 were as follows:

Change in Fair Value of Debt Fair Value of Debt as of Change in Fair Value of Debt Fair Value of Debt as of
Three Months Ended
September 30, Nine Months Ended
September 30, September 30, December 31, Three Months Ended March 31, March 31, December 31,
2020 2019 2020 2019 2020 2019 2021 2020 2021 2020

$550k Note - July 2016 $ 24,285 $ 17,455 $ 59,618 $ 52,708 $ 607,629 $ 548,010 $ 10,343 $ (10,757 ) $     — $ 719,790
$50k Note - July 2016 2,520 1,770 6,187 5,343 63,053 56,866 1,017 (1,116 ) — 71,611
$111k Note - May 2017 4,721 3,674 16,261 11,089 118,108 118,606 1,706 (3,036 ) — 120,659
$171.5k Note - October 2017 --- --- --- 1,781 --- ---
$357.5k Note - April 2019 14,567 --- 35,763 --- 364,490 328,727 6,180 (6,453 ) — 424,290

$ 46,093 $ 22,899 $ 117,829 $ 70,921 $ 1,153,280 $ 1,052,209 $ 19,246 $ (21,362 ) $ — $ 1,336,350

Extension and Conversion – January 2021
On January 6, 2021, the holder of the Company’s four remaining fixed rate convertible promissory notes with a face value of $1,038,500 – comprised of a $550,000 6% fixed convertible secured promissory note dated July 7, 2016 (the “$550k Note”), a $50,000 10% fixed convertible commitment fee promissory note dated July 7, 2016 (the “$50k Note”), $81,000 of principal remaining on a $111,000 10% fixed convertible secured promissory note dated May 22, 2017 (the “$111k Note”), and a $357,500 10% fixed convertible note dated April 15, 2019 (the “$357.5k Note” and together with the $550k Note, the $50k Note and the $111k Note, the “Remaining Notes”) – agreed to extend the maturity date on the Remaining Notes to January 14, 2021. In exchange for the extension, the Company agreed to extend the expiration date of 3,508,333 existing warrants held by the holder (the “Extended Warrants”) from dates between July 2021 and March 2022 until March 2023. Because the fair value of consideration issued was greater than 10% of the present value of the remaining cash flows under the modified Remaining Notes, the transaction was treated as a debt extinguishment and reissuance of new debt instruments pursuant to the guidance of ASC 470-50. A loss on debt extinguishment was recorded in the amount of $126,502 in the three months ended March 31, 2021, equal to the incremental fair value of the Extended Warrants before and after the modification.
On January 14, 2021, the Company and the holder of the Remaining Notes entered into a series of agreements pursuant to which (i) the holder agreed to convert the full face value of $1,038,500 and $317,096 of accrued interest on the Remaining Notes into 13,538,494 shares of common stock pursuant to the original conversion terms of the underlying notes, (ii) the holder agreed to a 180-day leak out provision, whereby, from and after January 14, 2021, it may not sell in shares of the Company’s common stock in excess of 5% of the Company’s daily trading volume for the first 90 days and 10% of the Company’s daily volume for the next 90 days, subject to certain exceptions, (iii) the holder agreed to release all security interests and share reserves related to the Remaining Notes, and (iv) the Company issued to the holder a new five-year warrant to purchase 13,538,494 shares of common stock at an exercise price of $0.30 per share. The carrying value of the converted debt at the time of conversion, which equaled its fair value, was $1,355,596. In connection with the conversion, the Company recognized a loss on debt extinguishment of $5,463,492 in the three months ended March 31, 2021, representing the excess of the fair value of the shares and warrant issued at conversion over the carrying value of the host instrument and accrued interest.
Convertible Note Payable ($550,000) – July 2016
On July 7, 2016, the Company entered into a 6% fixed convertible secured promissory note with an investor with a face value of $550,000. The $550k Note and related interest was convertible into shares of common stock at the discretion of the note holder at a fixed price of $0.08 per share of the Company’s common shares and is secured by all of the Company’s assets. The $550k Note was scheduled to mature on January 14, 2021. The $550k Note was carried at fair value due to an extinguishment and reissuance recorded in 2017 and was revalued at each period end, with changes to fair value recorded to the statement of operations under “Change in Fair Value of Debt.” The holder converted the full principal of $550,000, plus $180,129 of accrued interest, into 9,126,610 shares of common stock on January 14, 2021.

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 12 – CONVERTIBLE NOTES PAYABLE (CONTINUED)
Convertible Note Payable ($50,000) – July 2016
On July 7, 2016, the Company entered into a 10% fixed convertible commitment fee promissory note with an investor with a face value of $50,000. The $50k Note was scheduled to mature on January 14, 2021. The $50k note was issued as a commitment fee payable to the Investment Agreement investor in exchange for the investor’s commitment to enter into the Investment Agreement, subject to registration of the shares underlying the Investment Agreement. The $50k Note and related interest was convertible into shares of common stock at the discretion of the note holder at a fixed price of $0.10 per share. The $50k Note was carried at fair value due to an extinguishment and reissuance recorded in 2017 and is revalued at each period end, with changes to fair value recorded to the statement of operations under “Change in Fair Value of Debt.” The holder converted the full principal of $50,000 plus $22,630 of accrued interest into 726,302 shares of common stock on January 14, 2021.
Convertible Note Payable ($111,000) – May 2017

On May 22, 2017, the Company entered into a 10% fixed convertible secured promissory note with an investor with a face value of $111,000. The $111k Note isand related interest was convertible into shares of ~~the Company’s~~ common stock at the discretion of the note holder at a fixed price of $0.15 per share ~~or 740,000 of the Company’s common shares,~~ and is secured by all of the Company’s assets. The Company received $100,000 net proceeds from the note after an $11,000 original issue discount. At inception, the investors were also granted a five-year warrant to purchase 133,333 shares of ~~the Company’s~~ common stock at an exercise price of $0.75 per share. The $111k Note ~~matures~~was scheduled to mature on ~~December 31, 2020.~~January 14, 2021. On February 6, 2020, the holder of the $111k Note converted $30,000 principal on the note into 448,029 shares of ~~Company~~ common stock. In connection with the conversion, the Company recognized a loss on debt extinguishment of $25,394 in the three months ended March 31, 2020, representing the excess of the fair value of the shares issued at conversion over the carrying value of the portion of the host instrument and the bifurcated conversion feature converted. The holder converted the remaining principal of $81,000 plus $180,129 of accrued interest into 815,787 shares of common stock on January 14, 2021.
Convertible Note Payable ($357,500) – April 2019
On April 15, 2019, the Company issued a fixed convertible note with a face value of $357,500 (the “$357.5k Note”). The $357.5k Note had an interest rate of 10%, matures on December 31, 2020, and may be converted into common stock by the holder at any time, subject to a 9.99% beneficial ownership limitation, at a fixed conversion price per share of $0.15, or 2,383,333 shares. The holder converted the full principal of $357,500 plus $72,969 of accrued interest into 2,869,795 shares on January 14, 2021.
Convertible Note Payable ($154,000) – June 2019
On June 3, 2019, the Company issued a $154,000 convertible note (the “$154k Note”). During the three months ended March 31, 2020, the holder converted the remaining unpaid principal balance of $50,000 and accrued interest of $8,572 into 968,390 shares of common stock. In connection with the conversion, the Company recognized a loss on debt extinguishment of $125,865 in the three months ended March 31, 2020, representing the excess of the fair value of the shares issued at conversion over the carrying value of the portion of the host instrument and the bifurcated conversion feature converted.

~~Convertible Note Payable ($171,500) – October 2017~~
On October 27, 2017, the Company entered into a securities purchase agreement for the sale of a $171,500 convertible note (the “$171.5k Note”) to an individual lender. On February 7, 2019, the holder of the $171.5k Note converted the entire principal balance of $171,500 into 2,512,821 shares of Company common stock. In connection with the conversion, the Company recognized a loss on debt extinguishment of $139,798, representing the excess of the fair value of the shares issued at conversion over the carrying value of the host instrument and the bifurcated conversion feature at the time of conversion.
~~Convertible Notes Payable ($103,000) – October 2018~~
On October 18, 2018, the Company issued a $103,000 convertible note (the “$103k Note I”). On April 4, 2019, the Company prepaid the balance on the $103k Note I, including accrued interest, for a one-time cash payment of $134,500. In connection with the repayment, the Company recognized a gain on debt extinguishment of $28,169 in the nine months ended September 30, 2019, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.
~~Convertible Notes Payable ($103,000) – November 2018~~
On November 12, 2018, the Company issued a $103,000 convertible note (the “$103k Note II”). On May 7, 2019, the Company prepaid the balance on the $103k Note II, including accrued interest, for a one-time cash payment of $134,888. In connection with the repayment, the Company recognized a gain on debt extinguishment of $23,821 in the nine months ended September 30, 2019, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
~~NOTE 13 – CONVERTIBLE NOTES PAYABLE (CONTINUED)~~
~~Convertible Notes Payable ($153,000) – November 2018~~
On November 19, 2018, the Company issued a $153,000 convertible note (the “$153k Note”). During the nine months ended September 30, 2019, the holder converted the full principal in the amount of $153,000 and $8,768 of accrued interest into 1,070,894 shares of Company common stock. In connection with the conversion, the Company recognized a loss on debt extinguishment of $44,993, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.
~~Convertible Notes Payable ($103,000) – December 2018~~
On December 3, 2018, the Company issued a $103,000 convertible note (the “$103k Note III”). On May 31, 2019, the Company prepaid the balance on the $103k Note III, including accrued interest, for a one-time cash payment of $135,029. In connection with the repayment, the Company recognized a gain on debt extinguishment of $20,445 in the nine months ended September 30, 2019, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.
~~Convertible Note Payable ($78,000) – January 2019~~
On January 14, 2019, the Company issued a $78,000 convertible note (the “$78k Note”). The $78k Note, including accrued interest, was repaid in July 2019 for a one-time cash payment of $102,321. In connection with the repayment, the Company recognized a loss on debt extinguishment of $6,258 in the nine months ended September 30, 2019, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.
~~Convertible Note Payable ($78,000) – January 2019~~
On January 24, 2019, the Company issued a $78,000 convertible note (the “$78k Note II”). The $78k Note II, including accrued interest, was repaid in July 2019 for a one-time cash payment of $102,255. In connection with the repayment, the Company recognized a gain on debt extinguishment of $11,161 in the nine months ended September 30, 2019, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.
~~Convertible Note Payable ($103,000) – April 2019~~
On April 3, 2019, the Company entered into a securities purchase agreement for the sale of a $103,000 convertible note (the “$103k Note III”). During the fourth quarter of 2019, the Company prepaid the balance on the $103k Note III, including accrued interest, for a one-time cash payment of $135,099.
~~Convertible Note Payable ($104,500) – April 2019~~
On April 11, 2019, the Company entered into securities purchase agreements for the sale of a $104,500 convertible note (the “$104.5k Note I”). During the fourth quarter of 2019, the holder of the $104.5k Note I converted the full principal in the amount of $104,500 and $5,768 of accrued interest into 1,176,189 shares of Company common stock.
~~Convertible Note Payable ($104,500) – April 2019~~
On April 11, 2019, the Company entered into securities purchase agreements for the sale of a second $104,500 convertible note (the “$104.5k Note II”). During the fourth quarter of 2019, the Company prepaid the balance on the $104.5k Note II, including accrued interest, for a one-time cash payment of $142,500.
~~Convertible Note Payable ($357,500) – April 2019~~
On April 15, 2019, the Company issued a fixed convertible note with a face value of $357,500 (the “$357.5k Note”). The $357.5k Note has an interest rate of 10%, matures on December 31, 2020, and may be converted into common stock of the Company by the holder at any time, subject to a 9.99% beneficial ownership limitation, at a fixed conversion price per share of $0.15, or 2,383,333 shares.

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
~~NOTE 13 – CONVERTIBLE NOTES PAYABLE (CONTINUED)~~
~~Convertible Note Payable ($103,000) – May 2019~~
On May 7, 2019, the Company issued a $103,000 convertible note (the “$103k Note IV”). During the fourth quarter of 2019, the Company prepaid the balance on the $103k Note IV, including accrued interest, for a one-time cash payment of $133,900.
~~Convertible Note Payable ($154,000) – June 2019~~
On June 3, 2019, the Company issued a $154,000 convertible note (the “$154k Note”), of which $104,000 was converted in the fourth quarter of 2019. During the nine months ended September 30, 2020, the holder converted the remaining unpaid principal balance of $50,000 and accrued interest of $8,572 into 968,390 shares of Company common stock. In connection with the conversion, the Company recognized a loss on debt extinguishment of $125,865 in the nine months ended September 30, 2020, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest over the carrying value of the portion of the host instrument and the bifurcated conversion feature converted.
Convertible Note Payable ($67,925) – July 2019

On July 11, 2019, the Company issued a $67,925 convertible note (the “$67.9k Note I”). During the ~~nine~~three months ended ~~September 30,~~March 31, 2020, the holder converted the full principal of $67,925 and accrued interest of $3,926 into 885,847 shares of ~~Company~~ common stock. In connection with the conversion, the Company recognized a loss on debt extinguishment of $55,117 in the ~~nine~~three months ended ~~September 30,~~March 31, 2020, ~~equal to~~representing the excess of the ~~payment amount~~fair value of the shares issued at conversion over the carrying value of the ~~note, derivative embedded~~portion of the host instrument and the bifurcated conversion feature ~~and accrued interest.~~converted.

Convertible Note Payable ($67,925) – July 2019

On July 11, 2019, the Company issued a second $67,925 convertible note (the “$67.9k Note II”). During the ~~nine~~three months ended ~~September 30,~~March 31, 2020, the Company prepaid the balance on the $67.9k Note II, including accrued interest, for a one-time cash payment of $89,152. In connection with the repayment, the Company recognized a loss on debt extinguishment of $26,890 in the ~~nine~~three months ended ~~September 30,~~March 31, 2020, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 12 – CONVERTIBLE NOTES PAYABLE (CONTINUED)
Convertible Note Payable ($78,000) – July 2019

On July 16, 2019, the Company issued a $78,000 convertible note (the “$78k Note III”). During the ~~first quarter of~~three months ended March 31, 2020, the Company prepaid the balance on the $78k Note III, including accrued interest, for a one-time cash payment of $102,388. In connection with the repayment, the Company recognized a loss on debt extinguishment of $31,432 in the ~~nine~~three months ended ~~September 30,~~March 31, 2020, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.

Convertible Note Payable ($230,000) – July 2019

On July 18, 2019, the Company issued a convertible note with a face value of $230,000 (the “$230k Note”). During the ~~first quarter of~~three months ended March 31, 2020, the holder converted $80,000 of principal and $4,373 of accrued interest on the note into 1,236,668 shares of ~~Company~~ common stock and the Company repaid principal of $150,000 and accrued interest of $9,128 for cash payments totaling $181,554. The note was retired upon these conversions and repayments. In connection with the conversions and repayments, the Company recognized a loss on debt extinguishment of $112,498 in the ~~nine~~three months ended ~~September 30,~~March 31, 2020 equal to the excess of the cash payment amount and the fair value of the shares issued at conversion over the carrying value of the note, derivative embedded conversion feature and accrued interest.

Convertible Note Payable ($108,947) – August 2019

On August 26, 2019, the Company issued a convertible note with a face value of $108,947 (the “$108.9k Note”). During the ~~nine~~three months ended ~~September 30,~~March 31, 2020, the holder converted ~~the full~~ principal of ~~$108,947~~$75,000 and accrued interest of ~~$6,354~~$6,335 into ~~2,650,251~~1,779,322 shares of ~~Company~~ common stock. In connection with the ~~conversions,~~conversion, the Company recognized a loss on debt extinguishment of ~~$161,617~~$90,732 in the ~~nine~~three months ended September 30, 2020, representing the excess of the fair value of the shares issued at conversion over the carrying value of the portion of the host instrument and the bifurcated conversion feature converted.

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
~~NOTE 13 – CONVERTIBLE NOTES PAYABLE (CONTINUED)~~
~~Convertible Note Payable ($142,500) – October 2019~~
On October 1, 2019, the Company issued a convertible note with a face value of $142,500 (the “$142.5k Note”). During the nine months ended September 30, 2020, the holder converted the full principal of $142,500 and accrued interest of $14,250 into 2,855,191 shares of Company common stock. In connection with the conversions, the Company recognized a loss on debt extinguishment of $305,100 in the nine months ended September 30,March 31, 2020, representing the excess of the fair value of the shares issued at conversion over the carrying value of the portion of the host instrument and the bifurcated conversion feature converted.

~~Convertible Note Payable ($103,000) – October 2019~~
On October 1, 2019, the Company issued a $103,000 convertible note (the “$103k Note V”). On April 3, 2020, 2020, the Company prepaid the balance on the $103k Note V, including accrued interest, for a one-time cash payment of $135,205. In connection with the repayment, the Company recognized a loss on debt extinguishment of $43,777 in the nine months ended September 30, 2020, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.
~~Convertible Note Payable ($108,947) – October 2019~~
On October 30, 2019, the Company issued a convertible note with a face value of $108,947 (the “$108.9k Note II”). During the nine months ended September 30, 2020, the holder converted the full principal of $108,947 and accrued interest of $5,821 into 1,954,870 shares of Company common stock. In connection with the conversions, the Company recognized a loss on debt extinguishment of $76,895 in the nine months ended September 30, 2020, representing the excess of the fair value of the shares issued at conversion over the carrying value of the portion of the host instrument and the bifurcated conversion feature converted.
~~Convertible Note Payable ($128,500) – October 2019~~
On October 30, 2019, the Company issued a $128,500 convertible note (the “$128.5k Note”). During the nine months ended September 30, 2020, the holder converted the full principal of $128,500 and accrued interest of $8,832 into 3,197,877 shares of Company common stock. In connection with the conversion, the Company recognized a loss on debt extinguishment of $154,248 in the nine months ended September 30, 2020, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.
~~Convertible Note Payable ($103,000) – November 2019~~
On November 4, 2019, the Company issued a $103,000 convertible note (the “$103k Note VI”). On May 4, 2020, the Company prepaid the balance on the $103k Note VI, including accrued interest, for a one-time cash payment of $135,099. In connection with the repayment, the Company recognized a loss on debt extinguishment of $45,077 in the nine months ended September 30, 2020, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.
~~Convertible Note Payable ($78,750) – December 2019~~
On December 2, 2019, the Company issued a $78,750 convertible note (the “$78.8k Note”). On June 3, 2020, the Company prepaid the balance on the $78.8k Note, including accrued interest, for a one-time cash payment of $103,359. In connection with the repayment, the Company recognized a loss on debt extinguishment of $37,554 in the nine months ended September 30, 2020, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.
Convertible Note Payable ($131,250) – January 2020

On January 13, 2020, the Company issued a $131,250 convertible note (the “$131.3k Note”). On July 13, 2020, the Company prepaid the balance on the $131.3k Note, including accrued interest, for a one-time cash payment of $172,108. In connection with the repayment, the Company recognized a loss on debt extinguishment of $24,663 in the nine months ended September 30, 2020, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~

~~NOTE 13 – CONVERTIBLE NOTES PAYABLE (CONTINUED)~~
Convertible Note Payable ($78,000) – January 2020

On January 16, 2020, the Company issued a $78,000 convertible note (the “$78k Note IV”). On July 20, 2020, the Company prepaid the balance on the $78k Note IV, including accrued interest, for a one-time cash payment of $102,308. In connection with the repayment, the Company recognized a loss on debt extinguishment of $9,104 in the nine months ended September 30, 2020, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.

Convertible Note Payable ($157,500) – March 2020

On March 10, 2020, the Company issued a $157,500 convertible note (the “$157.5k Note”). On September 4, 2020, the Company prepaid the balance on the $157.5k Note, including accrued interest, for a one-time cash payment of $206,314. In connection with the repayment, the Company recognized a loss on debt extinguishment of $28,150 in the nine months ended September 30, 2020, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.
~~Convertible Note Payable ($157,500) – April 2020~~
On April 2, 2020, the Company issued a $157,500 convertible note (the “$157.5k Note II”). On September 4, 2020, the Company prepaid the balance on the $157.5k Note, including accrued interest, for a one-time cash payment of $205,235. In connection with the repayment, the Company recognized a loss on debt extinguishment of $31,490 in the nine months ended September 30, 2020, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.
~~Convertible Note Payable ($135,000) – April 2020~~
On April 6, 2020, the Company issued a $135,000 convertible note (the “$135k Note”). On September 4, 2020, the Company prepaid the balance on the $135k Note, including accrued interest, for a one-time cash payment of $175,592. In connection with the repayment, the Company recognized a loss on debt extinguishment of $18,479 in the nine months ended September 30, 2020, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.
~~Convertible Note Payable ($83,000) – April 2020~~
On April 6, 2020, the Company issued an $83,000 convertible note (the “$83k Note”). On September 18, 2020, the Company prepaid the balance on the $83k Note, including accrued interest, for a one-time cash payment of $108,127. In connection with the repayment, the Company recognized a loss on debt extinguishment of $13,012 in the nine months ended September 30, 2020, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.
~~Convertible Note Payable ($128,000) – April 2020~~
On April 30, 2020, the Company issued a $128,000 convertible note (the “$128k Note”). On September 18, 2020, the Company prepaid the balance on the $128k Note, including accrued interest, for a one-time cash payment of $165,962. In connection with the repayment, the Company recognized a loss on debt extinguishment of $21,000 in the nine months ended September 30, 2020, equal to the excess of the payment amount over the carrying value of the note, derivative embedded conversion feature and accrued interest.

NOTE 1413 – DERIVATIVE FINANCIAL INSTRUMENTS

Derivative financial instruments are comprised of the fair value of embedded conversion features (“ECFs”)~~embedded~~ in convertible promissory notes for which the conversion rate is not fixed, but instead is adjusted based on a discount to the market price of the Company’s common stock. The fair market value of the ECF derivative liabilities was calculated at inception of each convertible promissory note for which the conversion rate is not fixed and allocated to the respective convertible notes, with any excess recorded as a charge to “Financing cost.” Derivative financial instruments are revalued at the end of each period, with the change in value recorded to “Change in fair value of on derivative financial instruments.”

27
HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~SEPTEMBER 30, 2020~~MARCH 31, 2021
(UNAUDITED)

NOTE 1413 – DERIVATIVE FINANCIAL INSTRUMENTS (CONTINUED)

Derivative financial instruments and changes thereto recorded in the three ~~and nine~~ months ended ~~September 30,~~March 31, 2021 and 2020 ~~and 2019~~ include the following:

Three Months Ended
September 30,
Nine Months Ended
September 30,
Three Months Ended March 31,
2020 2019 2020 2019 2021 2020

Balance, beginning of period $ 257,384 $ 632,605 $ 991,288 $ 800,440 $ — $ 991,288
Inception of derivative financial instruments --- 472,644 211,498 1,276,703
Inception of derivative financial instruments related to issuance of convertible notes payable — 72,890
Change in fair value of derivative financial instruments (12,802 ) (158,691 ) (739,485 ) (574,205 ) — (740,355 )
Conversion or extinguishment of derivative financial instruments (244,582 ) (119,898 ) (463,301 ) (676,278 ) — (103,885 )

Balance, end of period $ --- $ 826,660 $ -- $ 826,660 $ — $ 219,938

Fair market value of the derivative financial instruments was measured using the following assumptions:

Nine Months Ended
September 30, Three Months Ended
March 31,
2020 2019 2021 2020

Pricing model utilized Binomial Lattice Black/Scholes Binomial Lattice Binomial Lattice
Risk free rate range 0.05% to 1.61% 1.75% to 2.73% — 0.05% to 1.61%
Expected life range (in years) 0.14 to 1.00 0.01 to 1.00 — 0.14 to 1.00
Volatility range 117.48% to 144.51% 119.04% to 293.97% — 117.48% to 125.32%
Dividend yield 0.00% 0.00% — 0.00%

In addition, specific assumptions regarding investor exercise behavior were used in ~~2020,~~the above periods, including probability assumptions related to estimated exercise behavior. The entire amount of derivative instrument liabilities is classified as current due to the fact that settlement of the derivative instruments could be required within twelve months of the balance sheet date.

During ~~the nine months ended September 30,~~ 2020, the Company ~~repaid 13 outstanding convertible notes and holders converted in part or in full an additional eight~~retired all convertible notes for which the conversion rate was adjusted based on a discount to the market price of the Company’s common stock, which gave rise to ECF-related derivative financial instruments. Accordingly, the Company had no further derivative financial instruments outstanding as of ~~September 30,~~March 31, 2021 or December 31, 2020.

NOTE 1514 – SHAREHOLDERS’ EQUITY ~~(DEFICIT)~~

~~Investment Transaction – August 2020~~
On August 20, 2020, the Company entered into the Contribution Agreement with the Trusts and Michael T. Dent, the Chief Executive Officer and Chairman of the board of directors of the Company. Pursuant to the Contribution Agreement, the Trusts contributed an aggregate of 76,026 shares of common stock of NeoGenomics, Inc. with a fair value of $3,006,889 to the Company. In consideration for the foregoing, the Company issued the Trusts an aggregate of 2,750,000 shares of the Company’s newly designated Series B Preferred stock and an aggregate of 24,522,727 shares of the Company’s common stock.

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
~~NOTE 15 – SHAREHOLDERS’ EQUITY (DEFICIT) (CONTINUED)~~
Beginning on December 31, 2022, each share of Series B Preferred Stock is convertible into five shares of the Company’s common stock, subject to customary anti-dilution adjustments, including in the event of any stock split. The Series B Preferred Stock ranks senior to the common stock. Upon a liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, the assets of the Company available for distribution to its stockholders will be distributed to holders of Series B Preferred Stock on an as converted basis and pro rata with the holders of common stock. Holders of Series B Preferred Stock are also entitled to participate in dividends declared or paid on the common stock on an as-converted basis.
The holders of Series B Preferred Stock generally are entitled to vote with the holders of the shares of common stock on all matters submitted for a vote of holders of shares of common stock (voting together with the holders of shares of common stock as one class). The holder of the shares of Preferred B Stock shall have that number of votes (identical in every other respect to the voting rights of the holders of common stock entitled to vote at any regular or special meeting of the shareholders) equal to 100 shares of common stock for each share of Preferred B Preferred Stock held (which shall never be deemed less than 51% of the vote required to approve any action), which Nevada law provides may or must be approved by vote or consent of the holders of common stock or the holders of other securities entitled to vote, if any.
At inception of the transaction, the Company recognized a beneficial conversion feature in the amount of $825,000, representing the difference between (i) the intrinsic price per share of the Series B Preferred based on the portion of proceeds allocated to the fair value of the Series B Preferred, and (ii) the fair value of the Company’s common stock. The beneficial conversion feature is being amortized as a deemed dividend from the inception date of the transaction through the end of the Series B Preferred conversion restriction on December 31, 2022. Amortization of the beneficial conversion feature is reflected in income or loss available to common stockholders on the statement of operations. Further, since the Company have negative retained earnings, so there is no change to APIC or anywhere else in net equity from the deemed dividend and therefore nothing to show on the statement of equity.
~~Other~~ Private Placements

During the ~~nine~~three months ended ~~September 30, 2019,~~March 31, 2021, the Company sold ~~1,550,001~~11,787,766 shares of common stock in ~~three~~46 separate private placement ~~transactions and~~transactions. The Company received ~~$415,000~~$3,488,725 in proceeds from the sales. In connection with the stock sales, the Company also issued ~~1,025,001~~5,893,889 five-year warrants to purchase shares of common stock ~~with~~at exercise prices between ~~$0.25~~$0.27 and ~~$0.50.~~$1.05 per share.

During the ~~nine~~three months ended ~~September 30,~~March 31, 2020, the Company sold ~~6,650,843~~2,412,087 shares of common stock in 20seven separate private placement ~~transactions and~~transactions. The Company received ~~$673,001~~$315,000 in proceeds from the sales. ~~The shares were issued at per share prices between $0.06 and $0.17.~~ In connection with the stock sales, the Company also issued ~~3,463,825~~1,134,616 five-year warrants to purchase shares of common stock at an exercise price ~~between $0.16~~of $0.23 and ~~$0.27~~71,429 five-year warrants to purchase shares of common stock at an exercise price of $0.24 per share. ~~Of these shares, 7,143 with respect to proceeds of $749 were issuable as of September 30, 2020.~~

Investment Agreement Draws

During ~~the nine~~three months ended ~~September 30,~~March 31, 2021 and 2020, ~~and 2019,~~ the Company issued ~~4,975,491~~3,006,098 and ~~4,273,779~~1,331,432 common shares, respectively, pursuant to draws made by the Company under the Investment Agreement and received an aggregate of ~~$426,299~~$900,636 and ~~$825,616,~~$122,433, respectively, in net proceeds from the draws.

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 14 – SHAREHOLDERS’ EQUITY (CONTINUED)
Shares issued to Consultants
During the three months ended March 31, 2021 and 2020, the Company issued 475,000 and -0- common shares, respectively, to consultants for services rendered. In connection with the issuances, the Company recognized expenses totaling $122,829 and $-0- in the three months ended March 31, 2021 and 2020, respectively.
Common Stock Issuable

As of ~~September 30, 2020~~March 31, 2021 and December 31, ~~2019,~~2020, the Company was obligated to issue the following shares:

September 30,
2020 December 31,
2019
Amount Shares Amount Shares

Shares earned by consultants, employees and directors but not yet issued $ 181,343 1,458,095 $ 100,538 568,142
Shares issuable pursuant to stock subscriptions received 749 7,143 59,000 479,762
$ 182,092 1,465,238 $ 159,538 1,047,904
March 31, 2021 December 31, 2020
Amount Shares Amount Shares

Shares issuable to consultants, employees and directors $ 361,817
2,178,770
$ 262,273 2,150,020
Shares issuable pursuant to warrant exercise 62,500 625,000 — —
$ 424,317
2,803,770
$ 262,273 2,150,020

During December 2019, the Company completed stock subscription agreements totaling $59,000 for the sale of 479,762 shares of common stock. The funds were received and shares were issued in January and February 2020.

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
~~NOTE 15 – SHAREHOLDERS’ EQUITY (DEFICIT) (CONTINUED)~~
Stock Warrants

Transactions involving our stock warrants during the ~~nine~~three months ended ~~September 30,~~March 31, 2021 and 2020 ~~and 2019~~ are summarized as follows:

2020 2019
Weighted Weighted
Average Average
Exercise Exercise
Number Price Number Price
Outstanding at beginning of the period 47,056,293 $ 0.17 46,161,463 $ 0.18
Granted during the period 3,463,825 $ 0.20 1,805,001 $ 0.35
Exercised during the period --- $ --- �� (4,099,256 ) $ (0.00 )
Expired during the period (50,000 ) $ 0.40 --- $ ---
Outstanding at end of the period 50,470,118 $ 0.18 43,867,208 $ 0.20

Exercisable at end of the period 50,470,118 $ 0.18 43,867,208 $ 0.20

Weighted average remaining life 3.4 years 3.0 years
2021 2020
Weighted Weighted
Average Average
Exercise Exercise
Number Price Number Price
Outstanding at beginning of the period 51,352,986 $ 0.14 47,056,293 $ 0.21
Granted during the period 19,585,790 $ 0.34 1,277,474 $ 0.23
Exercised during the period (11,196,742 ) $ (0.06 ) — $ —
Outstanding at end of the period 59,742,034 $ 0.22 48,333,767 $ 0.21

Exercisable at end of the period 59,742,034 $ 0.22 45,058,874 $ 0.21

Weighted average remaining life 3.7 years 3.5 years

The following table summarizes information about the Company’s stock warrants outstanding as of ~~September 30, 2020:~~March 31, 2021:

Warrants Outstanding Warrants Exercisable
Weighted-
Average Weighted- Weighted-
Remaining Average Average
Exercise Number Contractual Exercise Number Exercise
Prices Outstanding Life (years) Price Exercisable Price
$ 0.0001 to 0.09 15,287,011 4.2 $ 0.07 15,287,011 $ 0.07
$ 0.10 to 0.24 21,125,618 3.0 $ 0.18 21,125,618 $ 0.18
$ 0.25 to 0.49 10,117,489 3.7 $ 0.28 10,117,489 $ 0.28
$ 0.50 to 1.00 3,940,000 1.4 $ 0.28 3,940,000 $ 0.28
$ 0.05 to 1.00 50,470,118 3.4 $ 0.18 50,470,118 $ 0.18
Warrants Outstanding Warrants Exercisable
Weighted-
Average Weighted- Weighted-
Remaining Average Average
Exercise Number Contractual Exercise Number Exercise
Prices Outstanding Life (years) Price Exercisable Price
$ 0.0001 to 0.09 15,067,351 3.7 $ 0.07 15,067,351 $ 0.07
$ 0.10 to 0.24 11,549,499 2.8 $ 0.16 11,549,499 $ 0.16
$ 0.25 to 0.49 28,560,496 4.3 $ 0.31 28,560,496 $ 0.31
$ 0.50 to 1.00 4,564,688 2.3 $ 0.34 4,564,688 $ 0.34
$ 0.05 to 1.00 59,742,034 3.7 $ 0.22 59,742,034 $ 0.22

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 14 – SHAREHOLDERS’ EQUITY (CONTINUED)

During the ~~nine~~three months ended ~~September 30,~~March 31, 2021 and 2020, ~~and 2019,~~ the Company issued ~~3,463,825~~19,585,790 and ~~1,805,001~~1,277,474 warrants, respectively, the aggregate grant date fair value of which was ~~$222,987~~$4,496,555 and ~~$477,097,~~$100,547, respectively. The fair value of the warrants was calculated using the following range of assumptions:

Nine Months Ended September 30, Three Months Ended
March 31,
2020 2019 2021 2020

Pricing model utilized Binomial Lattice Black/Scholes Binomial Lattice Binomial Lattice
Risk free rate range 0.19% to 1.59% 1.66% to 2.52% 0.38% to 0.86% 1.38% to 1.59%
Expected life range (in years) 5.00 years 3.00 to 5.00 3.00 to 5.00 years 5.00 years
Volatility range 119.69% to 132.19% 119.34% to 212.98% 170.58% to 193.21% 119.69% to 124.02%
Dividend yield 0.00% 0.00% 0.00% 0.00%

In addition, specific assumptions regarding investor exercise behavior were used in ~~2020,~~the above periods, including probability assumptions related to estimated exercise behavior.

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~During the three months ended March 31, 2021, the Company received $62,500 upon the exercise of 625,000 warrants with an exercise price of $0.10. Additionally, the Company issued 9,047,332 shares upon cashless exercise of 10,571,742 warrant shares exercised using a cashless exercise feature in settlement of litigation and other disputes amounts totaling $614,221 that had been accrued in 2020. There were no warrants exercised during the three months ended March 31, 2020.

~~NOTE 15 – SHAREHOLDERS’ EQUITY (DEFICIT) (CONTINUED)~~
Employee Equity Incentive Plan

On January 1, 2016, the Company instituted the Employee Equity Incentive Plan (the “EIP”) for the purpose of having equity awards available to allow for equity participation by its employees. The EIP allows for the issuance of up to 15,503,680 shares of the Company’s common stock to employees, which may be issued in the form of stock options, stock appreciation rights, or restricted shares. The EIP is governed by the Company’s board, or a committee that may be appointed by the board in the future.

The following table summarizes the status of shares issued and outstanding under the EIP outstanding as of and for the ~~nine~~three months ended ~~September 30, 2020~~March 31, 2021 and ~~2019:~~2020:

2020 2019 2021 2020
Outstanding at beginning of the period 1,874,063 1,738,750 2,603,528 1,874,063
Granted during the period 664,465 135,313 87,500 207,500
Terminated during the period (62,500 ) ---
Forfeited during the period (2,500 ) (62,500 )
Outstanding at end of the period 2,476,028 1,874,063 2,688,528 2,019,063

Shares vested at period-end 2,176,028 1,510,313 2,488,528 1,700,313
Weighted average grant date fair value of shares granted during the period $ 0.14 $ 0.26 $ 0.11 $ 0.10
Aggregate grant date fair value of shares granted during the period $ 18,760 $ 12,805 $ 4,050 $ 17,000
Shares available for grant pursuant to EIP at period-end 9,778,403 9,592,868 9,748,402 10,275,368

Total stock-based compensation recognized for employee grants under the EIP was ~~$79,196~~$12,821 and ~~$10,534~~$17,696 during the three months ended ~~September 30,~~March 31, 2021 and 2020, ~~and 2019, respectively, and $109,349 and $69,128 during the nine months ended September 30, 2020 and 2019,~~ respectively. Total unrecognized stock compensation related to these grants was ~~$31,989~~$12,521 as of ~~September 30, 2020.~~March 31, 2021.

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 14 – SHAREHOLDERS’ EQUITY (CONTINUED)

A summary of the status of nonvested shares issued pursuant to the EIP as of and for the ~~nine~~three months ended ~~September 30,~~March 31, 2021 and 2020 ~~and 2019~~ is presented below:

2020 2019 2021 2020
Weighted Weighted Weighted Weighted
Average Average Average Average
Grant Date Grant Date Grant Date Grant Date
Shares Fair Value Shares Fair Value Shares Fair Value Shares Fair Value
Nonvested at beginning of period 332,500 $ 0.17 540,000 $ 0.16 200,000 $ 0.17 332,500 $ 0.17
Granted 664,465 $ 0.14 --- $ --- 87,500 $ 0.11 207,500 $ 0.10
Vested (609,465 ) $ 0.14 (176,250 ) $ 0.16 (87,500 ) $ 0.12 (158,750 ) $ 0.08
Forfeited (87,500 ) $ 0.06 --- $ --- — $ — (62,500 ) $ 0.07
Nonvested at end of period 300,000 $ 0.20 363,750 $ 0.16 200,000 $ 0.16 318,750 $ 0.19

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30,~~During the three months ended March 31, 2021 and 2020,
~~(UNAUDITED)~~ the Company issued 240,310 and 132,500 shares to employees under the EIP pursuant to the grants and vesting described in the tables above.

~~NOTE 15 – SHAREHOLDERS’ EQUITY (DEFICIT) (CONTINUED)~~
Employee Stock Options

The following table summarizes the status of options outstanding as of and for the ~~nine~~three months ended ~~September 30, 2020~~March 31, 2021 and ~~2019:~~2020:

2020 2019 2021 2020
Weighted Weighted Weighted Weighted
Average Average Average Average
Exercise Exercise Exercise Exercise
Number Price Number Price Number Price Number Price
Outstanding at beginning of the period 3,269,250 $ 0.21 3,707,996 $ 0.18 3,111,750 $ 0.20 3,269,250 $ 0.21
Granted during the period 60,000 $ 0.09 1,078,750 $ 0.26 — $ — 20,000 $ 0.11
Exercised during the period --- $ --- (154,166 ) $ 0.20 (12,500 ) $ (0.25 ) — $ —
Forfeited during the period (80,000 ) $ 0.26 (595,830 ) $ 0.20 (32,500 ) $ (0.16 ) (80,000 ) $ (0.26 )
Outstanding at end of the period 3,249,250 $ 0.20 4,036,750 $ 0.20 3,066,750 $ 0.20 3,209,250 $ 0.20

Options exercisable at period-end 2,012,375 1,486,000 2,276,750 1,926,125
Weighted average remaining life (in years) 7.0 7.9 6.4 7.4
Weighted average grant date fair value of options granted during the period $ 0.07 $ 0.20 $ — $ 0.08
Options available for grant at period-end 9,775,903 9,592,868 9,823,402 10,275,368

The following table summarizes information about the Company’s stock options outstanding as of ~~September 30, 2020:~~March 31, 2021:

Options Outstanding Options Outstanding Options Exercisable Options Outstanding Options Exercisable
Weighted- Weighted-
Average Weighted- Weighted- Average Weighted- Weighted-
Remaining Average Average Remaining Average Average
Exercise Exercise Number Contractual Exercise Number Exercise Exercise Number Contractual Exercise Number Exercise
Prices Prices Outstanding Life (years) Price Exercisable Price Prices Outstanding Life (years) Price Exercisable Price
$ --- to 0.10 1,283,000 5.2 $ 0.08 1,283,000 0.08 — to 0.10 1,283,000 4.7 $ 0.08 1,283,000 0.08
$ 0.11 to 0.31 1,966,250 8.1 $ 0.28 729,375 0.29 0.11 to 0.31 1,783,750 7.6 $ 0.28 993,750 0.29
$ 0.08 to 0.31 3,249,250 7.0 $ 0.20 2,012,375 $ 0.16 0.08 to 0.31 3,066,750 6.4 $ 0.20 2,276,750 $ 0.17

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 14 – SHAREHOLDERS’ EQUITY (CONTINUED)

Total stock-based compensation recognized related to option grants was ~~$19,305~~$18,334 and ~~$24,107~~$20,880 during the three months ended ~~September 30,~~March 31, 2021 and 2020, ~~and 2019, respectively, and $61,155 and $86,054 during the nine months ended September 30, 2020 and 2019,~~ respectively.

A summary of the status of nonvested options issued pursuant to the EIP as of and for the ~~nine~~three months ended ~~September 30,~~March 31, 2021 and 2020 ~~and 2019~~ is presented below:

2020 2019
Weighted Weighted
Average Average
Grant Date Grant Date
Shares Fair Value Shares Fair Value
Nonvested at beginning of period 1,636,250 $ 0.22 2,332,413 $ 0.13
Granted 60,000 $ 0.07 1,078,750 $ 0.20
Vested (379,375 ) $ 0.20 (264,583 ) $ 0.18
Forfeited (80,000 ) $ 0.21 (595,830 ) $ 0.02
Nonvested at end of period 1,236,875 $ 0.21 2,550,750 $ 0.18
37
2021 2020
Weighted Weighted
Average Average
Grant Date Grant Date
Shares Fair Value Shares Fair Value
Nonvested at beginning of period 1,044,375 $ 0.21 1,636,250 $ 0.22
Granted — $ — 20,000 $ 0.08
Vested (225,000 ) $ 0.21 (293,125 ) $ 0.20
Forfeited (29,375 ) $ 0.12 (80,000 ) $ 0.21
Nonvested at end of period 790,000 $ 0.22 1,283,125 $ 0.22

NOTE 15 – CONTINGENT ACQUISITION CONSIDERATION
Contingent acquisition consideration as of March 31, 2021 and December 31, 2020 was comprised of the following:
March 31, December 31,
2021 2020

Fair value of HCFM contingent acquisition consideration $ 312,544 $ 301,236
Fair value of CHM contingent acquisition consideration 715,913 682,661
Fair value of MOD contingent acquisition consideration 1,107,683 516,543

$ 2,136,140 $ 1,500,440
Contingent acquisition consideration relates to future earn-out payments potentially payable related to the Company’s acquisitions of HCFM, CHM and MOD. The terms of the earn-outs related to each acquisition require the Company to pay the former owners additional acquisition consideration for the achievement of prescribed revenue and/or earnings targets for performance of the underlying business for up to four years after the respective acquisition date. Contingent acquisition consideration for each entity is recorded at fair value using a probability-weighted discounted cash flow projection. The fair value of the contingent acquisition consideration is remeasured at the end of each reporting period and changes are included in the statement of operations under the caption “Change in fair value of contingent acquisition consideration.” Loss from the change in fair value of contingent acquisition consideration was $635,700 and $6,621 during the three months ended March 31, 2021 and 2020, respectively.
Maturities of contingent acquisition consideration were as follows as of March 31, 2021:
2021 (April to December) $ 689,083
2022 429,612
2023 507,557
2024 509,888
$ 2,136,140

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~SEPTEMBER 30, 2020~~MARCH 31, 2021
(UNAUDITED)

NOTE 16 – COMMITMENTS AND CONTINGENCIES

Contracts ~~related~~Related to Medicare ~~shared savings revenue~~Shared Savings Revenue

The Company acquired CHM and its subsidiary AHP on May 18, 2020. CHM and AHP combine to operate an ACO under the terms of the MSSP as administered by the CMS. The MSSP is a program created under the Affordable Care Act (the “ACA,” also known as “Obamacare”) designed to enhance the efficiency of healthcare provided to patients covered by Medicare. The program allows for the creation of ACOs, which are organizations that agree to take responsibility for the efficiency of healthcare services provided by a group of participating healthcare providers under Medicare. The ACO is held accountable for the efficiency of the healthcare services of its participating providers as measured against benchmarks prescribed in the MSSP and earns shared savings payments if such benchmarks are met.

The Company, via AHP is party to a Medicare Shared Savings Program Accountable Care Organization Participation Agreement with the CMS that establishes AHP as an ACO. The agreement is effective through December 31, 2024. The Company must comply with the terms and conditions of the agreement in order to maintain its status as an ACO and generate shared savings revenue.

The Company, via CHM, is party to 33 separate participant agreements with participating providers that are members of the Company’s ACO with expiration dates between 2020 and 2024. These agreements include certain restrictions and requirements to which the participating providers must adhere in order to maintain participation in the ACO.

Supplier Concentration
The Company relies on a sole supplier for the fulfillment of all of its product sales made through MOD, which was acquired by the Company in October 2020.
Service contracts

The Company carries various service contracts on its office buildings & certain copier equipment for repairs, maintenance and inspections. All contracts are short term and can be cancelled.

Litigation

From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not aware of any such legal proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.None.

On July 20, 2020, Empery Asset Master Ltd., Empery Tax Efficient, LP and Empery Tax Efficient II, LP, (the “Complainants”) filed a complaint against the Company in the Supreme Court of the State of New York. The Complaint alleges that the Company’s acquisition of CHM, in which the Company issued stock consideration of 2,240,838 common shares, triggered a change of control clause in warrants held by the Complainants that would allow the Complainants to demand cash value for their warrants. The Company believes that the asserted claims lack merit and intends to defend against all of the claims vigorously. Due to the inherent uncertainties of litigation, the Company cannot predict the outcome of the actions at this time and can give no assurance that the asserted claims will not have a material adverse effect on its financial position or results of operations. The Company has responded to the Complaint but discovery has not yet commenced as of the date of this filing.
On August 24, 2020, the Company entered into a settlement agreement in response to a complaint filed by Delaney Equity Group LLC seeking unpaid fees from a 2015 Advisor, Consulting and Investment Banking Agreement. Pursuant to the terms of the settlement, the Company agreed to make cash payments totaling $75,000 over a six-month period. If the payments are not made in full and timely, the amount due increases to $112,500.
Leases

Maturities of operating lease liabilities were as follows as of ~~September 30, 2020:~~March 31, 2021:

2020 $ 50,882
2021 205,430
2022 159,561
2023 68,457
Total lease payments 484,330
Less interest (180,430 )
Present value of lease liabilities $ 303,900

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
2021 (April to December) $ 213,854
2022 238,637
2023 140,944
Total lease payments 593,435
Less interest (202,377 )
Present value of lease liabilities $ 391,058

~~NOTE 16 – COMMITMENTS AND CONTINGENCIES (CONTINUED)~~
Our lease for office space for our NWC practice expired in July 2020. The Company entered into a new three-year lease agreement for a different facility in Naples facility comprised of 3,650 square feet commencing in August 2020.
Employment/Consulting Agreements

The Company has employment agreements with certain of its physicians, nurse practitioners and physical therapists in the Health Services division. The agreements generally call for a fixed salary at the beginning of the contract with a transaction to performance-based pay later in the contract.

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)
NOTE 16 – COMMITMENTS AND CONTINGENCIES (CONTINUED)

On July 1, 2016, the Company entered into an employment agreement with Dr. Michael Dent, Chief Executive Officer and a member of the Board of Directors. Dr. Dent’s employment agreement continues until terminated by Dr. Dent or the Company. If Dr. Dent’s employment is terminated by the Company (unless such termination is “For Cause” as defined in his employment agreement), then upon signing a general waiver and release, Dr. Dent will be entitled to severance in an amount equal to 12 months of his then-current annual base salary, as well as the pro-rata portion of any bonus that would be due and payable to him. In the event that Dr. Dent terminates the employment agreement, he shall be entitled to any accrued but unpaid salary and other benefits up to and including the date of termination, and the pro-rata portion of any unvested time-based options up until the date of termination.

On July 1, 2016, the Company entered into an agreement with Mr. George O’Leary, the Company’s Chief Financial Officer and a member of the Board of Directors, extending his prior agreement with the Company. ~~Mr. O’Leary’s employment agreement continues until terminated by Mr. O’Leary or the Company.~~ If Mr. ~~O’Leary~~O’Leary’s employment is terminated by the Company (unless such termination is “For Cause” as defined in his employment agreement), then upon signing a general waiver and release, Mr. O’Leary will be entitled to receive his base salary and the Company shall maintain his employee benefits for a period of twelve (12) months beginning on the date of termination. In the event that Mr. O’Leary terminates the agreement, he shall be entitled to any accrued by unpaid salary and other benefits up to and including the date of termination. On July 1, 2018, the Company and Mr. O’Leary entered into an Extension Letter Agreement pursuant to which Mr. O’Leary was increased to full time employment (previously half-time) and agreed to extend the term of his employment to September 30, 2022. In addition to a base salary, the extension provides Mr. O’Leary with certain performance-based cash bonuses, stock grants, and stock option grants.

On May 18, 2020, the Company entered into separate 4-year consulting services agreements with each of the two principals of the ACO/MSO business acquired in May 2020 that call for each person to earn fixed annual consulting fees and a share of Medicare shared savings revenue, consulting revenue and overall profits generated by the underlying business.

NOTE 17 – SEGMENT REPORTING

The Company has ~~three~~four reportable segments: Health Services, Digital Healthcare, ACO/MCO and ~~ACO/MCO.~~Medical Distribution. Health Services division is comprised of the operations of (i) Naples Women’s Center (“NWC”), a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology), and General Practice, (ii) Naples Center for Functional Medicine (“NCFM”), a Functional Medical Practice acquired in April 2019 that is engaged in improving the health of its patients through individualized and integrative health care, and (iii) Bridging the Gap Physical Therapy (“BTG”), a physical therapy practice in Bonita Springs, FL that provides hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery. The Company’s Digital Healthcare segment develops and plans to operate an online personal medical information and record archive system, the “HealthLynked Network,” which will enable patients and doctors to keep track of medical information via the Internet in a cloud-based system. The ACO/MSO Division is comprised of the business acquired with CHM, which assists physician practices in providing coordinated and more efficient care to patients via the MSSP as administered by the CMS, which rewards providers for efficiency in patient care. The Medical Distribution Division is comprised of the operations of MedOffice Direct LLC (“MOD”), a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States acquired by the Company on October 19, 2020.
The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies.

39

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~SEPTEMBER 30, 2020~~MARCH 31, 2021
(UNAUDITED)

NOTE 17 – SEGMENT REPORTING (CONTINUED)

Segment information for the three months ended ~~September 30, 2020 and 2019~~March 31, 2021 was as follows:

Three Months Ended September 30, 2020 Three Months Ended September 30, 2019
Health Services Digital Healthcare ACO / MSO Total Health Services Digital Healthcare ACO / MSO Total
Revenue
Patient service revenue, net $ 1,054,806 $ --- $ --- $ 1,054,806 $ 1,172,561 $ --- $ --- $ 1,172,561
Medicare shared savings revenue --- --- 767,744 767,744 --- --- --- ---
Consulting revenue --- --- 217,605 217,605 --- --- --- ---
Total revenue 1,054,806 --- 985,349 2,040,155 1,172,561 --- --- 1,172,561

Operating Expenses
Practice salaries and benefits 590,690 --- --- 590,690 708,571 --- --- 708,571
Other practice operating expenses 548,667 --- --- 548,667 521,341 --- --- 521,341
Medicare shared savings expenses --- --- 759,848 759,848 --- --- --- ---
General and administrative --- 958,874 --- 958,874 --- 733,360 --- 733,360
Depreciation and amortization 24,557 594 --- 25,151 24,385 595 --- 24,980
Total Operating Expenses 1,163,914 959,468 759,848 2,883,230 1,254,297 733,955 --- 1,988,252

Loss from operations $ (109,108 ) $ (959,468 ) $ 225,501 $ (843,075 ) $ (81,736 ) $ (733,955 ) $ --- $ (815,691 )

Other Segment Information
Interest expense $ 23,186 $ 49,349 $ --- $ 72,535 $ 5,165 $ 64,397 $ --- $ 69,562
Loss on sales of marketable securities $
---
$ 281,606 $
---
$ 281,606 $
---
$
---
$
---
$
---

Loss on extinguishment of debt $ --- $ 450,999 $ --- $ 450,999 $ --- $ (4,904 ) $ --- $ (4,904 )
Financing cost $ --- $ --- $ --- $ --- $ --- $ 12,009 $ --- $ 12,009
Amortization of original issue and debt discounts on convertible notes $ --- $ 65,816 $ --- $ 65,816 $ --- $ 362,728 $ --- $ 362,728
Change in fair value of debt $ --- $ 79,062 $ --- $ 79,062 $ --- $ 28,885 $ --- $ 28,885
Change in fair value of derivative financial instruments $ --- $ (12,802 ) $ --- $ (12,802 ) $ --- $ (158,691 ) $ --- $ (158,691 )
Change in fair value of contingent acquisition consideration $ --- $ (45,996 ) $ --- $ (45,996 ) $ --- $ --- $ --- $ ---
Three Months Ended March 31, 2021
Health Services Digital Healthcare ACO / MSO Medical Distribution Total
Revenue
Patient service revenue, net $ 1,514,376 $ — $ — $ — $ 1,514,376
Consulting and event revenue
— 11,113 76,542 — 87,655
Product revenue — — — 182,663 182,663
Total revenue 1,514,376 11,113 76,542 182,663 1,784,694

Operating Expenses
Practice salaries and benefits 663,937 — — — 663,937
Other practice operating expenses 730,784 — — — 730,784
Medicare shared savings expenses — — 211,507 — 211,507
Cost of product revenue — — — 168,596 168,596
Selling, general and administrative expenses — 1,305,320 — 60,817 1,366,137
Depreciation and amortization 28,323 595 — 182,740 211,658
Total Operating Expenses 1,423,044 1,305,320 211,507 412,153 3,352,619

(Loss) income from operations $ 91,332 $ (1,294,802 ) $ (134,965 ) $ (229,490 ) $ (1,567,925 )

Other Segment Information
Interest expense $ 4,197 $ 6,282 $ — $ 109 $ 10,588
Loss on extinguishment of debt $ — $ 5,589,994 $ — $ — $ 5,589,994
Change in fair value of debt $ — $ 19,246 $ — $ — $ 19,246
Change in fair value of contingent acquisition consideration $ — $ 635,700 $ — $ — $ 635,700

March 31, 2021

Identifiable assets $ 2,411,744 $ 3,043,929 $ 1,128,491 $ 3,287,628 $ 9,871,792
Goodwill $ — $ — $ 381,856 $ 766,249 $ 1,148,105
December 31, 2020
Identifiable assets $ 2,120,714 $ 192,568 $ 1,115,148 $ 3,450,013 $ 6,878,443
Goodwill $ — $ — $ 381,856 $ 766,249 $ 1,148,105

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
~~SEPTEMBER 30, 2020~~MARCH 31, 2021
(UNAUDITED)

NOTE 17 – SEGMENT REPORTING (CONTINUED)

Segment information for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 ~~and 2019~~ was as follows:

Nine Months Ended September 30, 2020 Nine Months Ended September 30, 2019 Three Months Ended March 31, 2020
Health Services Digital Healthcare ACO / MSO Total Health Services Digital Healthcare ACO / MSO Total Health Services Digital Healthcare ACO / MSO Medical Distribution Total
Revenue
Patient service revenue, net $ 3,502,836 $ --- $ --- $ 3,502,836 $ 2,845,941 $ --- $ --- $ 2,845,941 $ 1,336,940 $ — $ — $ — $ 1,336,940
Medicare shared savings revenue --- --- 767,744 767,744 --- --- --- ---
Consulting revenue --- --- 268,025 268,025 --- --- --- --- — — — — —
Product revenue — — — — —
Total revenue 3,502,836 --- 1,035,769 4,538,605 2,845,941 --- --- 2,845,941 1,336,940 — — — 1,336,940

Operating Expenses
Practice salaries and benefits 1,910,897 --- --- 1,910,897 1,762,662 --- --- 1,762,662 765,121 — — — 765,121
Other practice operating expenses 1,633,380 --- --- 1,633,380 1,287,432 --- --- 1,287,432 563,691 — — — 563,691
Medicare shared savings expenses --- --- 824,084 824,084 --- --- --- --- — — — — —
General and administrative --- 2,116,159 ---
2,116,159
--- 2,084,630 --- 2,084,630
Cost of product revenue — — — — —
Selling, general and administrative expenses — 510,976 — — 510,976
Depreciation and amortization 73,027 1,784 --- 74,811 46,561 1,784 --- 48,345 24,191 595 — — 24,786
Total Operating Expenses 3,617,304 2,117,943 824,084 6,559,331 3,096,655 2,086,414 --- 5,183,069 1,353,003 511,571 — — 1,864,574

Loss from operations $ (114,468 ) $ (2,117,943 ) $ 211,685 $ (2,020,726 ) $ (250,714 ) $ (2,086,414 ) $ --- $ (2,337,128 ) $ (16,063 ) $ (511,571 ) $ — $ — $ (527,634 )

Other Segment Information
Interest expense $ 35,096 $ 158,038 $ --- $ 193,134 $ 17,010 $ 159,219 $ --- $ 176,229 $ 5,536 $ 56,645 $ — $ — $ 62,181

Loss on sales of marketable securities $ --- $
281,606
$ --- $
281,606
$ --- $ --- $ --- $ ---

Loss on extinguishment of debt $ --- $ 1,347,371 $ --- $ 1,347,371 $ --- $ 62,459 $ --- $ 62,459 $ — $ 467,937 $ — $ — $ 467,937
Financing cost $ --- $ --- $ --- $ --- $ --- $ 133,244 $ --- $ 133,244
Amortization of original issue and debt discounts on convertible notes $ --- $ 530,930 $ --- $ 530,930 $ --- $ 841,725 $ --- $ 841,725 $ — $ 292,163 $ — $ — $ 292,163
Change in fair value of debt $ --- $ 198,764 $ --- $ 198,764 $ --- $ 88,991 $ --- $ 88,991 $ — $ (35,965 ) $ — $ — $ (35,965 )
Change in fair value of derivative financial instruments $ --- $ (739,485 ) $ --- $ (739,485 ) $ --- $ (574,205 ) $ --- $ (574,205 ) $ — $ (740,355 ) $ — $ — $ (740,355 )
Change in fair value of contingent acquisition consideration $ --- $ (687 ) $ --- $ (687 ) $ — $ 6,621 $ — $ — $ 6,621
Identifiable assets as of March 31, 2020 $ 2,175,990 $ 136,499 $ --- $ --- $ 2,312,489

September 30,
2020 December 31,
2019
Identifiable assets $ 2,250,647 $ 952,716 $ 901,736 $ 4,105,099 $ 2,356,886 $ 117,802 $ --- $ 2,474,688
Goodwill $ --- $ --- $ 1,454,856 $ 1,454,856 $ 71,866 $ --- $ --- $ 71,866
The Digital Healthcare segment recognized revenue of ~~$1,366~~$180 and ~~$1,164~~$1,356 in the three months ended ~~September 30,~~March 31, 2021 and 2020, ~~and 2019, respectively, and $3,797 and $5,075 in the nine months ended September 30, 2020 and 2019,~~ respectively, related to subscription revenue billed to and paid for by the Company’s physicians for access to the HealthLynked Network. The revenue for Digital Healthcare and related expense for Health Services were eliminated on consolidation.

~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~

NOTE 18 – FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate their respective fair values due to the short-term nature of such instruments. The Company measures certain financial instruments at fair value on a recurring basis, including certain convertible notes payable and related party loans which were extinguished and reissued and are therefore subject to fair value measurement, as well as derivative financial instruments arising from conversion features embedded in convertible promissory notes for which the conversion rate is not fixed. All financial instruments carried at fair value fall within Level 3 of the fair value hierarchy as their value is based on unobservable inputs. The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made.

The following table summarizes the conclusions reached regarding fair value measurements as of ~~September 30, 2020~~March 31, 2021 and December 31, ~~2019:~~2020:

Total As of March 31, 2021
Level 1 Level 2 Level 3 Fair Value Total
Convertible notes payable $ --- $ --- $ 1,153,279 $ 1,153,279
Level 1 Level 2 Level 3 Fair Value
Contingent acquisition consideration --- --- 926,597 926,597 $ — $ — $ 2,136,140 $ 2,136,140

Total $ --- $ --- $ 2,079,876 $ 2,079,876 $ — $ — $ 2,136,140 $ 2,136,140

HEALTHLYNKED CORP.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2021
(UNAUDITED)

As of December 31, 2019
Total
Level 1 Level 2 Level 3 Fair Value
Convertible notes payable $ --- $ --- $ 723,482 $ 723,482
Notes payable to related party --- --- 193,007 193,007
Derivative financial instruments --- --- 991,288 991,288
Contingent acquisition consideration --- --- 500,000 500,000

Total $ --- $ --- $ 2,407,777 $ 2,407,777
NOTE 18 – FAIR VALUE OF FINANCIAL INSTRUMENTS (CONTINUED)
As of December 31, 2020
Total
Level 1 Level 2 Level 3 Fair Value
Convertible notes payable $ — $ — $ 1,336,350 $ 1,336,350
Contingent acquisition consideration — — 1,500,440 1,500,440

Total $ — $ — $ 2,836,790 $ 2,836,790

The changes in Level 3 financial instruments that are measured at fair value on a recurring basis during the three ~~and nine~~ months ended ~~September 30,~~March 31, 2021 and 2020 ~~and 2019~~ were as follows:

Three Months Ended
September 30, Nine Months Ended
September 30,
2020 2019 2020 2019

Convertible notes payable $ (46,094 ) $ (22,899 ) $ (117,829 ) $ (70,921 )
Notes payable to related party (32,968 ) (5,986 ) (80,935 ) (18,070 )
Derivative financial instruments 12,802 158,691 739,485 574,205
Contingent acquisition consideration 45,996 --- 687 ---

Total $ (20,264 ) $ 129,806 $ 541,408 $ 485,214
42
~~HEALTHLYNKED CORP.~~
~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~
~~SEPTEMBER 30, 2020~~
~~(UNAUDITED)~~
Three Months Ended
March 31,
2021 2020

Convertible notes payable $ (19,246 ) $ 21,362
Notes payable to related party — 14,603
Derivative financial instruments — 740,355
Contingent acquisition consideration (635,700 ) (6,621 )

Total $ (654,946 ) $ 769,699

NOTE 19 – SUBSEQUENT EVENTS

On ~~October 19, 2020,~~May 6, 2021, the Company ~~entered into an Agreement~~received notification of forgiveness of $277,795 principal and ~~Plan of Merger (the “Merger Agreement”)~~$2,709 accrued interest related to certain PPP Loans taken by ~~and among~~ the Company ~~MOD FL, LLC, a Florida limited liability company~~during 2020.
Subsequent to March 31, 2021 and ~~wholly owned subsidiary of~~through May 14, 2021, the Company ~~(“Merger Sub”), MedOfficeDirect L.L.C. (“MOD”) and certain~~sold 375,276 shares of common stock in 6 separate private placement transactions. The Company received $260,000 in proceeds from the ~~members of MOD. The Merger Agreement provided that the Merger Sub would merge~~sales. In connection with ~~and into MOD, with MOD surviving as a wholly-owned subsidiary of~~these stock sales, the Company ~~(the “Merger”). As consideration for the Merger, the members of MOD are receiving consideration valued at up~~also issued 187,638 five-year warrants to ~~$6,010,000, including (i) the issuance of an aggregate of 19,045,563 restricted~~purchase shares of ~~the Company’s~~ common stock ~~valued~~ at to $2,704,470 upon the closing of the Merger (the “Closing Shares”), (ii) the issuance of an aggregate of up to 10,004,749 restricted shares of the Company’s common stock valued at up to $2,602,330 over a four year period based on MOD achieving certain revenue targets as set forth in the Merger Agreement (the “Earnout Shares”),exercise prices between $0.85 and (iii) the partial satisfaction of certain outstanding debt obligations of MOD in the amount of $703,200 in cash by the Company. The Company and MOD completed the Merger by filing the Certificate of Merger with the Florida Department of State. As a result of the Merger, with MOD surviving as a wholly-owned subsidiary of the Company, the Company acquired all of the assets of MOD. MOD is a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States. With over 13,000 name brand medical products in over 150 different categories, MOD leverages Group Purchasing Organization pricing discounts with a small unit-of-measure direct-to-consumer shipping model to make ordering medical supplies both convenient and highly cost effective for its users. Dr. Michael Dent, the Chief Executive Officer and the Chairman of the Board of Directors of the Company, George O’Leary, the Chief Financial Officer and a director of the Company, and Robert Gasparini, a director of the Company, were members of MOD and received Merger Consideration in connection with the Merger as follows: (1) Dr. Dent received 10,573,745 Closing Shares and may earn up to 5,554,452 additional Earnout Shares, (2) Mr. O’Leary received 1,130,213 Closing Shares and may earn up to 593,707 additional Earnout Shares, and (3) Mr. Gasparini received 99,437 Closing Shares and may earn up to 52,235 additional Earnout Shares.
$0.90 per share.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

You should read the following discussion and analysis of our financial condition and results of operations together with our ~~unaudited~~ financial statements and the related notes appearing elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled ~~“Risk~~“Item 1A. Risk Factors” included in our most recent Annual Report on Form 10-K. All amounts in this report are in U.S. dollars, unless otherwise noted.

Overview

HealthLynked Corp. (the “Company,” “we,” “our,” or “us”) was incorporated in the State of Nevada on August 4, 2014. We currently operate in ~~three~~four distinct divisions: the Health Services Division, the Digital Healthcare Division, the ACO/MSO (Accountable Care Organization / Managed Service Organization) Division, and ~~Digital Healthcare.~~the Medical Distribution Division. Our Health Services division is comprised of the operations of (i) Naples Women’s Center (“NWC”), a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology), and General Practice, (ii) Naples Center for Functional Medicine (“NCFM”), a Functional Medical Practice acquired in April 2019 that is engaged in improving the health of its patients through individualized and integrative health care, and (iii) Bridging the Gap Physical Therapy (“BTG”), a physical therapy practice in Bonita Springs, FL opened in January 2020 that provides hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery. Our Digital Healthcare division develops and ~~plans to operate~~operates an online personal medical information and record archive system, the “HealthLynked Network,” which ~~will enable~~enables patients and doctors to keep track of medical information via the Internet in a cloud-based system. Our ACO/MSO Division is comprised of the business acquired ~~with~~of Cura Health Management LLC (“CHM”) and its subsidiary ACO Health Partners LLC (“AHP”), which were acquired by the Company on May 18, 2020. CHM ~~which~~and AHP operate an Accountable Care Organization (“ACO”) and Managed Service Organization (“MSO”) that assists physician practices in providing coordinated and more efficient care to patients via the Medicare Shared Savings Program (“MSSP”) as administered by the Centers for Medicare and Medicaid Services (the “CMS”), which rewards providers for efficiency in patient care.
~~Recent Developments~~
In January 2020, we launched a new physical therapy practice in Bonita Springs, Florida called Bridging the Gap Physical Therapy. BTG employs two doctors who provide hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery.
~~On May 18, 2020, we acquired a 100% interest in Cura Health Management LLC (“CHM”) and its wholly owned subsidiary ACO Health Partners, LLC (“AHP”).~~ ~~CHM~~ Our Medical Distribution Division is a healthcare enablement company that empowers local providers to own and operate in a franchise-like model that extends their reach and capabilities to maximize revenue, deliver quality care and improve patient outcomes. CHM’s resources and solutions are administered as an extension of providers’ current in-practice resources, expanding care coordination, care management services and value-based analytics. These solutions support financial success within both traditional payment models and expansion to new services, allowing partners to succeed within current and ever emerging value-based payment models. AHP is an accountable care organization (“ACO”) with providers around the U.S. participating in the Medicare Shared Savings Program (“MSSP). The MSSP is a program created under the Affordable Care Act and administered by the Center for Medicare and Medicaid Services (the “CMS”) to enhance the efficiency of healthcare provided to patients covered by Medicare. The MSSP allows for the creation of ACOs, which are organizations that agree to take responsibility for the efficiency of healthcare services provided by a group of participating healthcare providers under Medicare. The ACO is held accountable for the efficiencycomprised of the ~~healthcare services~~operations of its participating providers as measured against prescribed MSSP benchmarks. If the ACO’s covered patient population meets the MSSP benchmarks, the ACO then receives an incentive payment, as determined by the CMS, for each calendar year if the global population of patient lives covered by all providers in the ACO meets the MSSP benchmark requirements.
On August 20, 2020, we completed a financing transaction (the “August 2020 Equity Transaction”) with trusts (the “Trusts”) controlled by our CEO, Dr. Michael Dent, pursuant to which the Trusts contributed an aggregate of 76,026 shares of common stock of NeoGenomics, Inc. (NEO” and the “NEO Shares”) with a fair value of $3,066,889 to us, in exchange for an aggregate of 2,750,000 shares of our newly designated Series B Preferred Stock and an aggregate of 24,522,727 shares of our common stock.
Using in part the proceeds from sale of the NEO Shares received in the August 2020 Equity Transaction, during the three months ended September 30, 2020 we retired debt with a face value of $1,658,750, including $1,012,750 convertible notes with adjustable conversion rates pegged to a fixed discount to the trading price of our common stock. As of September 30, 2020, we had no further outstanding convertible notes with such adjustable conversion rates. We also retired accrued interest of $292,678 related to repayment of debt obligations during the quarter, including forgiveness of $105,003 accrued interest on notes payable to our CEO, Dr. Michael Dent.

~~On October 19, 2020, we acquired MedOfficeDirect L.L.C.~~MedOffice Direct LLC (“MOD”), a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States. With over 13,000 name brand medical products in over 150 different categories, MOD leverages Group Purchasing Organization pricing discounts with a small unit-of-measure direct-to-consumer shipping model to make ordering medical supplies both convenient and highly cost effective for its users.States we acquired on October 19, 2020.

~~Business Update Regarding COVID-19~~Recent Developments

During the ~~first half~~three months ended March 31, 2021, we sold 11,787,766 shares of ~~2020,~~common stock in 46 separate private placement transactions. We received $3,488,725 in proceeds from the ~~spread~~sales. In connection with these stock sales, we also issued 5,893,889 five-year warrants to purchase shares of ~~a new strain~~common stock at exercise prices between $0.27 and $1.05 per share. During the same period, we also issued 3,006,098 shares pursuant to draws under the Investment Agreement for additional gross proceeds of ~~coronavirus~~$900,636. See “Liquidity and Capital Resources-Significant Liquidity Events-Investment Agreement” below for further details on the disease created by that virus, COVID-19, has created a global pandemic presenting substantial public health and economic challenges around the world. The global pandemic is affecting our employees, communities and business operations, as well as the global economy and financial markets. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets.Investment Agreement.

The disclosure in the remainder of this Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is qualified by the disclosure in this section on the impacts of COVID-19 and, to the extent that the disclosure in the remainder of this MD&A refers to a financial or performance metric that has been affected by a trend or activity, that reference is in addition to any impact discussed in this section of the impacts of the COVID-19 pandemic. The effect of the COVID-19 pandemic is rapidly evolving and, as such, the information contained herein is accurate as of the date hereof, but may become outdated due to changing circumstances beyond our present awareness or control.
Critical accounting policies and significant judgments and estimates

See Note 2, “Significant Accounting Policies,” in the Notes to ~~unaudited condensed~~ consolidated Financial Statements.

38
Results of Operations

Comparison of Three Months Ended ~~September 30,~~March 31, 2021 and 2020 ~~and 2019~~

The following table summarizes the changes in our results of operations for the three months ended ~~September 30, 2020~~March 31, 2021 compared with the three months ended ~~September 30, 2019:~~March 31, 2020:

Three Months Ended March 31, Change
Three Months Ended
September 30, Change 2021 2020 $ %
2020 2019 $ %
Patient service revenue, net $ 1,054,806 $ 1,172,561 $ (117,755 ) -10 % $ 1,514,376 $ 1,336,940 $ 177,436 13 %
Medicare shared savings revenue 767,744 --- 767,744 100 %
Consulting revenue 217,605 --- 217,605 100 %
Consulting and event revenue 87,655 — * *
Product revenue 182,663 — * *
Total revenue 2,040,155 1,172,561 867,594 74 % 1,784,694 1,336,940 447,754 33 %

Operating Expenses
Operating Expenses and Costs
Practice salaries and benefits 590,690 708,571 (117,881 ) -17 % 663,937 765,121 (101,184 ) 13 %
Other practice operating costs 548,667 521,341 27,326 5 %
Other practice operating expenses 730,784 563,691 167,093 30 %
Medicare shared savings expenses 759,848 --- 759,848 100 % 211,507 — * *
General and administrative 958,874 733,360 225,514 31 %
Cost of product revenue 168,596 — * *
Selling, general and administrative expenses 1,366,137 510,976 855,161 1,67 %
Depreciation and amortization 25,151 24,980 171 1 % 211,658 24,786 186,872 754 %
Loss from operations (843,075 ) (815,691 ) (27,384 ) -3 % (1,567,925 ) (527,634 ) (1,040,291 ) 197 %

Other Income (Expenses)
Loss on sales of marketable securities (281,606 ) --- (281,606 ) 100 %
Loss on extinguishment of debt (450,999 ) 4,904 (455,903 ) 9297 % (5,589,994 ) (467,937 ) (5,122,057 ) 1,095 %
Change in fair value of debt (79,062 ) (28,885 ) (50,177 ) -174 % (19,246 ) 35,965 (55,211 ) 154 %
Financing cost --- (12,009 ) 12,009 100 %
Amortization of original issue and debt discounts on notes payable and convertible notes (65,816 ) (362,728 ) 296,912 82 % — (292,163 ) 292,163 100 %
Change in fair value of derivative financial instruments 12,802 158,691 (145,889 ) 92 % — 740,355 (740,355 ) 100 %
Change in fair value of contingent acquisition consideration 45,996 --- 45,996 -100 % (635,700 ) (6,621 ) (629,079 ) 9,501 %
Interest expense (72,535 ) (69,562 ) (2,973 ) -4 % (10,588 ) (62,181 ) 51,593 83 %
Total other expenses (891,220 ) (309,589 ) (581,631 ) -188 % (6,255,528 ) (52,582 ) (6,202,946 ) 11,797 %

Net loss $ (1,734,295 ) $ (1,125,280 ) $ (609,015 ) -54 % $ (7,823,453 ) $ (580,216 ) $ (7,243,237 ) 1,248 %
* - Denotes new line item on statement of operations resulting from acquisitions of CHM in May 2020 and MOD in October 2020 for which there was no corresponding activity in the three months ended March 31, 2020.

Revenue

Patient service revenue ~~decreased~~increased by ~~$117,755,~~$177,436, or ~~10%, from 2019 to 2020,~~13% year-over-year, primarily as a result of ~~decreased in-person~~increased patient ~~services~~service revenue ~~as a result~~at our NCFM practice of ~~the Coronavirus pandemic.~~$136,113, increases at our BTG practice of $23,724, and increases at our NWC practice of $17,599.

~~Medicare shared savings~~Consulting and event revenue increased by $767,744, or 100% from 2019 to 2020. The primary source of revenue of CHM, which we acquired in May 2020, is from payments earned under the Medicare shared savings program. Such amounts are determined annually when we are notified by CMS of the amount of shared savings earned. Accordingly, we recognize Medicare shared savings revenue in the period in which the CMS notifies us of the exact amount of shared savings to be paid, which historically has occurred duringfor the three-month period ~~ended September 30 for the program year ended December~~ending March 31, ~~of the previous year. During September 2020, we were notified of, and received payment for, our shared savings revenue relating to program year 2019 in the amount of $767,744.~~
2021 was $87,655. Consulting revenue ~~increased by $217,605, or 100%, from 2019 to 2020. Consulting revenue~~of $76,452 was earned by the ~~newly formed~~ ACO/MSO Division comprised of the operations ofacquired with CHM ~~acquired~~ in May 2020. Event revenue of $11,113 was earned in connection with the HealthLynked Future of Healthcare Summit held in March 2021.
Product revenue was $182,663. Product revenue was earned by the Medical Distribution Division comprised of the operations acquired with MOD in October 2020.
Operating Expenses and Costs

Practice salaries and benefits decreased by ~~$117,881,~~$101,184, or ~~17%~~13%, in ~~2020~~the three months ended March 31, 2021 primarily as a result of ~~temporary pay reductions implemented in second~~downsizing efforts at our NWC practice totaling $39,010 and ~~third quarter 2020 due to the Coronavirus pandemic as well permanent reductions in staff~~cost reduction at ~~Naples Women’s Center in 2020.~~our NCFM practice of $55,253.

Other practice operating costs increased by ~~$27,326,~~$167,093, or 5%30%, in ~~2020 primarily as a result~~the three months ended March 31, 2021 corresponding to increased revenue at each of ~~the addition of BTG as a new practice at the beginning of 2020, offset by lower NWC practice operating costs resulting from cost reduction efforts.~~our three patient service practices.

Medicare shared savings expenses ~~increased by $759,848, or 100%, in 2020.~~for the three months ended March 31, 2021 was $211,507. Medicare shared savings expenses represent costs incurred to deliver Medicare shared savings revenue, including overhead and consulting fees related to advising participating physician practices, as well as the physicians’ contractual portion of any shared savings received by the ACO. There was no corresponding Medicare shared savings expense in ~~2019~~the three months ended March 31, 2020 as CHM was acquired in May 2020.

~~General~~Cost of product revenue was $168,596 in the three months ended March 31, 2021. Cost of product revenue relates to the cost of medical products sold by the newly formed Medical Distribution Division, which is comprised of the operations acquired with MOD in October 2020.
Selling, general and administrative costs increased by ~~$225,514,~~$855,161, or ~~31%~~167%, in ~~2020~~the three months ended March 31, 2021 primarily due to increased stock-based consulting fees, cash-based legal ~~accounting~~ and ~~software development~~consulting fees, more personnel in ~~2020 offset by lower~~our corporate ~~overhead expense~~function in connection with our continued expansion, and higher advertising and promotional costs associated with ~~a shift from a direct sales to an indirect sale approach for our Digital Healthcare segment.~~marketing of the HealthLynked Network and related products.

Depreciation and amortization increased the three months ended March 31, 2021 by ~~$171,~~$186,872, or 1%754%, compared to the same period in 2020, primarily as a result of ~~additional depreciation from~~amortization of finite-lived intangible assets acquired in the ~~NCFM~~MOD acquisition.

Loss from operations increased by ~~$27,384,~~$1,040,291, or 3%197%, in the three months ended March 31, 2021 when compared to the same period in 2020, primarily ~~due to an increase in~~as a result of increased selling, general and administrative ~~expense,~~costs related to our expansion as well as amortization of intangibles from MOD, offset by ~~profits from the ACO/MSO business acquired~~increases in ~~May 2020.~~
~~Loss on sales~~each of marketable securities increased by $281,606, or 100%, in 2020. Such losses arose from sales of marketable securities acquired in the August 2020 Equity Transaction at prices below the acquisition price.our revenue streams.

Other Income (Expenses)

Loss on extinguishment of debt in the three months ended March 31, 2021 increased by ~~$455,903,~~$5,122,057, or ~~9,297%~~1,095%, ~~to a loss of $450,999 in 2020~~as compared to ~~a gain of $4,904 in~~ the same period ~~of 2019, primarily~~in 2020, as a result of a January 2021 transaction pursuant to which the ~~impact of repayment and conversion~~holder of convertible notes ~~payable. Losses (gains)~~with a face value of $1,038,500 and $317,096 of accrued interest agreed to convert the notes pursuant to the original note terms and agreed to a leak-out provision on the received shares in exchange for a five-year warrant to purchase 13,538,494 shares of common stock at an exercise price of $0.30 per share. In connection with the conversion, we recognized a loss on debt extinguishment of ~~debt arise when~~$5,463,592 in the three months ended March 31, 2021, representing the excess of the fair value ~~consideration paid to retire a debt instrument exceeds (is less than)~~of the shares and warrant issued at conversion over the carrying value of the host instrument being retired, including any related derivative financial instruments such as embedded conversion features (“ECFs”). Moreover, during the first quarter of 2020 we changed from the Black-Scholes model to a binomial lattice model to estimate the fair value of certain financial instruments, including derivative financial instruments associated with outstanding convertible notes retired during 2020. The change in methodology generally resulted in lower values of our ECF derivative financial instruments, which in turn resulted in higher losses on debt extinguishment when such liabilities were retired.and accrued interest.

~~Losses from the change~~Change in fair value of debt increased by ~~$50,177,~~$55,211, or ~~174%~~154%, ~~in 2020. Such losses result primarily from certain convertible notes and notes payable to related parties that, in previous periods, were extended and treated as an extinguishment and reissuance~~ for ~~accounting purposes, requiring these notes to be subsequently carried at fair value. The change in fair value at~~ the ~~end of each reporting period is recorded as “Change in fair value of debt.”~~
~~Financing cost decreased by $12,009, or 100% in 2020. Financing cost arises~~three months ended March 31, 2021 when ~~the inception date fair value of embedded conversion features on a convertible note are greater than the face value of the note. No such notes were issued in 2020.~~
Amortization of original issue and debt discounts decreased by $296,912, or 82%, in 2020 as a result of amortization of convertible notes with smaller average discount balances being amortized in 2020.
~~Change in fair value of derivative financial instruments decreased by $145,889, or 92%, to $12,802~~ compared to gains of $158,691 in 2019. The change is due primarily to our change on January 1, 2020 from the Black-Scholes model to a binomial lattice model to estimate the fair value of certain financial instruments, including derivative financial instruments. We believe that the binomial lattice model results in a better estimate of fair value because it embodies all of the requisite assumptions (including the underlying price, exercise price, term, volatility, and risk-free interest-rate) necessary to fair value these instruments and, unlike the Black-Scholes model, also accommodates assumptions regarding investor exercise behavior and other market conditions that market participants would likely consider in negotiating the transfer of such an instruments. Moreover, we retired all derivative financial instruments in third quarter 2020 with the repayment of all adjustable-rate convertible notes payable that had associated embedded conversion feature derivatives.
~~Change in the fair value of contingent acquisition consideration was $45,996 in 2020. There was no corresponding change in~~ the same period 2019. Fair value of contingent acquisition consideration related to our acquisition of HCFM in April 2019 and CHM in May 2020 is estimated at each reporting period using a probability-weighted discounted cash flow model.
~~Interest expense increased by $2,973, or 4%, as a result of slightly higher average balance on convertible notes and notes payable to related parties during 2020.~~
Total other expenses increased by $581,631, or 188%, in 2020 primarily as a result of losses on sales of marketable securities incurred in 2020 with no corresponding charges in 2019, higher losses on extinguishment of debt related to repayment of convertible notes payable, and lower gains on change in fair value of derivative financial instruments in 2020 resulting from a change in estimate methodology, offset by lower amortization of original issue and debt discounts due to lower average debt discount balances.

Net loss increased by $609,015, or 54%, in 2020 primarily as a result of an increase in general and administrative expense, losses on sales of marketable securities incurred in 2020 with no corresponding charges in 2019, and higher losses on extinguishment of debt related to repayment of convertible notes payable, offset by profits from the ACO/MSO business acquired in May 2020 and lower amortization of original issue and debt discounts due to lower average debt discount balances.
~~Comparison of Nine months ended September 30, 2020 and 2019~~
~~The following table summarizes the changes in our results of operations for the nine months ended September 30, 2020 compared with the nine months ended September 30, 2019:~~
Nine Months Ended
September 30, Change
2020 2019 $ %
Patient service revenue, net $ 3,502,836 $ 2,845,941 $ 656,895 23 %
Medicare shared savings revenue 767,744 --- 767,744 100 %
Consulting revenue 268,025 --- 268,025 100 %
Total revenue 4,538,605 2,845,941 1,692,664 59 %

Operating Expenses
Practice salaries and benefits 1,910,897 1,762,662 148,235 8 %
Other practice operating costs 1,633,380 1,287,432 345,948 27 %
Medicare shared savings expenses 824,084 --- 824,084 100 %
General and administrative 2,116,159 2,084,630 31,529 2 %
Depreciation and amortization 74,811 48,345 26,466 55 %
Loss from operations (2,020,726 ) (2,337,128 ) 316,402 14 %

Other Income (Expenses)
Loss on sales of marketable securities (281,606 ) --- (281,606 ) 100 %
Loss on extinguishment of debt (1,347,371 ) (62,459 ) (1,284,912 ) -2057 %
Change in fair value of debt (198,764 ) (88,991 ) (109,773 ) -123 %
Financing cost --- (133,244 ) 133,244 100 %
Amortization of original issue and debt discounts on notes payable and convertible notes (530,930 ) (841,725 ) 310,795 37 %
Change in fair value of derivative financial instruments 739,485 574,205 165,280 -29 %
Change in fair value of contingent acquisition consideration 687 --- 687 -100 %
Interest expense (193,134 ) (176,229 ) (16,905 ) -10 %
Total other expenses (1,811,633 ) (728,443 ) (1,083,190 ) -149 %

Net loss $ (3,832,359 ) $ (3,065,571 ) $ (766,788 ) -25 %
Patient service revenue increased by $656,895, or 23%, from 2019 to 2020, primarily as a result of higher revenue from NCFM (which was acquired April 15, 2019 and therefore only reflected in our operating results for five-and-a-half months of the 2019 period) and revenue from BTG (which started January 9, 2020 with no corresponding revenue in 2019), offset by lower revenue from NWC.
Medicare shared savings revenue increased by $767,744, or 100% from 2019 to 2020. The primary source of revenue of CHM, which we acquired in May 2020, is from payments earned under the Medicare shared savings program. Such amounts are determined annually when we are notified by CMS of the amount of shared savings earned. Accordingly, we recognize Medicare shared savings revenue in the period in which the CMS notifies us of the exact amount of shared savings to be paid, which historically has occurred during the three-month period ended September 30 for the program year ended December 31 of the previous year. During September 2020, we were notified of, and received payment for, our shared savings revenue relating to program year 2019 in the amount of $767,744.

~~Consulting revenue increased by $268,025, or 100%, from 2019 to 2020. Consulting revenue was earned by the newly formed ACO/MSO Division comprised of the operations acquired with CHM in May 2020.~~
Practice salaries and benefits increased by $148,235, or 8%, in 2020 primarily as a result of primarily as a result of new practice salary and benefits expense from the inception of BTG in 2020 and a full nine months of NCFM operating costs in 2020 compared to only five-and-a-half months in 2019.
Other practice operating costs increased by $345,948, or 27%, in 2020 primarily as a result of a full period of practice operating costs related to BTG and NCFM in 2020, offset by lower practice operating costs corresponding to lower revenue at NWC.
Medicare shared savings expenses increased by $824,084, or 100%, in 2020. Medicare shared savings expenses represent costs incurred to deliver Medicare shared savings revenue, including overhead and consulting fees related to advising participating physician practices, as well as the physicians’ contractual portion of any shared savings received by the ACO. There was no corresponding Medicare shared savings expense in 2019 as CHM was acquired in May 2020.
General and administrative costs increased by $31,529, or 2%, in 2020 primarily due to increased legal, accounting and software development fees in 2020 offset by lower corporate overhead expense associated with a shift from a direct sales to an indirect sale approach for our Digital Healthcare segment.
~~Depreciation and amortization increased by $26,466, or 55%, in 2020 primarily as a result of depreciation of assets acquired in the NCFM acquisition.~~
Loss from operations decreased by $316,403, or 14%, in 2020 primarily as a result of profits from the ACO/MSO business acquired in May 2020 and improved profits from the Health Services Division, offset by higher general and administrative costs.
Loss on sales of marketable securities increased by $281,606, or 100%, in 2020. Such losses arose from sales of marketable securities acquired in the August 2020 Equity Transaction at prices below the acquisition price.
Loss on extinguishment of debt increased by $1,284,912, or 2,057%, primarily as a result of the impact of repayment and conversion of convertible notes payable. Losses on extinguishment of debt arise when the fair value consideration paid to retire a convertible note exceeds the carrying value of the instrument being retired, including any related derivative financial instruments such as embedded conversion features (“ECFs”). Moreover, during the first quarter of 2020 we changed from the Black-Scholes model to a binomial lattice model to estimate the fair value of certain financial instruments, including derivative financial instruments associated with outstanding convertible notes retired during 2020. The change in methodology generally resulted in lower values of our ECF derivative financial instruments, which in turn resulted in higher losses on debt extinguishment when such liabilities were retired.
~~Losses from the change in fair value of debt increased by $109,773, or 123%,~~ in 2020. Such gains and losses result from certain convertible notes and notes payable to related parties that, in previous periods, were extended and treated as an extinguishment and reissuance for accounting purposes, requiring these notes to be subsequently carried at fair value. The change in fair value at the end of each reporting period is recorded as “Change in fair value of debt.”
~~Financing cost decreased by $133,244, or 100%~~ After conversion of our remaining convertible notes outstanding in ~~2020. Financing cost arises when the inception date~~January 2021, we had no further debt carried at fair ~~value of embedded conversion features on a convertible note are greater than the face value of the note. No such notes were issued in 2020.~~value.

Amortization of original issue and debt discounts ~~decreased by $310,795, or 37%,~~was $292,163 for the three months ended March 31, 2021i due to the retirement in 2020 ~~as a result~~ of ~~the amortization of~~all floating rate convertible notes that with ~~smaller average discount balances being amortized in 2020.~~discounts subject to amortization.

Gains from the change in fair value of derivative financial instruments ~~increased by $165,280, or 29%. The change is due primarily to our change on January 1, 2020 from~~was $740,355 for the ~~Black-Scholes model to a binomial lattice model to estimate the fair value of certain financial instruments, including derivative financial instruments.~~three months ended March 31, 2021. We believe that the binomial lattice model results in a better estimate of fair value because it embodies all of the requisite assumptions (including the underlying price, exercise price, term, volatility, and risk-free interest-rate) necessary to fair value these instruments and, unlike the Black-Scholes model, also accommodates assumptions regarding investor exercise behavior and other market conditions that market participants would likely consider in negotiating the transfer of such an instruments. Moreover, we retired all derivative financial instruments in ~~third quarter~~ 2020 with the repayment of all adjustable-rate convertible notes payable that had associated embedded conversion feature ~~derivatives.~~derivatives, so there were no such charges in 2021.

Change in ~~the~~ fair value of contingent acquisition consideration ~~was $687~~increased by $629,079, or 9,501%, in ~~2020. There was no corresponding change in~~the three months ended March 31, 2021 when compared to the same period ~~2019.~~in 2020. Fair value of contingent acquisition consideration relates to future acquisition consideration that may be payable if certain prescribed performance milestones are met by businesses acquired by us, including NCFM (acquired in April 2019), CHM (acquired in May 2020), and MOD (acquired in October 2020). The fair value of contingent acquisition consideration is remeasured at each reporting period using a probability-weighted discounted cash flow model. The large increase in 2021 was due primarily to the increase in fair value of contingent acquisition consideration related to our acquisition of ~~HCFM~~MOD, which is payable in ~~April 2019~~a fixed number of shares upon achievement of annual revenue milestones of the underlying business between 2021 and ~~CHM~~2024. Due in ~~May 2020 is estimated at each reporting period using a probability-weighted discounted cash flow model.~~large part to an increase in our stock price during the first quarter of 2021, the fair value of the liability increased by $591,140.

Interest expense ~~increased~~decreased by ~~$16,905,~~$51,593, or ~~10%~~83%, for the three months ended March 31, 2021 when compared to the same period in 2020, as a result of ~~higher average balance on~~the repayment and conversion of convertible notes and notes payable to related parties during ~~2020.~~2020, combined with low-interest government loans added to our balance sheet, resulting in substantially lower debt balances in 2021.

Total other expenses increased by ~~$1,083,190,~~$6,202,946, or ~~149%~~11,797%, in the three months ended March 31, 2021 when compared to the same period in 2020 primarily as a result of ~~higher losses~~a $5,589,994 loss on extinguishment of debt ~~related to repayment~~associated with the retirement of our last remaining convertible notes payable ~~and~~in 2021, an increase in losses ~~on sales of marketable securities incurred in 2020 with no corresponding charges in 2019, offset by lower amortization of debt discounts on convertible notes payable and higher gains~~ from the change in fair value of contingent acquisition due to the fixed-share structure of the MOD contingent consideration, and a gain in change in fair value of derivative financial ~~instruments.~~instruments in 2020 with no corresponding income or charge in 2021.

Net loss increased by ~~$766,788,~~$7,243,237, or ~~25%~~1,248%, in the three months ended March 31, 2021 when compared to the same period in 2020 primarily as a result of ~~higher losses~~a $5,589,994 loss on extinguishment of debt ~~related to repayment~~associated with the retirement of our last remaining convertible notes payable in 2021, increased selling, general and ~~losses on sales of marketable securities incurred~~administrative costs related to our expansion, an increase in 2020 with no corresponding charges in 2019, offset by profits from the ACO/MSO business acquired in May 2020, improved profits from the Health Services Division, lower amortization of debt discounts on convertible notes payable and higher gainslosses from the change in fair value of contingent acquisition due to the fixed-share structure of the MOD contingent consideration, and a gain in change in fair value of derivative financial ~~instruments.~~instruments in 2020 with no corresponding income or charge in 2021. The increased losses were offset by increases in each of our revenue streams totaling $416,237.

Seasonal Nature of Operations

We acquired CHM in May 2020. CHM’s primary source of revenue is derived from payments earned under the Medicare shared savings program. Such amounts are determined annually when we are notified by CMS of the amount of shared savings earned. Accordingly, we recognize Medicare shared savings revenue in the period in which the CMS notifies us of the exact amount of shared savings to be paid, which historically has occurred during the three-month period ended September 30 for the program year ended December 31 of the previous year. Medicare shared savings revenue for the program year ended December 31, 2019, for which we received notification and payment in September 2020, was $767,744. Future recognition of Medicare shared savings revenue is expected to result in a material increase in our consolidated revenues in the third fiscal quarter of each year compared to the first, second and fourth fiscal quarters. Likewise, in the period in which we recognize Medicare shared savings revenue, we also determine the amount of shared savings expense to be paid to physicians participating in our ACO. This expense is also expected to be recognized in the third fiscal quarter of each year and is expected to materially increase our total operating expenses in the third fiscal quarter compared to other quarters of the fiscal year.

Liquidity and Capital Resources
~~Going Concern~~

As of ~~September 30, 2020,~~March 31, 2021, we had acash balances of $3,341,728, working capital ~~deficit~~ of ~~$1,979,983~~$1,085,131 and accumulated deficit ~~$19,862,013.~~$29,608,363. For the ~~nine~~three months ended ~~September 30, 2020,~~March 31, 2021, we had a net loss of ~~$3,896,221~~$7,823,453 and net cash used by operating activities of ~~$1,094,495.~~$1,216,959. Net cash ~~provided by~~used in investing activities was ~~$2,425,870, including $2,740,806 received from the sale of marketable securities received in an August 2020 financing transaction.~~$7,399. Net cash provided by financing activities was ~~$271,308, resulting principally~~$4,403,902, including $4,389,361 received from ~~$1,045,669 proceeds from loans~~sales of our common stock in private placement transactions and ~~grants issued by~~puts pursuant to the ~~federal government under the Payroll Protection Act, $827,500 net~~July 2016 $3 million investment agreement (see “Significant Liquidity Events-Investment Agreement” below) and $65,650 proceeds from the ~~issuance~~exercise of stock options and warrants. During January 2021, the holder of $1,038,500 fixed rate convertible debt converted the entire face value of $1,038,500, plus $317,096 of accrued interest on such notes, ~~and $149,000 proceeds from~~into 13,538,494 shares of common stock pursuant to the ~~issuance~~original conversion terms of ~~related party loans.~~the underlying notes. Following the conversion, we had no further convertible debt outstanding.

~~Our cash balance~~We intend that the longer term (i.e., beyond twelve months) cost of completing additional intended acquisitions, implementing our development and revenues generated are not currently sufficient and cannot be projected to cover our operating expenses for the next twelve months from the date of this report. These matters raise substantial doubt about our ability to continue as a going concern. Management’s plans include attempting to improve its business profitability and its ability to generate sufficient cash flow from its operations to meet its needs on a timely basis, obtaining additional working capital funds through equity and debt financing arrangements, and restructuring on-going operations to eliminate inefficiencies to raise cash balance in order to meet our anticipated cash requirements for the next twelve months from the date of this report. However, there can be no assurance that these plans and arrangements will be sufficient to fund our ongoing capital expenditures, working capital, and other requirements. Management intends to make every effort to identify and develop sources of funds. The outcome of these matters cannot be predicted at this time. There can be no assurance that any additional financings will be available to us on satisfactory terms and conditions, if at all.
Our ability to continue as a going concern is dependent upon our ability to raise additional capital and achieve profitable operations. The accompanying consolidated financial statements do not include any adjustmentssales efforts related to the ~~recoverability or classification~~HealthLynked Network and maintaining existing and expanding overhead and administrative costs will be financed from (i) cash on hand resulting from fund raising efforts in 2021, (ii) profits generated by NCFM, BTG and CHM (including expected Medicare Shared Savings revenue projected to be received annually in the third fiscal quarter of ~~asset-carrying amounts or~~each year), and (iii) the ~~amounts~~use of further outside funding sources. No assurances can be given that we will be able to access additional outside capital in a timely fashion. If necessary funds are not available, our business and ~~classification of liabilities that may result should~~operations would be materially adversely affected and in such event, we ~~be unable~~would attempt to ~~continue as a going concern.~~ reduce costs and adjust our business plan.

A novel strain of coronavirus, COVID-19, that was first identified in China in December 2019, has surfaced in several regions across the world and resulted in travel restrictions and business slowdowns or shutdowns in affected areas. In March 2020, the World Health Organization declared the outbreak of COVID-19 a pandemic. The outbreak of the pandemic is materially adversely affecting the Company’s employees, patients, communities and business operations, as well as the U.S. economy and financial markets. The further spread of COVID-19, and the requirement to take action to limit the spread of the illness, may impact our ability to carry out our business as usual and may materially adversely impact global economic conditions, our business and financial condition, including our potential to conduct financings on terms acceptable to us, if at all. The extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. In response to COVID-19, the Company implemented additional safety measures in its patient services locations and its corporate headquarters.
Significant Liquidity Events
Historically, we have funded our operations principally through a combination of convertible promissory notes, private placements of our common stock, promissory notes and related party debt, as described below.
First Quarter 2021 Equity Transactions
During the three months ended March 30, 2021, we sold 11,787,766 shares of common stock in 46 separate private placement transactions. We received $3,488,725 in proceeds from the sales. In connection with these stock sales, we also issued 5,893,889 five-year warrants to purchase shares of common stock at exercise prices between $0.27 and $1.05 per share. We also issued 3,006,098 shares pursuant to draws under the Investment Agreement for additional gross proceeds of $900,636.
42
Investment Agreement

In July 2016, we entered into an Investment Agreement (the “Investment Agreement”) with Iconic Holdings, LLC (the “Investor”), pursuant to which the Investor agreed to purchase up to $3,000,000 of our common stock over a three-year period starting upon registration of the underlying shares, with such shares put to the Investor by us pursuant to a specified formula that limits the number of shares able to be put to the Investor to the number equal to the average trading volume of our common shares for the ten consecutive trading days prior to the put notice being issued. In May 2020, the Investment Agreement, which was scheduled to expire on May 15, 2020, was extended an additional two years to May 15, 2022. During the ~~nine~~three months ended ~~September 30,~~March 31, 2021 and 2020, we issued 3,006,098 and ~~2019, we received $426,299 and $825,616, respectively, from the proceeds of the sale of 4,975,491 and 4,273,779~~1,331,432 shares ~~respectively,~~ pursuant to ~~the Investment Agreement.~~
We intend that the cost of completing additional intended acquisitions, implementing our development and sales efforts related to the HealthLynked Network, maintaining existing and expanding overhead and administrative costs, and repaying outstanding convertible notes, which have an aggregate face value of $1,038,500 as of September 30, 2020, will be financed from (i) profits generated by NCFM, CHM and AHP and MOD, which was acquired in October 2020, and (ii) outside funding sources, including the put rights associated withdraws under the Investment Agreement, ~~sales~~respectively, for gross proceeds of ~~common stock, government loans~~$900,636 and issuance of additional convertible notes. No assurances can be given that the Company will be able to access sufficient outside capital in a timely fashion in order to repay the convertible notes before they mature. If necessary funds are not available, the Company’s business and operations would be materially adversely affected and in such event, the Company would attempt to reduce costs and adjust its business plan.$122,423, respectively.

~~Significant Liquidity Events~~
Through September 30, 2020, we have funded our operations principally through a combination of convertible promissory notes, private placements of our common stock, promissory notes and related party debt, as described below.
~~August 2019 Equity Transaction~~
On August 20, 2020, we completed the August 2020 Equity Transaction with Trusts controlled by our CEO, Dr. Michael Dent, pursuant to which the Trusts contributed an aggregate of 76,026 NEO Shares with a fair value of $3,066,889 to us, in exchange for an aggregate of 2,750,000 shares of our newly designated Series B Preferred Stock and an aggregate of 24,522,727 shares of our common stock. During the nine months ended September 30, 2020, we sold 74,900 of the NEO Shares and received proceeds of $2,740,806. As of September 30, 2020, the Company held 1,126 NEO Shares with a fair value of $44,477.

~~Investment Agreement~~
On July 7, 2016, we entered into the Investment Agreement with the Investor pursuant to which it agreed to invest up to $3,000,000 to purchase the Company’s common stock, par value of $.0001 per share. The purchase price for such shares shall be 80% of the lowest volume weighted average price of our common stock during the five consecutive trading days prior to the date on which written notice is sent by us to the Investor stating the number of shares that the Company is selling to the Investor, subject to certain discounts and adjustments. Further, pursuant to an Amended Investment Agreement dated March 22, 2017, we granted to the Investor warrants to purchase an aggregate of seven (7) million shares of common stock with the following fixed exercise prices: (i) four million shares at $0.25 per share; (ii) two million shares at $0.50 per share; and (iii) one million shares at $1.00 per share. The warrants also contain a “cashless exercise” provision and the shares underlying the warrants will not be registered. During the nine months ended September 30, 2020 and years ended December 31, 2019 and 2018, we received proceeds from the sale of shares pursuant to the Investment Agreement totaling $426,299 (4,975,491 shares), $929,986 (5,074,068 shares) and $440,523 (2,440,337 shares), respectively. During May 2020, the Investment Agreement was extended by two years and now expires on May 15, 2022.
~~Other Sales of Common Stock~~
~~During the nine months ended September 30, 2020, we sold 6,650,843 shares of common stock in 20 separate private placement transactions and received $673,001 in proceeds from the sales.~~
~~During the nine months ended September 30, 2019, we sold 1,550,001 shares of common stock in three separate private placement transactions and received $415,000 in proceeds from the sales.~~
~~Convertible Notes Payable~~
~~As of September 30, 2020, we had outstanding convertible notes payable with aggregate face value of $1,038,500 maturing on December 31, 2020, as follows:~~
Interest Price/
Face Value Rate Discount Maturity
$550k Note - July 2016 $ 550,000 6 % $ 0.08 December 31, 2020
$50k Note - July 2016 50,000 10 % $ 0.10 December 31, 2020
$111k Note - May 2017 81,000 10 % $ 0.35 December 31, 2020
$357.5k Note - April 2019 357,500 10 % $ 0.20 December 31, 2020
$ 1,038,500
Plan of operation and future funding requirements

Our plan of operations is to profitably operate our Health Services business and continue to invest in our Digital Healthcare business, including our cloud-based online personal medical information and record archiving system, the “HealthLynked Network.”

We intend to market the HealthLynked Network via ~~direct sales force~~telesales targeting physicians’ offices, direct to patient marketing, affiliated marketing campaigns, co-marketing with ~~online medical supplies~~our Medical Distribution businesses retailer ~~MedOffice Direct,~~MOD, and expanded southeast regional sales efforts. We intend that our initial primary sales strategy will be ~~direct~~ physician ~~sales~~telesales through the use of ~~regional sales~~telesales representatives whom we will hire as access to capital allows. In combination with our ~~direct sales,~~telesales, we intend to also utilize Internet based marketing to increase penetration to targeted geographical areas. These campaigns will be focused on both physician providers and patient members. We also intend to leverage MOD’s discounted medical supplies as an offering to our patient and physician members in both the HealthLynked Network and our ACO network and plans. If we fail to complete the development of, or successfully market, the HealthLynked Network, our ability to realize future increases in revenue and operating profits could be impacted, and our results of operations and financial position would be materially adversely affected.

A summarized timeline of our strategic acquisition transactions and the related funding sources is as follows:

● In July 2018 we raised approximately $1.8 million in the ~~July 2018 Private Placement~~a private placement for the purpose of technology enhancement, sales and marketing initiatives and to fund a portion of the first phase of our planned acquisition strategy.
● In 2019, we began implementation of our plan to acquire health service businesses and offer physician owners cash, stock, and deferred compensation.
● On April 15, 2019, we acquired HCFM for $750,000 in cash, $750,000 in shares of our common stock and $500,000 in a three-year performance-based payout.
● On May 18, 2020, we acquired CHM for $214,000 in cash, $201,675 in shares of our common stock, up to $223,000 cash and $660,000 in shares of our common stock based on a target MSSP payment of $1,725,000 in the current year, and up to $437,500 in a four-year performance-based payout.

● On August 20, 2020, we completed the August 2020 Equity Transaction with Trusts controlled by our CEO, Dr. Michael Dent, pursuant to which the Trusts contributed an aggregate of 76,026 NEO Shares with a fair value of $3,066,889 to us, in exchange for an aggregate of 2,750,000 shares of our newly designated Series B Preferred Stock and an aggregate of 24,522,727 shares of our common stock.
● On October 19, 2020, the Company acquired MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States, in exchange for (i) 19,045,563 restricted shares of the Company’s common stock valued at to $2,704,470, (ii) the issuance of an aggregate of up to 10,004,749 restricted shares of ~~Buyer’s~~the buyer’s common stock valued at up to $2,602,330 over a four year period based on MOD achieving certain revenue targets, and (iii) the partial satisfaction of certain outstanding debt obligations of MOD in the amount of $703,200 in cash by us.
● During the second half of 2020, we retired floating rate convertible debt with a face value of $1,012,750 through conversions and repayments and repaid related party notes with a face value of $646,000 in an effort to improve our balance sheet.
● During January 2021, the holder of $1,038,500 fixed rate convertible debt converted the full face value of $1,038,500, plus $317,096 of accrued interest on such notes, into 13,538,494 shares of common stock pursuant to the original conversion terms of the underlying notes. Following the conversion, we had no further convertible debt outstanding.
● During the three months ended March 31, 2021, we sold 11,787,766 shares of common stock in 46 separate private placement transactions. We received $3,488,725 in proceeds from the sales. In connection with these stock sales, we also issued 5,893,889 five-year warrants to purchase shares of common stock at exercise prices between $0.27 and $1.05 per share. We also issued 3,006,098 shares pursuant to draws under the Investment Agreement for additional gross proceeds of $900,636.

Currently, we are focusing on acquiring additional profitable ACOs with a concentration on physician-based ACOs in Florida, the Southeast, Texas, New ~~York~~Jersey and ~~Michigan.~~Arizona. ACOs’ objectives are to reduce patients’ healthcare costs while improving their health. Our initial targets are physician-based Florida Medicare ACOs. Profitable ACOs have shared savings, which are payments made by the Medicare governing body CMS to ACOs whose Medicare patients have aggregate total savings over the regional threshold for all Medicare patients in the territory and that meet CMS’ quality standards. Given HealthLynked’s goal to improve healthcare and reduce healthcare costs for all patients, we anticipate that the ACO acquisition model can help us expand both physician and patient utilization of the HealthLynked Network while continuing to add incremental revenue and profit from to our health services and ACO segments.
We plan to raise additional capital to fund our ongoing acquisition strategy. In addition, during 2019 we extended a significant portion of our outstanding debt until December 31, 2020, including convertible notes payable held by the Investor with an aggregate face value of $1,038,500.

Historical Cash Flows
Nine Months Ended
September 30, Three Months Ended March 31,
2020 2019 2021 2020
Net cash (used in) provided by:
Operating activities $ (1,094,495 ) $ (1,728,934 ) $ (1,216,959 ) $ (384,187 )
Investing Activities 2,425,870 (475,056 ) (7,399 ) —
Financing activities 271,308 2,170,624 4,403,902 478,012
Net increase (decrease) in cash $ 1,602,683 $ (33,366 )
Net increase in cash $ 3,179,544 $ 93,825

Operating Activities – During the ~~nine~~three months ended ~~September 30, 2020,~~March 31, 2021, we used cash from operating activities of ~~$1,094,495,~~$1,216,959, as compared with ~~$1,728,934~~$384,187 in the same period of ~~2019.~~2020. The ~~decrease~~increase in cash usage results primarily from ~~profits generated by~~increased selling, general and administrative costs increased related to our ~~ACO/MSO business, NCFM and BTG in 2020.~~continued expansion.

Investing Activities – During the ~~nine~~three months ended ~~September 30, 2020,~~March 31, 2021, we ~~generated $2,425,870 from~~used $7,399 in investing activities including $2,740,806 received from the sale of marketable securities received in an August 2020 financing transaction, offset by $164,005 used to acquire CHM (net of $49,995 cash received), $137,390 paid against contingent acquisition consideration related to the acquisitions of NCFM and CHM and $13,541 for the acquisition of computers and equipment. During the same period of ~~2019,~~2020, we used ~~$465,000 for the acquisition of HCFM (net of $35,000 cash received) and $10,056 for the acquisition of computers and equipment.~~$-0- in investing activities.

Financing Activities – During the ~~nine~~three months ended ~~September 30,~~March 31, 2021 and 2020, ~~and 2019,~~ we realized ~~$3,012,114~~$4,403,902 and ~~$42,170,624,~~$478,012, respectively, in investing activities. Cash realized in 2020 was comprised mainly of ~~$1,099,300~~$4,389,361 from the sale of common stock pursuant to private placements and puts under the Investment Agreement and $65,650 proceeds from the exercise of options and warrants. We also made cash repayments against a vendor note in the amount of $51,109, retiring the note in full. During the three months ended March 31, 2020, we realized $437,433 from the proceeds of the sale of shares of common stock to investors and pursuant to the Investment Agreement, $1,045,669 net proceeds from government loans, $827,500 from the issuance of convertible notes, $149,000 from related party loans and. We also repaid $1,882,405 of convertible loans and $967,756 of related party loans. During the nine months ended September 30, 2019, we realized $1,240,616 from the proceeds of the sale of shares of common stock to investors and pursuant to the Investment Agreement and $1,540,000$344,000 net proceeds from the issuance of convertible notes ~~while repaying $608,992~~and $149,000 net proceeds from the issuance of related party loans. We also repaid $373,094 of convertible ~~notes.~~loans.

Off Balance Sheet Arrangements

We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable Securities and Exchange Commission rules.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

The Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined in Rule 229.10(f)(1).

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our internal control over financial reporting as of September 30, 2020 based on the framework in “Internal Control – Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013. Based on that evaluation, our management concluded that our internal control over financial reporting was effective at ~~September 30, 2020.~~March 31, 2021.

Changes in Internal Control over Financial Reporting

There was no change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the fiscal quarter ended ~~September 30, 2020~~March 31, 2021 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

~~On July 20, 2020, Empery Asset Master Ltd., Empery Tax Efficient, LP and Empery Tax Efficient II, LP, (the “Complainants”) filed a complaint against the Company~~We are not aware of any such legal proceedings that we believe will have, individually or in the Supreme Court of the State of New York. The Complaint alleges that the Company’s acquisition of CHM, in which the Company issued stock consideration of 2,240,838 common shares, triggered a change of control clause in warrants held by the Complainants that would allow the Complainants to demand cash value for their warrants. The Company believes that the asserted claims lack merit and intends to defend against all of the claims vigorously. Due to the inherent uncertainties of litigation, the Company cannot predict the outcome of the actions at this time and can give no assurance that the asserted claims will not haveaggregate, a material adverse effect on ~~its~~our business, financial ~~position~~condition or ~~results of operations. The Company has responded to the Complaint but discovery has not yet commenced as of the date of this filing~~operating results.
On August 24, 2020, the Company entered into a settlement agreement in response to a complaint filed by Delaney Equity Group LLC seeking unpaid fees from a 2015 Advisor, Consulting and Investment Banking Agreement. Pursuant to the terms of the settlement, the Company agreed to make cash payments totaling $75,000 over a six-month period. If the payments are not made in full and timely, the amount due increases to $112,500.

Item 1A. Risk Factors
~~During the period presented in this report, we have identified the material changes to our risk factors listed below as a result of our acquisition of CHM.~~
The Affordable Care Act, or ACA, and subsequent rules promulgated by CMS, including any repeal, replacement or modification to the ACA, could have a material adverse effect on our business and financial results.

The ~~ACA was signed into law in March 2010 and legislated broad-based changes~~Company is not required to provide the U.S. health care system which continue to have a material impact on our business. There is considerable discussion within the new Presidential administration and Congress about repealing and replacing the ACA. Atinformation required by this ~~time,~~item as it is uncertain whether, when, and what changes will be made to the ACA, and what impact such changes could have on our business. However, any changes to the ACA, including through any repeal and replacement to the ACA, could have a ~~material adverse effect on our business, financial position and results of operations.~~
Under the MSSP, CMS has historically made payments to ACOs for a measurement year in the second half of the following year, which negatively impacts our cash flows. In order to receive revenues from CMS under the MSSP, the ACO must meet certain minimum savings rates (i.e. save the federal government money) and meet certain quality measures. More specifically, an ACO’s medical expenses for its assigned beneficiaries during a relevant measurement year must be below the benchmark established“smaller reporting company,” as defined by CMS for such ACO. Notwithstanding our efforts, our ACO may be unable to meet the required savings rates or may not satisfy the quality measures, which may result in our receiving no revenues and losing our investment in the acquisition and operation of CMS and AHP. In addition, the MSSP presents challenges and risks associated with the timeliness and accuracy of data and interpretation of complex rules, which may impact the timing and amount of revenue we can recognize and could have a material adverse effect on our ability to recoup any of our investment in this new business. Further, there can be no assurance that we will maintain positive relations with our ACO partners which may result in certain of the ACOs terminating our relationship, which could result in a potential loss of our investment. We continue to evaluate our ACO based on a variety of factors, including the level of commitment by the physicians in the ACO and the likelihood of the ACO achieving shared savings.Rule 229.10(f)(1).

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Except as previously disclosed in a Current Report on Form 8-K, or as set forth below, the Company has not sold securities that were not registered under the Securities Act of 1933, as amended (the “Securities Act”), during the period covered by this report.

On August 20, 2020, we entered into the Contribution Agreement with the Trusts and Michael T. Dent, the Chief Executive Officer and Chairman of the board of directors of the Company. Pursuant to the Contribution Agreement, the Trusts contributed an aggregate of 76,026 shares of common stock of NeoGenomics, Inc. with a fair value of $3,066,889 to the Company. In consideration for the foregoing, we issued the Trusts an aggregate of 2,750,000 shares of newly designated Series B Preferred Stock and an aggregate of 24,522,727 shares of common stock.
During the three months ended ~~September 30, 2020,~~March 31, 2021, we sold ~~2,624,202~~11,787,766 shares of common stock for cash in 946 separate private placement transactions ~~and~~to accredited investors. We received ~~$214,500~~$3,488,725 in proceeds from the sales. ~~The shares were issued at per share prices between $0.06 and $0.17.~~ In connection with ~~the~~these stock sales, we also issued ~~1,312,100~~5,893,889 five-year warrants to purchase shares of common stock at exercise ~~price~~prices between ~~$0.16~~$0.27 and ~~$0.27~~$1.05 per share.

During the three months ended ~~September 30, 2020,~~March 31, 2021, we issued ~~2,855,191 shares of common stock upon the full or partial conversion of a convertible note payable. The shares retired $142,500 of convertible note payable principal and $14,250 of accrued interest.~~
~~During the three months ended September 30, 2020, we issued 731,471~~475,000 shares of common stock to two separate consultants for services provided.

During the three months ended ~~September 30, 2020,~~March 31, 2021, we issued ~~1,835,626~~9,047,332 shares upon exercise of ~~common stock to the selling shareholders of CHM in satisfaction of contingent acquisition consideration related to earnout payments.~~outstanding warrants.

The sales of the above securities were exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder, as transactions by an issuer not involving any public offering. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment purposes only and not with a view to or for sale in connection with any distribution thereof, and appropriate restrictive legends were placed upon the stock certificates issued in these transactions.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

45
Item 6. Exhibits

Exhibit No. Exhibit Description
~~3.1~~10.1 ~~Articles of Incorporation~~Warrant made to Iconic Holdings, LLC, dated January 14, 2021 (Filed as Exhibit ~~3.1 to the Company’s Draft Registration Statement on Form S-1 filed with the Commission on January 9, 2017)~~
~~3.2~~ ~~Amended and Restated Articles of Incorporation (Filed as Exhibit 3.2 to the Company’s Draft Registration Statement on Form S-1 filed with the Commission on January 9, 2017)~~
~~3.3~~ ~~By-Laws (Filed as Exhibit 3.3 to the Company’s Draft Registration Statement on Form S-1 filed with the Commission on January 9, 2017)~~
~~3.4~~ ~~Certificate of Designation of Series A Convertible Preferred Stock (Filed as Exhibit 3.4 to the Company’s Draft Registration Statement on Form S-1 filed with the Commission on January 9, 2017)~~
~~3.5~~ ~~Certificate of Amended to Articles of Incorporation (Filed as Exhibit 3.1~~4.1 to the Company’s Current Report on Form 8-K filed with the Commission on ~~February 6, 2018)~~January 15, 2021)
~~3.6~~10.2 ~~Certificate of Designation of Series B Convertible Preferred Stock~~Agreement, by and between the Company and Iconic Holdings, LLC, dated January 14, 2021 (Filed as Exhibit ~~3.1~~10.1 to the Company’s Current Report on Form 8-K filed with the Commission on ~~August 26, 2020)~~January 15, 2021)
~~10.1~~10.3 ~~Contribution~~Form of Warrant made to DanKris1, LLC, dated February 26, 2021 (Filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Commission on March 2, 2021)
10.4 Form of Subscription Agreement, by and ~~among~~between the Company ~~The Michael T. Dent, Trustee of the Mary S. Dent Gifting Trust~~and DanKris1, LLC, dated ~~January 31, 2006, Michael Thomas Dent, Trustee under the Michael Thomas Dent Declaration of Trust dated March 23, 1998, as amended, and Michael T. Dent dated August 20, 2020~~February 26, 2021 (Filed as Exhibit 10.1 to the Company’s Form 8-K filed with the Commission on ~~August 26, 2020)~~March 2, 2021)
~~10.2~~ ~~Agreement and Plan of Merger (Filed as Exhibit 2.1 to the Company’s Form 8-K filed with the Commission on October 21, 2020)~~
31.1* Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
31.2* Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
32.1* Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
32.2* Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
101* XBRL Instance Document
XBRL Taxonomy Extension Schema Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Presentation Linkbase Document
* Filed herewith.

46
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: ~~November 16, 2020~~May 17, 2021

HEALTHLYNKED CORP.

By: /s/ Michael Dent
Name: Michael Dent
Title:
Chief Executive Officer and Chairman
(Principal Executive Officer)

By: /s/ George O’Leary
Name: George O’Leary
Title:
Chief Financial Officer
(Principal Financial Officer)


5847

		PAGE NO.

PART I	FINANCIAL INFORMATION	1
Item 1	Financial Statements (Unaudited)	1
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4438
Item 3	Quantitative and Qualitative Disclosures about Market Risk	5444
Item 4	Controls and Procedures	5444

Part II	OTHER INFORMATION	5545
Item 1	Legal Proceedings	5545
Item 1A	Risk Factors	5545
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	5645
Item 3	Defaults upon Senior Securities	5645
Item 4	Mine Safety Disclosure	5645
Item 5	Other Information	5645
Item 6	Exhibits	5746

	Three Months Ended March 31,
	2021			2020
Revenue
Patient service revenue, net	$	1,514,376		$	1,336,940
Consulting and event revenue		87,655			—
Product revenue		182,663			—
Total revenue		1,784,694			1,336,940

Operating Expenses and Costs
Practice salaries and benefits		663,937			765,121
Other practice operating expenses		730,784			563,691
Medicare shared savings expenses		211,507			—
Cost of product revenue		168,596			—
Selling, general and administrative expenses		1,366,137			510,976
Depreciation and amortization		211,658			24,786
Total Operating Expenses and Costs		3,352,619			1,864,574

Loss from operations		(1,567,925	)		(527,634	)

Other Income (Expenses)
Loss on extinguishment of debt		(5,589,994	)		(467,937	)
Change in fair value of debt		(19,246	)		35,965
Amortization of original issue and debt discounts on notes payable and convertible notes		—			(292,163	)
Change in fair value of derivative financial instruments		—			740,355
Change in fair value of contingent acquisition consideration		(635,700	)		(6,621	)
Interest expense		(10,588	)		(62,181	)
Total other expenses		(6,255,528	)		(52,582	)

Net loss before provision for income taxes		(7,823,453	)		(580,216	)

Provision for income taxes		—			—

Net loss	$	(7,823,453	)	$	(580,216	)

Deemed dividend - amortization of beneficial conversion feature and down round adjustment to warrants		(88,393	)		—

Net loss to common stockholders	$	(7,911,846	)	$	(580,216	)

Net loss per share to common stockholders, basic and diluted:
Basic	$	(0.04	)	$	(0.01	)
Fully diluted	$	(0.04	)	$	(0.01	)

Weighted average number of common shares:
Basic		213,279,052			114,601,960
Fully diluted		213,279,052			114,601,960

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Revenue
Patient service revenue, net	$	1,054,806		$	1,172,561		$	3,502,836		$	2,845,941
Medicare shared savings revenue		767,744			---			767,744			---
Consulting revenue		217,605			---			268,025			---
Total revenue		2,040,155			1,172,561			4,538,605			2,845,941

Operating Expenses
Practice salaries and benefits		590,690			708,571			1,910,897			1,762,662
Other practice operating expenses		548,667			521,341			1,633,380			1,287,432
Medicare shared savings expenses		759,848			---			824,084			---
General and administrative		958,874			733,360			2,116,159			2,084,630
Depreciation and amortization		25,151			24,980			74,811			48,345
Total Operating Expenses		2,883,230			1,988,252			6,559,331			5,183,069

Loss from operations		(843,075	)		(815,691	)		(2,020,726	)		(2,337,128	)

Other Income (Expenses)
Loss on sales of marketable securities		(281,606	)		---			(281,606	)		---
Gain (loss) on extinguishment of debt		(450,999	)		4,904			(1,347,371	)		(62,459	)
Change in fair value of debt		(79,062	)		(28,885	)		(198,764	)		(88,991	)
Financing cost		---			(12,009	)		---			(133,244	)
Amortization of original issue and debt discounts on notes payable and convertible notes		(65,816	)		(362,728	)		(530,930	)		(841,725	)
Change in fair value of derivative financial instruments		12,802			158,691			739,485			574,205
Change in fair value of contingent acquisition consideration		45,996			---			687			---
Interest expense		(72,535	)		(69,562	)		(193,134	)		(176,229	)
Total other expenses		(891,220	)		(309,589	)		(1,811,633	)		(728,443	)

Net loss before provision for income taxes		(1,734,295	)		(1,125,280	)		(3,832,359	)		(3,065,571	)

Provision for income taxes		---			---			---			---

Net loss	$	(1,734,295	)	$	(1,125,280	)	$	(3,832,359	)	$	(3,065,571	)

Deemed dividend - amortization of beneficial conversion feature		(63,862	)		---			(63,862	)		---

Net loss to common stockholders	$	(1,798,157	)	$	(1,125,280	)	$	(3,896,221	)	$	(3,065,571	)

Net loss per share to common stockholders, basic and diluted:
Basic	$	(0.01	)	$	(0.01	)	$	(0.03	)	$	(0.03	)
Fully diluted	$	(0.01	)	$	(0.01	)	$	(0.03	)	$	(0.03	)

Weighted average number of common shares:
Basic		147,366,619			102,644,860			129,234,540			96,603,087
Fully diluted		147,366,619			102,644,860			129,234,540			96,603,087

	Number of Shares								Common			Additional					Total
	Common		Preferred		Common		Preferred		Stock			Paid-in		Accumulated			Shareholders'
	Stock		Stock		Stock		Stock		Issuable			Capital		Deficit			Equity (Deficit)
	*(#)*		*(#)*		*($)*		*($)*		*($)*			*($)*		*($)*			*($)*
Balance at December 31, 2020		187,967,881		2,750,000		18,797		2,750		262,273			22,851,098		(21,784,910	)		1,350,008

Sales of common stock		14,793,864		—		1,479		—					2,981,367		—			2,982,846
Fair value of warrants allocated to proceeds of common stock		—		—		—		—					1,406,515		—			1,406,515
Conversion of convertible notes payable to common stock		13,538,494		—		1,354		—					4,060,194		—			4,061,548
Fair value of warrants issued and modified in connection with conversion and retirement of convertible notes payable		—		—		—		—		—			3,201,138		—			3,201,138
Fair value of warrants issued for professional services		—		—		—		—		—			32,426		—			32,426
Consultant and director fees payable with common shares and warrants		475,000		—		48		—		114,500			122,781		—			237,329
Shares and options issued pursuant to employee equity incentive plan		240,310		—		24		—		(14,956	)		52,337		—			37,405
Exercise of stock warrants		9,047,332		—		905		—		62,500			613,316		—			676,721
Exercise of stock options		12,500		—		1		—					3,149		—			3,150
Net loss		—		—		—		—		—			—		(7,823,453	)		(7,823,453	)

Balance at March 31, 2021		226,075,381		2,750,000		22,608		2,750		424,317			35,324,321		(29,608,363	)		6,165,633

Balance at December 31, 2019		109,894,490		—		10,990		—		159,538			13,016,446		(16,029,654	)		(2,842,680	)

Sale of common stock		4,187,566		—		419		—		(59,000	)		407,181					348,600
Fair value of warrants allocated to proceeds of common stock		—		—		—		—		—			88,833		—			88,833
Conversion of convertible notes payable to common stock		4,672,612		—		467		—		51,652			600,441		—			652,560
Consultant and director fees payable with common shares and warrants		—		—		—		—		60,212			6,666		—			66,878
Shares and options issued pursuant to employee equity incentive plan		132,500		—		13		—		(7,161	)		45,724		—			38,576
Net loss		—		—		—		—		—			—		(580,216	)		(580,216	)

Balance at March 31, 2020		118,887,168		—		11,889		—		205,241			14,165,291		(16,609,870	)		(2,227,449	)

Cash	$	500,000
Common Stock (3,968,254 shares)		1,000,000
Contingent acquisition consideration subject to earn-out		299,672

Fair Value of Total Consideration	$	1,799,672

Cash	$	35,000
Hyperbaric Chambers		452,289	$	452,289
Medical Equipment		29,940		29,940
Computer Equipment/Software		19,739		19,739
Office Furniture & Equipment		23,052		23,052
Inventory		72,114		72,114
Leasehold Improvements		25,000		25,000
Website		41,000		41,000
Patient Management Platform Database		1,101,538		1,101,538

Fair Value of Identifiable Assets Acquired	$	1,799,672	$	1,764,672

Cash paid at closing	$	214,000
Shares issued at closing (2,240,838 shares)		201,675
Cash and shares contingent upon 2019 program year MSSP payment target		778,192
Cash contingent upon four-year earn-out		279,593
Less cash received		(49,995	)

	$	1,423,465

Cash paid at closing	$	214,000
Shares issued at closing		201,675
Cash and shares contingent upon 2019 program year MSSP payment target		778,192
Cash contingent upon four-year earn-out		279,593

	$	1,473,460

Cash	$	49,995
Accounts receivable		90,197		$	90,197
Prepayments		15,294			15,294
ACO physician contracts		1,073,000			1,073,000
Goodwill		381,856			381,856
Accounts payable		(32,846	)		(32,848	)
Deferred revenue		(104,034	)		(104,034	)

Fair Value of Identifiable Assets Acquired and Liabilities Assumed	$	1,473,460		$	1,423,465

Shares issued at closing (19,045,563 shares)	$	2,704,470
Payment of MOD debt obligations in cash		703,200
Shares contingent upon four-year earn-out		649,108
Less cash received		(57,048	)

	$	3,999,730

Website	$	3,538,000
Goodwill		766,249
Accounts payable and accruals		(160,762	)
Notes payable		(90,759	)
Deferred revenue		(52,998	)

Fair Value of Identifiable Assets Acquired and Liabilities Assumed	$	3,999,730

	As of September 30, 2020						As of December 31, 2019
	Operating		Financing		Total		Operating		Financing		Total		March 31,		December 31,
	Leases		Leases		Leases		Leases		Leases		Leases		2021		2020
Lease assets	$	297,050	$	---	$	297,050	$	273,196	$	4,482	$	277,678	$	385,653	$	417,913

Lease liabilities
Lease liabilities (short term)	$	105,233	$	---	$	105,233	$	197,041	$	4,482	$	201,523	$	162,770	$	150,251
Lease liabilities (long term)		198,667		---		198,667		80,510		---		80,510		228,288		273,790
Total lease liabilities	$	303,900	$	---	$	303,900	$	277,551	$	4,482	$	282,033	$	391,058	$	424,041

		Interest	September 30,		December 31,
Inception Date	Maturity Date	Rate	2020		2019
January 12, 2017	December 31, 2020	10%	$	---	$	38,378	*
January 18, 2017	December 31, 2020	10%		---		21,904	*
January 24, 2017	December 31, 2020	10%		---		54,696	*
February 9, 2017	December 31, 2020	10%		---		32,715	*
April 20, 2017	December 31, 2020	10%		---		10,754	*
June 15, 2017	December 31, 2020	10%		---		34,560	*
August 17, 2017	December 31, 2020	10%		---		20,997	*
August 24, 2017	December 31, 2020	10%		---		39,312	*
September 7, 2017	December 31, 2020	10%		---		36,586	*
September 21, 2017	December 31, 2020	10%		---		27,621	*
September 29, 2017	December 31, 2020	10%		---		12,487	*
December 21, 2017	December 31, 2020	10%		---		14,318	*
January 8, 2018	December 31, 2020	10%		---		76,415	*
January 11, 2018	December 31, 2020	10%		---		9,164	*
January 26, 2018	December 31, 2020	10%		---		17,712	*
January 3, 2014	December 31, 2020	10%		---		296,336	*

			$	---	$	743,955

	Amortization of Debt Discount								Interest Expense				Amortization of Debt Discount
	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended March 31,				Three Months Ended March 31,
	2020		2019		2020		2019		2021		2020		2021		2020

$103k Note I - October 2018	$	---	$	---	$	---	$	33,972
$103k Note II - November 2018		---		---		---		44,952
$153k Note - November 2018		---		1,733		---		91,451
$103k Note III - December 2018		---		---		---		42,611
$78k Note I - January 2019		---		4,286		---		52,000
$78k Note II - January 2019		---		6,346		---		47,858
$103k Note III - April 2019		---		28,628		---		56,012
$104.5k Note - April 2019		---		26,268		---		49,109
$104.5k Note II - April 2019		---		26,268		---		49,109
$550k Note - July 2016									$	2,351	$	8,225	$	—	$	—
$50k Note - July 2016										219		1,247		—		—
$111k Note - May 2017										333		4,694		—		—
$357.5k Note - April 2019		---		91,230		---		166,593		1,469		829		—		—
$103k Note IV - May 2019		---		31,906		---		50,633
$154k Note - June 2019		---		38,710		1,093		50,071		—		46		—		1,093
$67.9k Note - July 2019		---		16,277		7,252		16,277		—		707		—		7,252
$67.9k Note II - July 2019		---		16,277		2,813		16,277		—		177		—		2,813
$78k Note III - July 2019		---		20,512		6,208		20,512		—		492		—		6,208
$230k Note - July 2019		---		46,503		58,527		46,503		—		3,041		—		58,526
$108.9k Note - August 2019		---		7,784		21,038		7,785		—		2,545		—		20,960
$142.5k Note - October 2019		21,804		---		92,663		---		—		5,739		—		35,430
$103k Note V - October 2019		---		---		29,143		---		—		2,568		—		28,213
$108.9k Note II - October 2019		---		---		33,205		---		—		2,716		—		21,730
$128.5k Note - October 2019		---		---		51,705		---		—		3,204		—		31,949
$103k Note VI - November 2019		---		---		39,450		---		—		2,568		—		28,720
$78.8k Note II - December 2019		---		---		27,111		---		—		1,963		—		15,917
$131.3k Note - January 2020		1,158		---		16,205		---		—		2,805		—		6,945
$78k Note IV - January 2020		1,608		---		14,955		---		—		1,603		—		6,030
$157.5k Note - March 2020		7,432		---		20,044		---		—		906		—		2,365
$157.5k Note II - April 2020		9,127		---		21,436		---
$135k Note - April 2020		7,744		---		17,718		---
$83k Note II - April 2020		6,675		---		13,767		---
$128k Note - April 2020		10,268		---		18,097		---

	$	65,816	$	362,728	$	492,430	$	841,725	$	4,372	$	46,075	$	—	$	274,151

	Unamortized Discount as of
	September 30,		December 31,
	2020		2019

$154k Note - June 2019	$	---	$	21,175
$67.9k Note - July 2019		---		20,497
$67.9k Note II - July 2019		---		20,497
$78k Note III - July 2019		---		32,657
$230k Note - July 2019		---		125,684
$108.9k Note - August 2019		---		59,392
$142.5k Note - October 2019		---		107,070
$103k Note V - October 2019		---		70,686
$108.9k Note II - October 2019		---		72,592
$128.5k Note - October 2019		---		106,732
$103k Note VI - November 2019		---		81,740
$78.8k Note II - December 2019		---		58,946

	$	---	$	777,668

	Change in Fair Value of Debt								Fair Value of Debt as of				Change in Fair Value of Debt					Fair Value of Debt as of
	Three Months Ended September 30,				Nine Months Ended September 30,				September 30,		December 31,		Three Months Ended March 31,					March 31,		December 31,
	2020		2019		2020		2019		2020		2019		2021		2020			2021		2020

$550k Note - July 2016	$	24,285	$	17,455	$	59,618	$	52,708	$	607,629	$	548,010	$	10,343	$	(10,757	)	$	—	$	719,790
$50k Note - July 2016		2,520		1,770		6,187		5,343		63,053		56,866		1,017		(1,116	)		—		71,611
$111k Note - May 2017		4,721		3,674		16,261		11,089		118,108		118,606		1,706		(3,036	)		—		120,659
$171.5k Note - October 2017		---		---		---		1,781		---		---
$357.5k Note - April 2019		14,567		---		35,763		---		364,490		328,727		6,180		(6,453	)		—		424,290

	$	46,093	$	22,899	$	117,829	$	70,921	$	1,153,280	$	1,052,209	$	19,246	$	(21,362	)	$	—	$	1,336,350

	September 30, 2020				December 31, 2019
	Amount		Shares		Amount		Shares

Shares earned by consultants, employees and directors but not yet issued	$	181,343		1,458,095	$	100,538		568,142
Shares issuable pursuant to stock subscriptions received		749		7,143		59,000		479,762
	$	182,092		1,465,238	$	159,538		1,047,904

	March 31, 2021				December 31, 2020
	Amount		Shares		Amount		Shares

Shares issuable to consultants, employees and directors	$	361,817		2,178,770	$	262,273		2,150,020
Shares issuable pursuant to warrant exercise		62,500		625,000		—		—
	$	424,317		2,803,770	$	262,273		2,150,020

	2020					2019
				Weighted					Weighted
				Average					Average
				Exercise					Exercise
	Number			Price		Number			Price
Outstanding at beginning of the period		47,056,293		$	0.17		46,161,463		$	0.18
Granted during the period		3,463,825		$	0.20		1,805,001		$	0.35
Exercised during the period		---		$	---	��	(4,099,256	)	$	(0.00	)
Expired during the period		(50,000	)	$	0.40		---		$	---
Outstanding at end of the period		50,470,118		$	0.18		43,867,208		$	0.20

Exercisable at end of the period		50,470,118		$	0.18		43,867,208		$	0.20

Weighted average remaining life		3.4 years					3.0 years

Warrants Outstanding								Warrants Exercisable
				Weighted-
				Average		Weighted-				Weighted-
				Remaining		Average				Average
Exercise		Number		Contractual		Exercise		Number		Exercise
Prices		Outstanding		Life (years)		Price		Exercisable		Price
$	0.0001 to 0.09		15,287,011		4.2	$	0.07		15,287,011	$	0.07
$	0.10 to 0.24		21,125,618		3.0	$	0.18		21,125,618	$	0.18
$	0.25 to 0.49		10,117,489		3.7	$	0.28		10,117,489	$	0.28
$	0.50 to 1.00		3,940,000		1.4	$	0.28		3,940,000	$	0.28
$	0.05 to 1.00		50,470,118		3.4	$	0.18		50,470,118	$	0.18

Options Outstanding	Options Outstanding							Options Exercisable				Options Outstanding							Options Exercisable
				Weighted-											Weighted-
				Average		Weighted-				Weighted-					Average		Weighted-				Weighted-
				Remaining		Average				Average					Remaining		Average				Average
Exercise	Exercise	Number		Contractual		Exercise		Number		Exercise		Exercise	Number		Contractual		Exercise		Number		Exercise
Prices	Prices	Outstanding		Life (years)		Price		Exercisable		Price		Prices	Outstanding		Life (years)		Price		Exercisable		Price
$	--- to 0.10		1,283,000		5.2	$	0.08		1,283,000		0.08	— to 0.10		1,283,000		4.7	$	0.08		1,283,000		0.08
$	0.11 to 0.31		1,966,250		8.1	$	0.28		729,375		0.29	0.11 to 0.31		1,783,750		7.6	$	0.28		993,750		0.29
$	0.08 to 0.31		3,249,250		7.0	$	0.20		2,012,375	$	0.16	0.08 to 0.31		3,066,750		6.4	$	0.20		2,276,750	$	0.17

2021 (April to December)	$	689,083
2022		429,612
2023		507,557
2024		509,888
	$	2,136,140

2020	$	50,882
2021		205,430
2022		159,561
2023		68,457
Total lease payments		484,330
Less interest		(180,430	)
Present value of lease liabilities	$	303,900

2021 (April to December)	$	213,854
2022		238,637
2023		140,944
Total lease payments		593,435
Less interest		(202,377	)
Present value of lease liabilities	$	391,058

	Three Months Ended September 30, 2020											Three Months Ended September 30, 2019
	Health Services			Digital Healthcare			ACO / MSO		Total			Health Services			Digital Healthcare			ACO / MSO		Total
Revenue
Patient service revenue, net	$	1,054,806		$	---		$	---	$	1,054,806		$	1,172,561		$	---		$	---	$	1,172,561
Medicare shared savings revenue		---			---			767,744		767,744			---			---			---		---
Consulting revenue		---			---			217,605		217,605			---			---			---		---
Total revenue		1,054,806			---			985,349		2,040,155			1,172,561			---			---		1,172,561

Operating Expenses
Practice salaries and benefits		590,690			---			---		590,690			708,571			---			---		708,571
Other practice operating expenses		548,667			---			---		548,667			521,341			---			---		521,341
Medicare shared savings expenses		---			---			759,848		759,848			---			---			---		---
General and administrative		---			958,874			---		958,874			---			733,360			---		733,360
Depreciation and amortization		24,557			594			---		25,151			24,385			595			---		24,980
Total Operating Expenses		1,163,914			959,468			759,848		2,883,230			1,254,297			733,955			---		1,988,252

Loss from operations	$	(109,108	)	$	(959,468	)	$	225,501	$	(843,075	)	$	(81,736	)	$	(733,955	)	$	---	$	(815,691	)

Other Segment Information
Interest expense	$	23,186		$	49,349		$	---	$	72,535		$	5,165		$	64,397		$	---	$	69,562
Loss on sales of marketable securities	$	---		$	281,606		$	---	$	281,606		$	---		$	---		$	---	$	---
Loss on extinguishment of debt	$	---		$	450,999		$	---	$	450,999		$	---		$	(4,904	)	$	---	$	(4,904	)
Financing cost	$	---		$	---		$	---	$	---		$	---		$	12,009		$	---	$	12,009
Amortization of original issue and debt discounts on convertible notes	$	---		$	65,816		$	---	$	65,816		$	---		$	362,728		$	---	$	362,728
Change in fair value of debt	$	---		$	79,062		$	---	$	79,062		$	---		$	28,885		$	---	$	28,885
Change in fair value of derivative financial instruments	$	---		$	(12,802	)	$	---	$	(12,802	)	$	---		$	(158,691	)	$	---	$	(158,691	)
Change in fair value of contingent acquisition consideration	$	---		$	(45,996	)	$	---	$	(45,996	)	$	---		$	---		$	---	$	---

	Three Months Ended March 31, 2021
	Health Services		Digital Healthcare			ACO / MSO			Medical Distribution			Total
Revenue
Patient service revenue, net	$	1,514,376	$	—		$	—		$	—		$	1,514,376
Consulting and event revenue		—		11,113			76,542			—			87,655
Product revenue		—		—			—			182,663			182,663
Total revenue		1,514,376		11,113			76,542			182,663			1,784,694

Operating Expenses
Practice salaries and benefits		663,937		—			—			—			663,937
Other practice operating expenses		730,784		—			—			—			730,784
Medicare shared savings expenses		—		—			211,507			—			211,507
Cost of product revenue		—		—			—			168,596			168,596
Selling, general and administrative expenses		—		1,305,320			—			60,817			1,366,137
Depreciation and amortization		28,323		595			—			182,740			211,658
Total Operating Expenses		1,423,044		1,305,320			211,507			412,153			3,352,619

(Loss) income from operations	$	91,332	$	(1,294,802	)	$	(134,965	)	$	(229,490	)	$	(1,567,925	)

Other Segment Information
Interest expense	$	4,197	$	6,282		$	—		$	109		$	10,588
Loss on extinguishment of debt	$	—	$	5,589,994		$	—		$	—		$	5,589,994
Change in fair value of debt	$	—	$	19,246		$	—		$	—		$	19,246
Change in fair value of contingent acquisition consideration	$	—	$	635,700		$	—		$	—		$	635,700

	March 31, 2021
Identifiable assets	$	2,411,744	$	3,043,929	$	1,128,491	$	3,287,628	$	9,871,792
Goodwill	$	—	$	—	$	381,856	$	766,249	$	1,148,105

	December 31, 2020
Identifiable assets	$	2,120,714	$	192,568	$	1,115,148	$	3,450,013	$	6,878,443
Goodwill	$	—	$	—	$	381,856	$	766,249	$	1,148,105

	Nine Months Ended September 30, 2020											Nine Months Ended September 30, 2019											Three Months Ended March 31, 2020
	Health Services			Digital Healthcare			ACO / MSO		Total			Health Services			Digital Healthcare			ACO / MSO		Total			Health Services			Digital Healthcare			ACO / MSO		Medical Distribution		Total
Revenue
Patient service revenue, net	$	3,502,836		$	---		$	---	$	3,502,836		$	2,845,941		$	---		$	---	$	2,845,941		$	1,336,940		$	—		$	—	$	—	$	1,336,940
Medicare shared savings revenue		---			---			767,744		767,744			---			---			---		---
Consulting revenue		---			---			268,025		268,025			---			---			---		---			—			—			—		—		—
Product revenue																								—			—			—		—		—
Total revenue		3,502,836			---			1,035,769		4,538,605			2,845,941			---			---		2,845,941			1,336,940			—			—		—		1,336,940

Operating Expenses
Practice salaries and benefits		1,910,897			---			---		1,910,897			1,762,662			---			---		1,762,662			765,121			—			—		—		765,121
Other practice operating expenses		1,633,380			---			---		1,633,380			1,287,432			---			---		1,287,432			563,691			—			—		—		563,691
Medicare shared savings expenses		---			---			824,084		824,084			---			---			---		---			—			—			—		—		—
General and administrative		---			2,116,159			---		2,116,159			---			2,084,630			---		2,084,630
Cost of product revenue																								—			—			—		—		—
Selling, general and administrative expenses																								—			510,976			—		—		510,976
Depreciation and amortization		73,027			1,784			---		74,811			46,561			1,784			---		48,345			24,191			595			—		—		24,786
Total Operating Expenses		3,617,304			2,117,943			824,084		6,559,331			3,096,655			2,086,414			---		5,183,069			1,353,003			511,571			—		—		1,864,574

Loss from operations	$	(114,468	)	$	(2,117,943	)	$	211,685	$	(2,020,726	)	$	(250,714	)	$	(2,086,414	)	$	---	$	(2,337,128	)	$	(16,063	)	$	(511,571	)	$	—	$	—	$	(527,634	)

Other Segment Information
Interest expense	$	35,096		$	158,038		$	---	$	193,134		$	17,010		$	159,219		$	---	$	176,229		$	5,536		$	56,645		$	—	$	—	$	62,181

Loss on sales of marketable securities	$	---		$	281,606		$	---	$	281,606		$	---		$	---		$	---	$	---

Loss on extinguishment of debt	$	---		$	1,347,371		$	---	$	1,347,371		$	---		$	62,459		$	---	$	62,459		$	—		$	467,937		$	—	$	—	$	467,937
Financing cost	$	---		$	---		$	---	$	---		$	---		$	133,244		$	---	$	133,244
Amortization of original issue and debt discounts on convertible notes	$	---		$	530,930		$	---	$	530,930		$	---		$	841,725		$	---	$	841,725		$	—		$	292,163		$	—	$	—	$	292,163
Change in fair value of debt	$	---		$	198,764		$	---	$	198,764		$	---		$	88,991		$	---	$	88,991		$	—		$	(35,965	)	$	—	$	—	$	(35,965	)
Change in fair value of derivative financial instruments	$	---		$	(739,485	)	$	---	$	(739,485	)	$	---		$	(574,205	)	$	---	$	(574,205	)	$	—		$	(740,355	)	$	—	$	—	$	(740,355	)
Change in fair value of contingent acquisition consideration	$	---		$	(687	)	$	---	$	(687	)												$	—		$	6,621		$	—	$	—	$	6,621
Identifiable assets as of March 31, 2020																							$	2,175,990		$	136,499		$	---	$	---	$	2,312,489

							Total		As of March 31, 2021
	Level 1		Level 2		Level 3		Fair Value								Total
Convertible notes payable	$	---	$	---	$	1,153,279	$	1,153,279
									Level 1		Level 2		Level 3		Fair Value
Contingent acquisition consideration		---		---		926,597		926,597	$	—	$	—	$	2,136,140	$	2,136,140

Total	$	---	$	---	$	2,079,876	$	2,079,876	$	—	$	—	$	2,136,140	$	2,136,140